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Dissolution testing and physiological based pharmacokinetic modeling are the essential 
methods during drug development. However, there is a lack of a sound approach and 
understanding of the parameter that controls dissolution and absorption of amorphous 
formulations. Robust dissolution conditions and setup and PBPK models that have a 
predictability of in vivo results will expedite and facilitate the drug development 
process. In this project, cefuroxime axetil, CA (Zinnat® as the amorphous formulations); 
itraconazole, ITR (Sporanox® as the amorphous formulation) and a compound 
undergoing clinical trial, Compound X, CX (CX tablet as the amorphous formulation) 
were chosen. The design of experiments for the in vitro dissolution studies using 
different apparatus, media and setup which closely simulate the physiological condition 
of humans (CA and ITR) and dogs (CX) were implemented. The dissolution of CA, ITR 
and CX formulations was successfully characterised using different dissolution 
apparatus, setting and media (compendial, biorelevant and modified media) to simulate 
the changes of pH, contents, hydrodynamic conditions (flow rate and rotation speed) in 
human gastrointestinal tract (fasted and fed state). The change of hydrodynamics 
combined with media change that corresponded to the physiological conditions created 
with USP apparatus 4 and biorelevant dissolution media were able to mimic the in vivo 
performance of the tested formulations. Furthermore, surface UV dissolution imaging 
methodology that could be used to understand the mechanism of CA and ITR (Active 
compounds and their amorphous formulations) dissolution were developed in this 
project. The UV images developed using surface UV imaging apparatus provided a 
visual representation and a means for the qualitative as well as quantitative 
assessment of the differences in dissolution rates and concentration for the model 
compounds used. In this project, validated PBPK models for fasted state (CA, ITR) and 
fed state (CA, ITR and CX) were developed. These models incorporated in vitro 
degradation, particle size distribution, in vitro solubility and dissolution data as well as 
in vivo human/ dog pharmacokinetics data. Similarly, the results showed that level A 
IVIVCs for all three model compounds were successfully established. Dissolution 
profiles with USP apparatus 4 combined with biorelevant media showed close 
correlation with the in vivo absorption profiles. Overall, this project successfully 
provides a comprehensive biorelevant methodology to develop PBPK models and 






1.1 Amorphous state  
Solid forms are classified into crystalline and amorphous states based on the order of 
molecular packing (1-3). Molecules aggregate together with long-range order in the 
crystalline state. The term “long range order” refers to molecular units in a crystal 
lattice that are repeated according to a three-dimensional pattern in crystallographic 
directions. The relative location and orientation between neighbouring components of a 
solid that has long range order can be accurately described at the molecular level (4). 
But, this is not the case for the amorphous state (1, 5). The amorphous state is 
characterised by random distribution in the relative orientation of neighbouring 
molecular units. Furthermore, the translational and rotational orders are present in the 
crystalline solids but they are absent in the amorphous solids (Figure 1). 
Figure 1. Schematic structure of crystalline and amorphous states. 
 
The crystalline state and the liquid state above the melting temperature (Tm) are 
thermodynamically stable. On the other hand, amorphous materials are 
thermodynamically unstable. The kinetic stability of amorphous material depends on 
the physical state of the material. Two physical states can be defined for amorphous 
material: the amorphous state and the super-cooled liquid state. The amorphous state 
is the preferred type of drug formulation because it is kinetically stable. This implies 
that the equilibrium state, i.e. crystalline, is not reached within the timeframe of the 
experiment or the shelf life of the product. It should be noted that in some definitions 
the terms “glass/glassy”, “amorphous” and “non-crystalline” are synonymous and 
interchangeable (6).  
 
1.1.1 Preparation of amorphous solids 
In the pharmaceutical industry, some drug candidates during the pre-formulation phase 




Solid with orientational and positional long-
range order in three dimensions. 
Amorphous state 




methods (e.g., lyophilisation) or a higher impurity level (7). As a solid state of 
increasing importance, the amorphous state of a compound can be formed by various 
methods such as lyophisation, spray drying, melt extrusion, melt quench cooling, 
solution evaporation and solid dispersion (8).  
 
1.1.1.1 Solid dispersion 
Solid dispersion can be defined as one type of method to produce an amorphous 
compound by incorporating a hydrophobic drug into a hydrophilic carrier (9). It also can 
be referred to as a product formed by converting a fluid drug-carrier combination to the 
solid state (10). Essentially, it is a group of solid products consisting of at least two 
different components, generally a hydrophilic matrix and a hydrophobic drug. The 
matrix can be either in crystalline or amorphous form. Alternatively, the drug can be 
dispersed or dissolved molecularly throughout the carrier matrix (termed as a solid 
solution) (9). 
 
It is one of the most studied methods to solubilise and to enhance dissolution rates of 
Biopharmaceutical Classification System (BCS) class 2 compounds (11). For instance, 
a solid dispersion of ritonavir (12) and ER-3421 (a dual 5-
lipoxygenase/cyclooxygenase inhibitor) (13) were found to have a much higher 
dissolution rate than the crystalline counterpart and resulted in higher AUC and Cmax in 
in vivo study.  Another example is solid dispersion of piroxicam in polyvinylpyrrolidone 
K-30 at ratio 1:4 generating the amorphous state of the drug. An approximate 38-fold 




1.1.2 Solubility of amorphous compound 
 
The amorphous form has attracted increasing interest within the pharmaceutical field 
because its higher solubility could achieve better dissolution rate, absorption rate and 
increase the bioavailability of poorly water-soluble compounds (15). The solubility 
increment of amorphous forms over crystalline states depends on the potential energy 
difference between these physical states (16, 17). It was estimated that 10-1600 folds 
of solubility increment can be achieved by applying the amorphous form (18-22).  
 
From the physical stability point of view, the drug which is formulated in an amorphous 
state should be preserved and stabilised to exert its solubility advantage even during 
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the dissolution process. There are only a handful of oral pharmaceutical products 
containing amorphous compound that have been successfully marketed despite 
several decades of effort in research and development. These products are Zinnat® 
(CA), Sporanox® (ITR), Rezulin® (troglitazone), Intelence® (etravirine), Rezulin® 
(everolimus) and Crestor® (rosuvastatin). The limited commercial success indicates the 
challenges with the stability of the amorphous formulations (8, 23). One of the issues 
relating to the stability of the amorphous state is its solution-mediated transformation 
characteristic. Solution-mediated transformation of amorphous to crystalline state is the 
conversion of metastable solids such as amorphous solids to the crystalline state when 
the solids are exposed to a solvent. The transformation to the more thermodynamically 
stable crystalline state occurs at a higher rate because of the higher mobility in the 
solution state than in the solid (8, 23). 
 
In drug process development, characterisation of solution mediated transformations in 
the amorphous state is important because it describes information on amorphous 
crystallisation (24). The schematic representation of concentrations in the solution, as 
well as the solid compositions as a function of time, is shown in Figure 2 for a typical 
solution-mediated transformation process (24). 
 
 
Figure 2. Concentrations in the solution and the solid compositions as a function of time during 
the solution-mediated phase transformation. Reproduced with permission from (24). 
 
As depicted in Figure 2, three consecutive steps are involved in a solution-mediated 
transformation (25-27): (1) Initial dissolution of the metastable phase into the solution 
to reach and exceed the solubility of the stable phase; (2) Nucleation of the stable 
phase. (3) Crystal growth of the stable phase coupled with the continuous dissolution 
of the metastable phase. For the overall solution-mediated transformation process, 
step (2) is usually the slowest. Therefore, this is the rate-determining step as 
nucleation is involved. When step (2) is the rate-determinant, factors such as the 
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solubility and the solubility difference between the phases, processing temperature, 
contact surfaces, agitation, and soluble excipients/impurities that affect nucleation will 
influence the overall transformation.  
1.1.3 Saturation, supersaturation and precipitation 
Amorphous compounds are high energy solid systems that are capable of reaching 
higher kinetic solubility values (supersaturation) than would be expected from the 
equilibrium solubility of a crystalline material (28). Amorphous solid dispersions aim at 
generating high and possibly supersaturated intraluminal concentrations of poorly 
water soluble compounds. The dissolution characteristics of solid dispersions depend 
to a large extent on the physical state (ideally: amorphous), drug dispersivity (ideally: 
molecular dispersion) and particle size (29). Research has shown supersaturation of a 
compound can be achieved using several methods: 
 
1. The in vivo gastrointestinal conditions: effect of pH and content changes from 
stomach to intestine 
Due to the pH gradient in the GI lumen (pH 1.5–2 in the stomach compared with pH 5–
8 in the intestine), the solubility of weak bases in gastric fluid (ionised form) typically 
exceeds their solubility in the intestinal fluid (unionised form). Therefore, higher 
dissolution of poorly water-soluble weak bases in the stomach before transfer to the 
intestine may result in supersaturation (29, 30). 
 
2. Solubilised formulations 
The hydrophobic drug is formulated as a solution which is in dissolved form. For 
example, drugs are solubilised in the formulation in a mixture of hydrophilic cosolvents, 
water-soluble and water–insoluble surfactants, complexing agents (e.g., cyclodextrins) 
and oils (29). 
 
3. High-energy and rapidly dissolving solid forms 
As mentioned earlier, amorphous state requires less energy to dissolve, resulting in 
higher apparent solubility and increased dissolution rates (22). Methods such as 
particle size reduction through milling and co-grinding that can form an amorphous 
state may increase dissolution rates by enhancing the surface area available for 
dissolution (29, 31). Co-crystals and crystalline salt forms may provide improved 
solubility and dissolution properties without being thermodynamically unstable (32). 
 
In recent pharmaceutical literature, the terms “equilibrium (thermodynamic) solubility” 
and “kinetic or apparent solubility” are often used for the systems with stable and 
metastable equilibria, respectively (33, 34). Essentially, solubility can be defined as the 
6 
 
analytical composition of a mixture or solution that is saturated with one of the 
components of the mixture or solution, expressed in terms of the proportion of the 
specific component in the mixture or solution (35).   
 
A solid phase is crystallised from solution if the chemical potential of the solid phase is 
less than that of the dissolved component. A solution in which the chemical potential of 
the solute is the same as that of the corresponding solid phase and is in equilibrium 
with the solid phase under the given conditions (temperature, pH, and concentration) is 
called a saturated solution (35). In order for crystallisation from solution to occur, 
however, this equilibrium concentration or solubility must be exceeded. This excess 
concentration or chemical potential, called the supersaturation, is the driving force for 
nucleation and crystal growth (36). 
 
For poorly water-soluble drugs, the maximum achievable intraluminal drug 
concentration may limit absorption. However, the intraluminal concentration of a drug is 
not necessarily limited by its solubility in gastrointestinal fluids (29). Drugs may be in 
solution at a concentration above their saturation solubility, that is, in a state of 
supersaturation. The degree of supersaturation can be expressed by the 
supersaturation ratio, S (Equation 1) (29): 
                           ⁄                 Equation 1 
where C and Ceq represent the solubility and equilibrium solubility (saturation) 
respectively. Theoretically, supersaturated states may be created by increasing the 
solute concentration or decreasing the solute (36).  
 
A solution is defined as unsaturated, saturated or supersaturated based on the 
following relationships: S < 1, S = 1 or S > 1, respectively (29). 
 
A supersaturated drug solution is thermodynamically unstable compared to the 
equilibrium condition (saturation). Thus, it has the tendency to return to the equilibrium 
state (lowest chemical potential) by drug precipitation. The higher the supersaturation 
the more precipitation will take place as the former is the driving force for the latter 
(37). 
 
A thermodynamically unstable, supersaturated solution of a drug can only be 
generated from a higher energy form of the drug (as compared to the crystalline 
powder) such as an amorphous form. The delivery of high-energy solid forms that 
provides an accelerated dissolution and a higher apparent solubility could induce the 
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generation of supersaturated solutions in the gastrointestinal lumen that can result in 
increased flux across the intestinal wall (29).  
 
This higher initial solubility may be sufficient to ensure increased and more rapid 
absorption for a drug with good permeability such as BCS class 1 and 2 compound. 
But a more thermodynamically stable form may crystallise at any time inside the GIT 
and the crystallisation would have a major impact on the product performance in vivo 
(31, 36). The higher dissolution rate and apparent solubility of an amorphous 
compound usually causes supersaturation during in vivo dissolution. Therefore, this 
may lead to precipitation in the GI tract (as the supersaturation is the driving force for 
the precipitation) and compromise oral bioavailability (29). If a crystallisation-inhibitory 
polymer is incorporated into the amorphous solid dispersion, the in vivo precipitation 
may be delayed or completely eliminated, resulting in much improved oral absorption. 
It is ideal if the polymeric carrier can function as a precipitation (crystallisation) inhibitor 
during in vivo dissolution (24).  
 
In the stomach and intestine, drug solubility can be enhanced by food and bile 
components such as bile salts, lecithin, and fatty acids. Supersaturation in the intestinal 
fluid is an important property that can play a significant role in drug absorption. For 
compounds with poor intrinsic solubility in the intestinal fluid, solubility is often a limiting 
factor for absorption. For many of these compounds, it may not be possible to enhance 
the saturation solubility to the extent required such that the whole dose is dissolved in 
the GI fluid. In this case, creating or maintaining supersaturation in the intestinal fluid 




1.2 In vitro dissolution testing  
 
In this section, the application of in vitro dissolution testing in industry and research is 
presented. Then, the characteristics of a surfactant and some commonly used 
surfactants are discussed. This is followed by a detailed description of the dissolution 
media (compendial, biorelevant and modified media) and three major dissolution 
apparatus namely basket (USP apparatus 1), paddle (USP apparatus 2) and flow-
through cell (USP apparatus 4). The biorelevant dissolution media, apparatus and test 
conditions will be discussed with emphasis on their relevance to the physiological 
factors, including the pH, composition of the GI fluids, volume, GI hydrodynamics/ 
motility and food effect. A brief review of statistical approaches of comparing in vitro 
dissolution profiles is presented as well. 
 
1.2.1 Applications of in vitro dissolution testing 
Dissolution testing is an essential test in the development and production of solid 
dosage forms. For example, at the early stage of drug research and development, 
dissolution testing is used for active compound characterisation and formulation 
screening. It is also used to develop and evaluate the performance of new formulations 
by examining drug dissolution from dosage forms, evaluating the stability of these 
formulations, and monitoring and assessing the formulation consistency and changes 
(38, 39). Dissolution testing is also used in process development and scale up. For 
example, it is used to determine the critical process variables for formulations. It is 
used to show the effect of different polymer or excipients on manufacture variables and 
to determine changes in the formulation or manufacturing process (40, 41). Meanwhile, 
dissolution testing serves as an important quality control (QC) tool to verify 
manufacturing and product consistency (42). It is also employed to evaluate the 
stability of the product during its shelf life. 
 
Moreover, appropriate dissolution methods can be developed to obtain an in vitro-in 
vivo correlation  (IVIVC) and dissolution specifications (43) and other biorelevant 
information that will guide bioavailability and bioequivalent assessment of drug 
products (44, 45). For example, dissolution testing was used to understand and 
improve the prediction of in vivo dissolution and absorption of lipophilic compounds 
(46), poorly soluble weak bases (47) and several BCS Class 2 compounds (48). 
Similarly, the dosage-form related food effects for marketed nifedipine tablets that were 
previously observed in human bioequivalence studies could be predicted with 
dissolution testing (49). It is noteworthy that the stomach to intestine pH-shift can be 
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simulated in dissolution testing (such as with USP apparatus 4 with media change 
setup). A dissolution study at a single pH is not able to predict the performance of 
formulations of weak bases in vivo (50). For instance, a study demonstrated that the 
results of in vitro dissolution tests in an acidic medium and in vivo absorption for four 
solid dispersions of a poorly soluble weak base compound did not correlate well as 
faster release and increased supersaturation in an acidic medium correlated with lower 
bioavailability (51). Presumably, this effect can be explained by differences in the 
recrystallisation rate upon transfer to the small intestine (increased driving force for 
precipitation in case of higher supersaturation). 
 
As mentioned earlier, dissolution serves as an in vitro surrogate for in vivo 
bioequivalence studies by development of in vivo – in vitro correlation (IVIVC) which 
can be used to support a biowaiver, especially for BCS (Biopharmaceutics 
Classification System) Class I compounds. A biowaiver allows the use of dissolution 
results as a surrogate to bioequivalent results to prove bio-equivalence of formulation 
or effect of change in the manufacturing process. This approach minimises the cost 
and time of the drug approval process because dissolution testing is used instead of 
human study (41).  
 
1.2.2 Biorelevant dissolution method  
 
Biorelevant dissolution testing refers to the in vitro dissolution study utilising the 
dissolution media that mimic the conditions in the GI tract and the apparatus that can 
simulate the dynamic environments that the dosage form experiences in the GIT as 
well as evaluate the fate of the dosage form and active compound in the GI lumen (52). 
Thus, in comparison to dissolution methods used for quality control (QC) (compendial 
dissolution method), which at best simulate pH effects and/or osmolality on the drug 
release under in vivo conditions, biorelevant dissolution media are generally more 
complex and more predictive of in vivo dissolution (53).  
 
Under the current industry setting, the design of dissolution testing used for QC is 
primarily based upon the selection of discriminatory media, apparatus, and conditions 
that can be used routinely for QC purposes (53). Nevertheless, there is an increasing 
demand for the development of biorelevant dissolution methods that can provide some 
predictive estimates of the drug release with respect to the in vivo drug product 




In biorelevant dissolution testing, the experimental conditions represent and simulate 
the GI tract environment, thus this type of testing is predictive of complex in vivo 
dissolution behavior of poorly-soluble compounds (46, 54-56). Currently, a large 
number of different media are used, from water to various buffer solutions having 
different pH values as described in the USP monographs (42), biorelevant dissolution 
media (52, 57) and modified media which contain artificial surfactants such as SLS and 





1.3 The dissolution medium  
 
Literature has reported a wide range of dissolution media for simulating gastric and 
intestinal contents (60). Compendial media are simple aqueous preparations used to 
simulate mainly the pH and ionic strength of the fasted human GI compartments (54). 
The compendial media do not include surfactants and therefore are less likely to 
simulate the solubilisation and the wetting effect that occur in vivo because compounds 
which are sparingly water-soluble are solubilised in the body by endogenous 
surfactants such as bile acids, bile salts, lecithin, etc before the drug molecules are 
absorbed. Media containing artificial surfactant and biorelevant media (prepared using 
bio-surfactant, bile salt and lecithin) with more complex composition aimed to mimic 
osmolality, buffer capacity and surface tension of different GI segments were 
introduced at a later stage (60). 
 
1.3.1 Compendial media  
 
In the 1970’s two main compendial media were introduced in pharmacopeia (61). Such 
media mainly simulate the pH and ionic environment of gastric and intestinal 
environments (54).  
 
The first medium is used to simulate the fasted human stomach (simulated gastric fluid, 
SGF). SGF consists of an unbuffered aqueous sodium chloride solution with the pH 
adjusted to 1.2 with hydrochloric acid (Table 1). According to the United States 
Pharmacopeia, SGF could be prepared with or without the addition of pepsin (3.2 
mg/mL), an enzyme that exists in the human stomach (42). 
 
The second medium is formulated to represent the human fasted buffered intestine 
fluid (simulated intestinal fluid, SIF). SIF is a mixture of phosphate buffer and sodium 
hydroxide solution at pH 6.8 (Table 1). This medium can also be prepared with or 
without pancreatin (62). Pepsin and pancreatin play a minimum role in drug dissolution; 
nevertheless these enzymes could enhance dissolution of a cross-linked hard gelatin 
capsule (57, 62).  It is noteworthy that the concentration of pepsin indicated in the SGF 
described in the USP (3.2 mg/mL) (42) is too high compared with that in the basal 
gastric pepsin output in vivo (the upper limit of pepsin concentration is 0.8 mg/mL in an 






Table 1. Composition of SGF and SIF 
 SGF (42). SIF (42). 
NaCl (mM) 34.2 - 





Sodium hydroxide (mM)  15.4 
pH 1.2 6.8 
Surface tension (mN/m) 70 70 
Buffer capacity (mmol/l/∆pH) Not buffered 18.4±0.2 
Osmolality (mOsm/kg) Not reported 113 
 
1.3.2 Media containing artificial surfactant 
 
Bile salt used in biorelevant media presents some practical problems in terms of assay 
requirements and cost. Thus, for routine quality assurance, it would be favourable to 
exchange with synthetic surfactant systems that match the surface tension lowering 
and solubilisation properties of the natural surfactants (64). It is likely that the 
wettability of pharmaceutical materials may be different for bile salt compared to other 
surfactants, and currently there is no consensus as to which surfactants, and amount, 
should be used to accurately simulate in vivo behaviour (65). The use of synthetic 
surfactants such as SLS and HTAB in dissolution of poorly soluble compounds is 
expected to be more biorelevant to the in vivo situations than the addition of co-
solvents or hydroalcoholic media (38, 64). 
 
Sodium Lauryl Sulfate 
Sodium Lauryl Sulfate (SLS), also known as sodium dodecyl sulfate (SDS) 
(CH3(CH2)11OSO3Na (MW 288.38), is an ionic surfactant. The molecule has a tail of 12 
carbon atoms (Figure 3), attached to a sulfate group, giving the molecule the 




Figure 3. Chemical structure of SLS   
 
Hexadecyltrimethylammonium bromide  
 
Figure 4. Chemical structure of HTAB 
Hexadecyltrimethylammonium bromide or HTAB (C19H42BrN, Figure 4) has a molecular 
weight of 364.5 (67). It is a cationic surfactant and its activity is neutralised by soaps 
and anionic detergents, such as SLS. It is freely soluble in water (solubility 100 mg/mL) 
and is stable in acidic solution (67). 
 
 
1.3.3 Biorelevant dissolution media 
 
The biorelevant dissolution media (BDM) are designed with the aim of simulating the 
human physiological fluids for drug compound dissolution and solubility assessment 
(68).  
 
It is a well-known fact that better understanding of the intraluminal factors that affect 
dissolution in both fasted and fed state would allow a definition of more appropriate 
biorelevant media (29). For example, the biopharmaceutic scientists still need to know 
more about the influence of endo and exogeneous components such as bile salts, 
phospholipids and food digestion products on the rate and extent of intraluminal 








Physiologically the volume of gastric fluid in the fasted state is in the range of 15–50 
mL (70, 71). It was reported that average gastric pH ranges from 1.5 to 2.9 and its 
values vary among individuals (72, 73). Gastric fluid is hypo-osmotic (≤200 mOsm/kg) 
(72, 74, 75) and the main cation and anion is Na+ and Cl− respectively.  Literature 
suggests that the surface tension in fasted gastric fluids is in the range of 41.9-
45.7mN/m, lower than water (approximately 70 Nm/m) (73). It was reported that pepsin 
can only partly be responsible for this reduced surface tension because it is not able to 
reduce the surface tension to less than 55 Nm/m (46). Thus the presence of low 
amounts of bile salts, refluxed from the duodenum, or lyso-phospholipids, from 
breakdown of gastric mucosal cells might explain the low surface tension in the 
preprandial state (76). 
Furthermore the pH of the SGF medium is only 1.2, an acidity level that is rarely 
observed even in young healthy volunteers (especially after the ingestion of a glass of 
water). Values between 1.5 and 2.5 are more the norm in such subjects. In order to 
tackle this issue, fasted-state simulated gastric fluid (FaSSGF) as a dissolution medium 
simulating the preprandial stomach was developed. This medium has a pH of 1.6 with 
34.2 mM NaCl, 0.1 mg/mL pepsin, 80 μM bile salts and 20μM lecithin. The medium has 
a surface tension of 42.6 mN/m and osmolality of 120.7±2.5 mOsmol/kg which are 





It is a challenge to establish appropriate but easy to work dissolution media for 
simulating the fed-state stomach. Firstly, conditions in the stomach after meal intake 
can vary largely, depending on meal type. Initially, the composition of the gastric fluids 
will be close to the composition of the meal with regard to pH, osmolality and surface 
tension. Over time, with secretion of gastric juices and following gastric emptying, 
values will return to those of the fasted state (73). A study has suggested that the 
capacity of the human stomach is 1–1.6 L (77). The time to return to fasted state 
values has been reported to be between 1 and 4 h, depending on the composition and 




Milk (3.5% fat) has been used to simulate fed conditions in the stomach because it 
contains nutrients comparable to a typical western diet (80, 81). The surface tension of 
milk decreases with increasing fat content (up to 4% fat); for example the surface 
tension of skimmed milk and whole milk are 52.5 and 47.5 mNm-1 respectively (82). 
These values are much higher than the surface tension of the fed stomach of a human 
(30-31 mNm-1(83)). Furthermore, milk has much lower osmolality and buffer capacity 
values than a homogenised meal, making it less suitable as a fed state simulated 
gastric fluid (84). Milk has a pH of about 6.5 and research has shown that it might be 
too high for the later stages of gastric digestion, even for the initial post-prandial state 
(76). Generally, milk and/or nutritional liquid products can be used only for simulation of 
initial gastric conditions in the fed state because the composition of the stomach 
contents in the fed state changes with time as secretions, digestion and gastric 
emptying proceed. Under in vivo conditions, lipids and casein micelles in the milk are 
partly digested during gastric residence, so the addition of enzymes might simulate the 
physiological conditions even closer (76). 
Later on, researchers proposed to change intragastric composition through a gradually 
digesting milk technique (63, 85) and to use “snapshot” milk-based media to represent 
the changing composition of gastric content (57) (Table 2). Both techniques use 
homogenized long-life milk (3.5% fat) as the initial liquid medium. The lower nutrient 
content of milk compared to nutritional liquid products provides closer simulation of the 
intra-gastric conditions, where significant secretions (dilution of meal) take place. In 
addition, the ratio of carbohydrate/protein/fat in milk is close to that observed in the 
stomach of healthy volunteers after the administration of meals typically administered 
in BA/BE studies in the fed state (73). 
 
The first technique establishes the concept of gradual digestion of the meal during the 
dissolution experiment (63). The initial medium is homogenized long-life milk (3.5% fat) 
which is gradually digested by integrating physiologically relevant amounts of a 
hydrochloric solution (1.83 M) containing 1.1 mg of protein (pepsin) per mL into the 
vessel every 15 min from 0 to 90 min. This concept of digestion of milk was modified in 
this current project with the aim of testing the effect of digested protein (as observed in 
the fed human stomach) to the dissolution of one of the model compounds, ITR. The 
study was modified by changing the milk (pH 7.5) with early FeSSGF (a milk solution 
with the ionic strength adjusted using sodium chloride and pH adjusted to pH 6.4) 















Sodium chloride (mM) 148 148 237.02 122.6 
Acetic acid (mM) - - 17.12 - 
Sodium acetate (mM) - - 29.75 - 
Ortho-phosphoric acid (mM) - - - 5.5 
Sodium dihydrogen phosphate (mM) - - - 32 
Milk : buffer 1: 0 1: 0 1: 1 1:3 
1.83 M HCl aq solution containing 
1.1mg/ mL pepsin 
- Addition of 1 
mL/15min 
- - 
Diluted HCl qs pH 6.4 - - - 
pH 6.4 Gradual 
reducing to pH 
1.5 
5 3 
Osmolality (mOsmol/kg) 559  10 No data 400  10 300  10 
Buffer capacity (mmol/l/pH) 21.33 No data 25 25 
Surface tension (mN/m) 49.7±0.3 No data 52.3±0.3 58.1±0.2 
 
 
In the second technique, three “snapshot” media were composed, each one 
corresponding to a certain post prandial timeframe (57). Medium composition was 
designed in order to reflect the pH value, buffer capacity and osmolality of the gastric 
contents during the first 75 min (early), from 75-165 min (middle) and after 165 min 
(late) following meal ingestion. Table 2 summarizes the composition of these media. 
The “middle” medium Fed State Simulated Gastric Fluid (FeSSGF) is considered as a 
representative of after food conditions for comparing formulations and/or predicting 
food effects compared with FaSSGF (57). 
 
Therefore fed-state simulated gastric fluid (FeSSGF) can be used to observe food 
effects in the stomach (86). It contains UHT-milk and acetate buffer mixed in equal 
volumes and has a pH of 5.0 (53) (Table 2). This medium nearly represents the gastric 
conditions observed in the 75 to 165 min time frame, postprandially. For example, a 
recent study has shown that the percentage dissolved of a lipid-based formulation of 
RZ-50 (a weakly acidic BCS class 2 drug with a pKa of 4.31) in FeSSGF with USP 









The pH of the GI fluids changes from acidic to neutral within a distance of a few 
centimetres when shifting from the stomach to the duodenum. Average pH values 
between 6 and 7.1 have been observed for the fasted duodenum and upper jejunum, 
bicarbonates being the principal species responsible for the buffer capacity (72, 73, 79, 
88). Osmolality is increased compared to the gastric fluids (270 mOsm/kg), with Na+ 
and Cl− still the dominant ions (72). 
 
Bile is supposedly only secreted as a response to food intake, but the fasted small 
intestine also contains low amounts of bile, which are partly responsible for the low 
surface tension (between 30 and 34mN/m) (73, 75). In human small intestinal fluids, 
mean values between 1.5 and 3mM bile salt have been reported under fasted 
conditions (89-91). Bile salts are secreted together with phospholipids, primarily 
phosphatidylcholine. In the fasted state, the ratio between bile salts and phospholipids 
have been reported to be between 2:1 and 10:1 in the intestinal fluids (90, 92).  
 
Subsequently, Dressmann and co-workers (54, 59) suggested a biorelevant medium, 
simulating the fluids in the fasted small intestine (FaSSIF-V1, Table 3). Since then, 
FaSSIF-V1 has been widely used in dissolution studies and to determinate the 
biorelevant solubility, both in industry and academia. The composition of FaSSIF-V1 
was developed by taking into consideration pH, osmolarity, buffer capacity and 
solubilizing capacity of the fluids in the fasted upper small intestine. Phospholipids such 
as lecithin are added in a 1:4 molar ratio to taurocholate, which is within the 
physiological relevant range. However, it must be noted that even with the addition of 
bile salt and lecithin the surface tension of both FaSSIF-V1 is much higher than the 
surface tension of human intestinal fluids (HIF) (54 vs 33.6 mN/m) (64). 
 
As research progressed, Jantratid et al. improved the composition of FaSSIF-V1 with 
some modifications and proposed FaSSIF-V2 (57). The amount of lecithin was 
decreased from 0.75 mM in FaSSIF-V1 to 0.2 mM in FaSSIF–V2, osmolality was 
lowered and a maleate buffer was used instead of a phosphate buffer (Table 3). 
Physiologically, the principal buffer compound in the fasted small intestine is the 
bicarbonates but it is problematic to use in a medium due to the constant need of 
sprinkling with carbon dioxide to maintain the desired pH, buffer capacity, ionic strength 
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and osmolality (93). Thus buffers are selected mainly according to their ability to 
achieve the desired combination of pH, osmolality and buffer capacity (57, 94). 
 
Table 3. Composition of the media to simulate the contents of the small intestine in the fasted 
state. 
 FaSSIF-V1 (62) FaSSIF-V2 (57) 
Sodium taurocholate (mM) 3 3 
Lecithin (mM) 0.75 0.2 
Dibasic sodium phosphate (mM) 28.65 - 
Maleic acid (mM) - 19.12 
Sodium hydroxide (mM) 8.7 34.8 




pH 6.5 6.5 
Osmolality (mOsmol/kg) 270  10 180  10 
Buffer capacity (mmol/L/pH) 12 10 







Similar to the fasted state in the stomach, the compositions of the fluids in the upper 
small intestine during the fed state will also be dependent on the type of food ingested 
but to a lower extent than in the stomach. Upon arrival in the duodenum, the chyme is 
mixed with bile and pancreatic secretions, both being slightly alkaline, which results in 
a pH in the duodenum to be in the range of 5.5 to 6.5; this is slightly lower than in the 
fasted state (73, 88, 90). 
Large fluctuations in the pH are observed in the proximal duodenum, but the 
fluctuations diminish when the chyme moves along the small intestine. In addition, 
there is a pH gradient which increases between the duodenum and the ileum (79). As a 
consequence of chyme and intestinal secretions, both buffer capacity and osmolality in 
the intestinal fluids have been reported to increase after meal intake. Values of 
approximately 18-30 mmol/L/pH and 300–400 mOsm/kg during the first 2 h after a 
meal have been reported for the buffer capacity and the osmolality, respectively (73). 
In contrast, surface tension does not change significantly between fasted and fed state 
(73, 90).   
Further studies have confirmed that food-induced bile secretions result in bile salt 
levels in the small intestine between 8 and 20mM with single measurements up to 
40Mm (95-97). The molar ratio between bile salts and phospholipids in the fed state 
will be dependent on the phospholipid level in the food and has been reported to be in 
the range of 2:1 to 5:1 (98). 
Together with FaSSIF-V1 mentioned above, a fed state simulated intestinal media 
(FeSSIF-V1) was developed (62). FeSSIF-V1 simulates the fluids in the fed upper 
small intestine in terms of bile salt and phospholipids levels, pH, osmolarity and buffer 
capacity. The pH was set at 5.0, which is in the lower end of what has lately been 
reported in the literature (83). By the addition of sodium chloride, the osmolality is 
adjusted to 635±10 mOsm/kg, and acetic acid is added to maintain a higher buffer 
capacity of 76 mmol/L/pH, both values aiming at simulating the fed state.  In vivo, the 
main buffer capacity probably originates from the food components, like generated 
peptides and amino acids (76). 
Like FaSSIF-V1, taurocholate is used as bile salt in FeSSIF-V1. The ratio between the 
bile salt and phospholipids is kept at 4:1, even though ingested food often contains 
phospholipids that will decrease this ratio (76). FeSSIF-V1 was found to be suitable for 
a qualitative prediction of formulation and food effects for a series of compounds tested 




As a comparison to FaSSIF-V1, FeSSIF-V1 has lower pH (pH 5) and higher ionic 
strength. Both these factors can also impact drug solubility and dissolution. Mefenamic 
acid, an analgesic agent with a log P of 5.3 and a pKa of 4.2, has a better dissolution in 
FaSSIF-V1 compared to FeSSIF-V1 since the drug is more soluble at pH 6.5 than 5.0 
(62). On the other hand, troglitazone, an antidiabetic drug, which is also a weak acid 
with pKa values of 6.1 and 12.0, shows a significantly improved dissolution in FeSSIF-
V1 compared to FaSSIF-V1 (99). Whether the bioavailability of troglitazone is 
dependent on food intake has not yet been published, but bioavailability of mefenamic 
acid has been shown to be independent of food intake (101) indicating that a 
comparison between dissolution curves in FaSSIF-V1 and FeSSIF-V1 might be 
predictive for in vivo behaviour. Charman et al. observed a three-fold increase in 
danazol bioavailability upon food intake (102) and it was closely simulated by using 
FaSSIF-V1 and FeSSIF-V1 as dissolution media; whereas compendial media 
incorrectly suggested the absence of a food effect (62). FeSSIF-V1 is considered a 
reasonable starting point for assessment of food effects on drug dissolution in the small 
intestine. However, it does not account for the presence of lipolytic products (free fatty 
acids and monoglycerides) from dietary or formulation triglycerides in the intestine and 
may underestimate dissolution of lipophilic compounds (99). 
As discussed in the fasted state, Jantratid et al. (57) modified the composition of 
FeSSIF-V1 based on recent studies related to the characterization of the fed intestinal 
contents under conditions simulating BA/BE (73), indicating that the pH in the upper 
small intestine decreases slowly after meal intake (57). In the updated media (FeSSIF-
V2), the presence of lipolysis products (glyceryl monooleate and sodium oleate) were 
taken into account in the fed intestinal contents which also contributes to the surface 
tension of 40.45 mN/m, a value close to the aspirates (32.2-36.7 mN/m (103)). On the 
other hand FeSSIF-V1, which does not contain a lipolysis product, has a surface 
tension of 46.3 ±0.1 mN/m (104). 
 
As with the biorelevant media simulating the contents of the stomach, FeSSIF-V2 
(Table 4) is suggested as a representative of postprandial conditions in the small 
intestine for comparing formulations and/or predicting food effects compared with 







Table 4. Composition of the media to simulate the contents of the small intestine in the fed state 
 FeSSIF-V1 (62) FeSSIF-V2 (57) 
Sodium taurocholate (mM) 15 10 
Lecithin (mM) 3.75 2 
Glyceryl monooleate (mM) - 5 
Sodium oleate (mM) - 0.8 
Acetic Acid 144 - 
Maleic acid (mM) -- 55.02 
Sodium hydroxide (mM) 101 81.65 
Sodium chloride (mM) 173 125.5 
pH 5.0 5.8 
Osmolality (mOsmol/kg) 63510 390  10 
Buffer capacity (mmol/l/pH) 76 25 
Surface tension (mN/m) 47.4 40.45 
 
1.4 Types of hydrodynamics  
 
Dissolution testing plays such an important role in the pharmaceutical industry that an 
individual chapter describing the types and detailed specifications of dissolution 
apparatus has been included in United States Pharmacopoeia (42), European 
Pharmacopoeia (105) and Japanese Pharmacopoeia (106). 
 
Wide variations in the hydrodynamic conditions can be obtained through the use of the 
four different USP test methods: the rotating basket (USP apparatus 1), the rotating 
paddle (USP apparatus 2), the reciprocating cylinder (USP apparatus 3) and the flow-
through cell (USP apparatus 4) (42). In addition, different conditions can be obtained 
within one apparatus by changing the stirring rate, reciprocating frequency, or flow rate. 
The USP apparatus 2 is the most widely used dissolution method. Despite the simple 
design of the USP paddle dissolution apparatus, the hydrodynamics are complex and 
likely to be variable at different sites in the vessel (107) as different fluid velocities exist 




1.4.1 USP apparatus 1 (Basket apparatus) and USP apparatus 2 (Paddle 
apparatus) 
 
In the 1970’s United States Pharmacopoeia first introduced USP apparatus 1 and 2 as 
official testing apparatuses and a number of monographs were used to determine 
compliance with dissolution requirement for a formulation. Since then the USP 
apparatus 1 and 2 have become the most commonly used in the modern 
pharmaceutical laboratory (61). The basic components of the USP apparatus 1 and 2 
are shown in Figure 5 and the set-up of the systems are standardised to the major 
references such as USP (42), British Pharmacopoeia (109) and the European 
Pharmacopoeia (105). 
 
Figure 5. Schematic diagram of the USP appratus 1 and 2. 
 
USP apparatus 1 is used for dosage forms that tend to float or disintegrate slowly, for 
example capsules and powders; these dosage forms can be held inside the basket, 
whereas USP apparatus 2 is normally used for tablets which are placed on the bottom 
of the vessel. The dissolution vessel is cylindrical with a spherical bottom which is used 
to hold the dissolution medium. The vessel is filled with a fixed volume of media to 
which the formulation is exposed throughout the experiment (42). 
 
1.4.2 USP apparatus 4 (Flow through cell apparatus) 
 
Chapter <724> USP 29 (42) describes the dimensions and test method of flow through 




Figure 6. Schematic diagram of the USP appratus 4, the inset shows the components 
of the flow-through cell 
 
The apparatus consists of a reservoir containing a dissolution medium, a pump that 
forces the medium upwards through the vertically positioned flow-through cell, and a 
water bath. Generally the bottom cone of the cell is filled with small glass beads of 
about 1 mm diameter and a ruby ball of about 5 mm diameter is placed at the bottom of 
the cell acting as a check valve and prevents glass beads from blocking the cell 
channel. A filter (often a glass fibre filter) is positioned at the inner top of the cell 
(Figure 6). The filter only allows the dissolved particles to pass through and keeps the 
undissolved particles within the cell. Normally single or combination filters of different 
pore sizes are used to optimise the filtration.   
 
The USP requirement for the pump is to deliver 4.0 mL, 8.0 mL and 16.0 mL per 
minute at 120 strokes with an accuracy of ±5%. In order to achieve this requirement 





1.5 Surface UV dissolution imaging 
 
Literature has shown that surface ultraviolet (UV) dissolution imaging is very useful in 
characterising active compounds and their formulations because the captured images 
illustrate the concentration distribution of drug compounds, which can be translated into 
the amount and rate of drug dissolution (110-115). The surface UV dissolution imaging 
is possible because most pharmaceutical drug substances contain a UV chromophore. 
The intensity of the measured light is converted to absorbance, creating a high-
resolution, real-time 2D absorbance and concentration map of dissolution events within 
the flow cell which presents a detailed view of the dissolution process occuring on the 
surface of the drug compact (116). The data can then be processed for measurement 
of the intrinsic dissolution rate (IDR) of the active compound, with the whole process 
typically taking around 20 min (117). Using surface UV imaging mechanistic 
information such as swelling of the formulation, particle release and dissolution can be 
obtained. The ActiPixTM Surface Dissolution Imager system (SDI) and the operational 
and mathematical principles are discussed in this section. 
 
1.5.1 Operational and intrinsic dissolution rate (IDR) of ActiPixTM 
 
The ActiPixTM SDI 300 (Paraytec Ltd., York, UK) comprises a sample flow cell, syringe 
pump, UV lamp and detector, and control and data analysis system. A single 
wavelength of light enters the flow cell while the dissolution medium is pumped into the 
cell at pre-set rates. The sample surface is parallel to the buffer flow but perpendicular 
to the light and camera creating a 4 dimensional array ( X,Y, intensity, time) which is 
used to extract data in and around the solid-liquid interface. The UV light transmission 
through the flow through cell is recorded by the camera chip behind the flow cell. The 
effluent will then leave the flow cell downstream from the sample surface via the waste 






Figure 7. Photograph of ActiPix
TM
 SDI 300 dissolution imaging system and the experimental UV 
imaging apparatus setup schematic (Reproduced with permission from (116)). 
Meanwhile, ActiPixTM software uses validated equation reported in literature to 
calculate the intrinsic dissolution rate (IDR; mass/time/area: unit in mg/min/cm2) (116, 
117). IDR values are calculated from the velocity at z (z, distance perpendicular to the 
surface horizon) and the drug concentration in the measurement zone (shown in Figure 
7) using Equation 2. 
 
                                                        
∑         
   
   
 
    Equation 2 
Where vz = velocity at z, M = molecular weight, cz = concentration at z, W = width of 
flow cell, ∆z = effective pixel height, S = surface area of sample, H = height of flow cell 




1.5.2 Applications and advantages of surface UV dissolution using ActiPix™ 
technology 
 
The ActiPix™ SDI300 is a multipurpose UV area imaging system which enables 
quantitative imaging of surface dissolution for various dosage forms such as active 
compound (110, 112, 114), transdermal patch (111), crystal (113), gels (118), polymer 
(119), cocrystal (120, 121) and oily liquid (122, 123). Using this system, temporal and 
high resolution spatial data from the solid-liquid interface can be observed. 
Measurement of this dissolution process offers insight into surface events such as 
boundary layer thickness, static diffusion rate, boundary layer gradient, surface 
concentration, contour distribution, concentration gradient profiles, and surface 
changes from swelling or gelling (124).  
 
The ActiPixTM SDI300 also supplies special insights into processes occurring in 
microns to millimetres from the surface, the crucial distance range for recognizing 
dissolution. It enables both disintegration and dissolution to be visualised 
simultaneously (117). For example, before the dissolved material is diluted when 
transported to the bulk solution, the highest concentration achievable from a drug 
compound is directly at the surface. By selecting the corresponding chromophore 
wavelength, the concentration of the tested compound can be determined in the 
immediate vicinity of the sample. 
 
Moreover, the dissolution medium can be changed easily (for example from simulated 
gastric medium to simulated intestinal medium) that will reveal the effect of medium 
(pH and buffer) and hydrodynamics (flow rate) to the precipitation and dissolution of the 
tested compound. The resulting images with media change setup may increase the 
understanding of the in vivo dissolution process, which may also increase the 
predictive ability of this dissolution test method. Owing to the fact that the flow cell 
volume is small, flow rate changes can be rapidly achieved. For example, the flow rate 
can go from high velocity (4 mL/min) down to no velocity (static, 0 mL/min) instantly. 
Similarly, the low volume also means that less dissolution medium is required. For 
example, for an experiment running at 1 mL/min for 20 min, a mere 20 mL of medium 
would be used. It is cost-effective when expensive media such as biorelevant media 
are used. The dissolution setup is very useful for screening potential drug compounds 
during the pre-formulation stages because the intrinsic dissolution rates can be 
obtained in less than 20 min compared to 24 h equilibrium IDR using the traditional 






1.6 Oral Drug Absorption and PBPK modeling 
 
1.6.1 Parameters to be considered in drug absorption modeling 
 
Drug absorption from the human GIT is a very complex process (53). Parameters to be 
considered in drug absorption modeling can be divided into four categories: (1) 
Physiological (2) Biochemical (3) Physicochemical and (4) Dosage form and 
formulation parameters. The first and second categories consist of physiological 
parameters of the GIT  such as gastrointestinal pH, gastric emptying, small intestinal 
transit time, active transport and efflux as well as gut metabolism (125-127). The third 
category represents physicochemical parameters of the drug such as pKa, solubility, 
stability, diffusivity and lipophilicity. The last category comprises formulation related 
parameters such as drug particle size, crystal form, surface area and type of dosage 
form such as tablet, capsule, solution, suspension (125, 126).  
 
 
1.6.1.1 Physiological parameters 
 
The human GIT physiology allows maximum drug absorption in the small intestine, 
mainly due to the vast presence of villi and microvilli in the small intestine cell lining 
that provide large surface area and blood flow. For example, the surface area of the 
small intestine is approximately 200 m2 and an estimated 1 L of blood is pumped 
through the intestinal capillaries each minute. To contrast, the corresponding estimates 
for the stomach are 1 m2 and 0.15 L/min (128). Once the drug compound is emptied by 
the stomach to the small intestine, then the fate of the drug compound depends on the 
motility pattern (in vivo hydrodynamics) and small intestine transit time which determine 
the exposure of the drug to the absorption site.  
Meanwhile, in order to reach the blood circulation, dissolved compounds have to pass 
a physical barrier, consisting of a mucous layer and the intestinal monolayer of 
enterocytes (Figure 8). Molecules (both nutrients and xenobioitics) can cross this 
monolayer via the paracellular (intercellular) or transepithelial (transcellular) route 
(Figure 8). As the intercellular space is very limited (e.g. 0.8 nm in human jejunum, 0.3 
nm in human colon) due to the presence of tight junctions between the enterocytes, 
only small, highly hydrophilic molecules can use the paracellular route (129). However, 
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most drug molecules cross the monolayer through transepithelial transport following 
simple passive diffusion (130). 
The absorbed drugs will be transported via the blood circulation to the liver where 
certain drugs will be metabolised during the hepatic first pass metabolism. Some drugs 
will undergo degradation and precipitation inside the lumen. Subsequently, the drug 
compound will go to the colon where minimum drug absorption takes place.  The 
processes involved are illustrated in Figure 8. 
 
Figure 8. Schematic illustration of intestinal drug absorption processes. 
 
The various physiological parameters that could affect the intestinal drug absorption 
can be classified as organic (related to GI organ system) parameters (e.g., gastric 
emptying, intestinal motility patterns, GI transit time, GI fluids characteristics (volume, 
osmolality, pH, buffer capacity) and biochemical parameters (e.g., GI and liver enzyme 
metabolism, efflux transporters and active uptake transporters) (126, 131-133). 
 
1.6.1.2 Biochemical parameters 
 
Apart from serving as a physical barrier, the intestinal epithelium also behaves as a 
biochemical (metabolism and efflux) barrier for the permeated drug molecules. Both 
the GI lumen and the intestinal enterocytes behave as a site of drug metabolism as 
they contains numerous enzymes, including esterases, phosphatase and cytochrome 
P450 (CYP450) isoenzymes. They may play an important role in the absorption of 
prodrugs and may limit oral absorption of substrate compounds of CYP3A isoenzymes 




Transporter-mediated uptake and elimination 
 
Intestinal efflux may affect the absorption of various compounds by the active secretion 
of molecules from epithelial cells into the luminal or serosal side of intestine. These 
transporters have broad substrate specificity and can be found in other organs as well, 
resulting in various effects on drug disposition. Thus, approximately 400 membrane 
transporters had been identified in human genomic study. 
Examples of efflux transporters in the apical membrane of epithelial cells include P-gp, 
multi drug resistance-associated protein 2 (MRP2) and breast cancer resistance 
protein (BCRP) and ATP-binding cassette (ABC) proteins (134, 135). P-gp is an efflux 
transporter belongs to the ABC family. P-gp is considered to be a main contributor of 
non-linear absorption kinetics of many compounds (136). In the intestine, P-gp 
mediated efflux can reduce the bioavailability of drugs that are administered orally 
(137). Due to its very broad substrate specificity, P-gp mediated transport processes 
have been reported for a variety of drugs including: vincristine, vinblastine, doxorubicin, 
daunorubicin, etoposide, paclitaxel, cyclosporine A, ketoconazole, verapamil, and 
digoxin (138). Many newly marketed drugs had been tested to be substract of P-gp, for 
example UK-343,664 (Pfizer Inc.) (136) and PLX4032 (Roche Inc.) (139). 
 
 
Cytochrome P450 metabolism  
 
Cytochrome P450 is a haem-containing superfamily of enzymes which includes 
isoenzymes that metabolise exogenous substrates including absorbed drug molecules. 
The CYP3A subfamily constitutes about 20% of CYP content in the liver and 50-70% of 
CYP content in the intestine. In humans, it has been shown that CYP3A4 is the most 
important Phase I enzyme involved in drug metabolism in the sense that approximately 
50% of marketed drugs are CYP3A4 substrates (140).  Thus, if a drug is strong CYP3A 
isoenzymes enzymes substrates, significant first-pass metabolism by the intestinal wall 
and hepatocytes could have a significant impact for its bioavailability (141). 
 
Although the liver has long been thought to play the major role in drug 
biotransformation, the metabolic capacity of the intestine is increasingly recognised. 
Several in vivo studies have demonstrated that significant first-pass metabolism by the 
intestinal wall has implications for the bioavailability of many drugs (142, 143).  
Furthermore, the relevance of drug transporters in this process has been proven (143). 
Similarly, intestinal metabolism can result in a non-linear absorption kinetic behaviour 
that is mainly attributed to saturation of the intestinal metabolism, which will be 
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associated with a non-linear appearance in the mesenteric blood, rather than a 
saturable intestinal absorption from the lumen (144).  
 
CYP3A4 and P-gp interplay of drug metabolism and efflux in the intestine 
 
CYP3A and P-gp overlap in substrate specificity and both are commonly localised near 
the apical membrane of enterocytes (145, 146). It has been hypothesised that for many 
drugs, the combined activity of CYP3A and P-gp increases efficiency of intestinal first-
pass metabolism of orally administered drugs as a result of a potentially synergistic 
collaboration (147, 148).  
Two mechanistic arguments have been brought forward to support a possible 
synergistic action of intestinal P-gp and CYP3A. First, the function of P-gp would lower 
the enterocyte intracellular concentration of a substrate drug and might thus prevent 
saturation of the CYP3A enzymes by keeping the concentration more within the linear 
range of the enzyme metabolising capacity. Consequently, a larger fraction of the 
intracellular drug can be metabolised, without increasing the speed of metabolism. P-
gp activity would simply afford CYP3A more time to metabolise its substrates 
extensively. Thus, P-gp would allow CYP3A to efficiently metabolise drugs over a far 
higher dose range (145). Second, it has been suggested that the efflux function of P-gp 
combined with subsequent drug re-uptake may allow drug substrates to have repeated 
and therefore prolonged access to enterocyte CYP3A, thereby increasing the 
possibility that a drug will be metabolised. This repeated cycling of drugs would 
increase the total metabolism, even without considering saturating or non-saturating 
conditions for CYP3A4 (149, 150).  
 
Successful prediction of the interplay between P-gp and CYP34 for their substrate 
compounds (e.g., CX and ITR) on intestinal absorption could be one of the critical 
factors in PBPK modeling. Thus, in this project it was intended to elucidate the 
contribution of interplay between P-gp and CYP3A in the non-linear absorption kinetics 
of ITR and CX (model compounds used in this project) using PBPK modeling. 
 
1.6.1.3 Drug physicochemical parameters 
 
Solubility and intestinal permeation are important physicochemical parameters that 
affect the rate and extent of absorption of an oral drug product. However, drug 
solubility and permeability are not intrinsic properties of drug compounds and will be 
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influenced by formulation parameters and gastrointestinal variables. They are of course 
related to more fundamental physicochemical drug properties, including crystalline or 
amorphous form, lipophilicity, pKa, hydrogen-bonding capacity, molecular surface area 




The pH dependent solubility and stability of a drug plays an important role in its 
absorption. In order to permeate across the biological membrane, drug molecule 
(especially BCS Class 1 and 2 compounds) must be in a solubilised, stable and 
unionised form (135). Differences in regional pH can affect solubilisation or provide an 
environment for degradation of the drug (83). This is why understanding the ionisation 
properties of a drug candidate are essential for the absorption potential. Most of drugs 
are weakly acidic or weakly basic compounds that cannot be ionised completely in 
aqueous media. Dissolution of ionised drugs is greatly dependent on the pH of the 
medium which is generally described by Henderson-Hasselbach equation which 
correlates pH and drug ionisation for weak acids and weak bases. For example, poorly 
soluble weak bases dissolve more readily in the stomach fluid (pH 1.6-3) than in the 
intestinal fluid (pH 6-7) (83). This can result in supersaturation as the drug moves from 
acidic to basic conditions. Upon the movement to basic pH, the degree of ionisation 




Permeability is a parameter that reveals the degree of a solute penetration into a 
membrane over a specific time span. It is expressed in velocity units length per time 
(133, 151). The permeability is the main parameter used for the quantification of a drug 
compound's penetration capacity across the biological membrane layers. Effective 
permeability (Peff) quantifies permeability across the intestinal membrane. Peff depends 
on properties of the drug and the membrane. It is referred to as “effective” because it 
characterises absorption whether by passive diffusion, active transport, facilitated 






1.6.1.4 Dosage form and formulation parameters 
  
The type of dosage form such as immediate release, enteric coated, modified release 
and formulation such as amorphous, micronised and lipid based delivery system would 
determine the scale and extent of drug release and dissolution (152). For example 
immediate  release formulations are designed to be absorbed quickly, whereas 
modified release formulations are produced with controlled release profiles in different 
compartment of GIT (153) . Furthermore various excipients can be used to in order to 
produce desired dissolution profiles. For instance, disintegrants such as lactose helps 
to break the tablet apart. Wetting agents such as SLS can be added to the formulation 
to aid the penetration of water into the tablets.  
 
With the advancement of drug delivery system, poorly soluble compounds can be 
formulated as a nanosuspension, cocrystal complexes, salt form and amorphous 
formulation in order to improve bioavailability (154). In this project, the main focus is on 
amorphous formulations which the details on the amorphous formulation 
characteristics is discussed in Section 2.3. 
 
1.6.2 PBPK modeling 
 
1.6.2.1 Physiologically-based pharmacokinetic (PBPK) models for the prediction 
of oral absorption 
 
The advent of computer science catalysed the advancement of theoretical models 
capable of predicting oral drug absorption in humans (155-157). Once the drug is 
absorbed, its metabolism and excretion out of body compartments is an important 
factor for drug bioavailability. The Absorption-Distribution-Metabolism-Excretion 
(ADME) of a drug is a complex process. Advanced PBPK (physiological based 
pharmacokinetics) tools have the ability to generate plasma-concentration time profiles 
for the drugs, with detailed information about fraction absorbed across the apical 
membrane of the enterocytes (fa), fraction of the absorbed dose that is not metabolised 
in the gut wall (fg) and drug availability in the central compartment.  
 
There are a few commercially available programmes based on the physiologically-
based pharmacokinetic models such as Simcyp™ by Certara Inc. (158), PK-Sim™ by 
Bayer Inc. and GastroPlus™ by Simulations Plus Inc. (159). These software packages 
use physiologically based models, which try to account for all known factors influencing 
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the oral drug absorption and to predict the behaviour of a drug molecule interaction 
with the body system using mathematical approaches (160, 161). 
 
1.6.2.2 Advanced Compartmental Absorption and Transit (ACAT) model 
 
Dissolution and permeation are the major factors governing the rate and extent of drug 
absorption. Developing reliable PBPK models for the prediction of in vivo dissolution 
and absorption of orally administered compounds will significantly improve and 
expedite the drug discovery and development process (126, 162).  
 
In the ACAT model, the GIT is divided into nine compartments and the drug release, 
dissolution, precipitation, absorption and transit across the compartments are all 
described by specific integrated or differential mathematical equations. The estimation 
of fraction of drug absorbed through the gastrointestinal mucosa in GastroPlus™ is 
based on the ACAT (advanced compartmental absorption and transit) model (126, 
163). The mathematical models/equations take into account the physicochemical 
properties of the drug under study, e.g. pKa, solubility, diffusion coefficient and 
effective permeability; and the physiological variables e.g. pH, transit times, volume, 
length, enzymes and transporter proteins (influx/efflux) affecting drug absorption (161, 
164, 165). 
 
The model also includes linear transfer kinetics and non-linear metabolism transport 
kinetics, six states of drug component (unreleased, undissolved, dissolved, degraded, 
metabolised, and absorbed) and three states of excreted material (unreleased, 
undissolved, and dissolved). The unreleased row of sub-compartments is used only for 
controlled release dosage forms. For controlled release, the drug can be released into 
solution (dissolved) or as solid particles (undissolved). Undissolved material transits 
and dissolves to give dissolved material. Dissolved material undergoes transit, luminal 
degradation, absorption and may potentially precipitate back to undissolved material if 
its concentration exceeds the local solubility within a particular compartment. The 
undissolved (solid particles) and dissolved (drug in solution) drug undergoes linear 
kinetics transit through the GIT (126, 162). For tablet dosage forms, if a tablet was not 
absorbed before the end of the transit process, the drug would eventually be excreted 




Figure 9. Schematic of ACAT model interpretation of in vivo drug behaviour. This diagram 
illustrates a total of nine compartments, each of which is divided into four sub-compartments: 
unreleased, undissolved, dissolved, and enterocyte. 
 
In Figure 9, each arrow represents a process, hence a differential equation. Besides 
the dissolution process, all other processes (carrier-mediated transport in the gut, gut 
metabolism and liver metabolism) are taken into account as being linear processes. 
The transit of any form of material (unreleased, undissolved or dissolved) is permitted 
only to the same sub-compartment of the next compartment: undissolved material can 
only transit into the next compartment's undissolved sub-compartment. Modifications in 
form (unreleased to undissolved or dissolved, undissolved to dissolved, and dissolved 
to absorbed, undissolved, or degraded) are exclusively permitted to take place within a 
compartment (162, 164). Drug absorption can be passive and driven by the 
concentration gradient across the apical barrier or mediated by influx and efflux 
transporters in the enterocytes. The absorbed drug can also be subject to metabolism 
in the enterocytes. In GastroPlusTM, the enterocytes act as well-mixed tanks where 
efflux, basolateral transport and gut metabolism compete for the drug (126, 164). Once 
the drug crosses the basolateral intestinal barrier, it reaches the portal vein and then 
the liver. First pass extraction and systemic extraction of the drug both take place in the 
liver. The drug escaping metabolism reaches the systemic circulation from where it will 
be distributed to peripheral compartments following the compartmental 
pharmacokinetics model. Meanwhile, renal and other forms of elimination can occur 
from the central and peripheral compartments (126).  
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1.7 In vitro-in vivo correlations/relationships (IVIVC/Rs)  
 
Dissolution is the rate limiting step in absorption for Biopharmaceutics Classification 
System (BCS) class 2 and class 4 compounds which exhibit low solubility (48). 
Appropriate selection of in vitro conditions (media and hydrodynamics) that simulate 
the in vivo conditions can lead to the development of successful in vitro-in vivo 
correlations (IVIVC) (54, 166). An established IVIVC can be further used to set 
meaningful dissolution specifications that take clinical consequences into account in 
the hope of facilitating regulatory approvals of post approval changes (167) and Quality 
by Design (168). 
For the last three decades, there has been considerable interest within the 
pharmaceutical industry, academia, and regulatory sectors in in vitro-in vivo 
correlations (IVIVCs) of oral dosage forms (169); in particular, since the publication 
from the FDA Guidance of dissolution testing of immediate- release (IR) (43) and IVIVC 
of extended-release (ER) dosage forms in 1997 (170) and subsequent notes for 
guidance issued by the European regulatory authorities, EMA (171). The guidelines 
increase confidence and success in using in vitro tests to evaluate or predict in vivo 
performance of solid drug products based on IVIVC, especially ER dosage forms (172-
179). 
 
FDA defines IVIVC as a predictive mathematical model to describe the relationship 
between an in vitro property (usually the extent or rate of drug release), and a relevant 
in vivo response (e.g., plasma concentration or amount of drug absorbed) (170). In 
vitro-in vivo relationship (IVIVR) is defined as a qualitative or semi-quantitative 
association between the in vitro dissolution/ release and in vivo absorption data (180).      
 
1.7.1 The Levels of Correlation 
 
The levels of correlation are categorised as: 
1.7.1.1 Level A correlation 
 
Level A correlation is defined as a hypothetical model which describes the relationship 
between the fraction of drug absorbed and the fraction of drug dissolved (170). It is 
considered as a predictive model for the relationship between the entire in vitro release 
time courses (181).  Among all levels of correlation, Level A is the most meaningful for 
predicting purpose because it provides a relationship that directly links in vivo drug 
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absorption to in vitro dissolution. This level of correlation should be valid for a 
reasonably wide range of values of formulation and manufacturing parameters that are 
essential for the drug release characteristics. This level can be used as a surrogate for 
in vivo performance of a drug product (170). Therefore, in vitro dissolution data, without 
any additional in vivo data, can be employed to justify a change made in manufacturing 
sites, raw material supplies, minor formulation modifications, strength of dosage form 
(170). For Level A IVIVC, when in vitro curve and in vivo curve are superimposable, it 
is said to be a 1:1 relationship. On the contrary, if scaling factor is required to make the 
curve superimposable, the relationship is called a point-to-point relationship (182). 
 
1.7.1.2 Level B correlation 
 
It means in vitro dissolution time (MDT) is compared with either the mean in vivo 
residence time (MRT) or mean in vivo dissolution time derived by using the principle of 
statistical moment analysis (170). Therefore, it does not reflect the actual in vivo 
plasma concentration curve. Although it utilises all in vitro and in vivo data, it is not 
considered a point-to-point correlation because the numbers of in vivo curves can 
produce similar residence time value (170). Hence, it is the least useful for regulatory 
purposes. 
1.7.1.3 Level C Correlation 
 
A level C correlation represents a single-point relationship between a dissolution 
parameter (e.g., t50%) and a pharmacokinetic parameter (e.g., AUC, Tmax, Cmax). This 
correlation does not reflect the entire plasma-concentration–time curve or dissolution 
profile (170); therefore, it is considered the lowest correlation level. However, Level C 
correlation can provide useful information in early formulation development (183). 
 
1.7.1.4 Multiple Level C correlation 
 
A multiple level C correlation compares one or more pharmacokinetic parameters of 
interest (e.g., Cmax, AUC) to the amount of drug dissolved at several time points of the 
dissolution profile (170). This level of correlation may support a biowaiver if the 
correlation has been established over the entire dissolution profile with one or more 
pharmacokinetic parameters of interest. If a multiple level C correlation is possible, 





1.7.2 Application of an IVIVC 
 
Occasionally during the formulation development process, some changes to the 
formulation composition, manufacturing process or equipments are introduced. These 
changes normally require human clinical trials to demonstrate bioequivalence of new 
product with the biobatch. However, if IVIVC is successfully developed then it could be 
utilised to replace human studies (173, 179). Alternatively, IVIVC could serve as 
surrogate for in vivo bioavailability and biowaiver consideration (43). Other purpose of 
IVIVC is to assist in validating or setting dissolution specifications. The dissolution 
specifications are needed to ensure batch to- batch consistency within a range that 
guarantees acceptable biopharmaceutical performance in vivo and to distinguish 
between good and bad batches (182). An IVIVC includes in vivo relevance to in vitro 
dissolution specification which means that the dissolution specifications are set based 
on the in vivo performance of the biobatch (170).  
 
It is important to note that in 1995, Biopharmaceutics Classification System (BCS), a 
theoretical framework that was based on the underlying processes controlling oral drug 
absorption was proposed (48). The BCS classifies drug compounds based on solubility 
and permeability of the compound (Table 5). Normally for rapidly dissolving BCS Class 
1 compounds, IVIVC may not be possible because of their high solubility and high 
permeability characteristics; the in vivo dissolution is not the rate-limiting step (48, 
184). For BCS Class 2 compounds, on the other hand, dissolution is the limiting step of 
the drug absorption. Therefore, an IVIVC may be expected (43, 54). More research is 
needed to develop and validate in vitro dissolution methods for class 2 compounds so 
that they can be used to predict in vivo dissolution (185). For BCS Class 3 compounds, 
permeability is the limiting step of the absorption, and a limited IVIVC may be 
expected. Finally, for BCS Class IV compounds, IVIVC is difficult. The compound will 
have both limited dissolution and permeability. So, it will be difficult to develop a 









Table 5. IVIVC expectations for immediate release products based on BCS  
Class Solubility Permeability 
Absorption 
rate control 
IVIVC expectations for Immediate 
release product 
I High High 
Gastric 
emptying 
IVIVC expected, if dissolution rate is 
slower than gastric emptying rate, 
otherwise limited or no correlations 
II Low High 
Dissolution IVIVC expected, if in vitro dissolution 
rate is similar to in vivo dissolution rate, 
unless dose is very high. 
III High Low 
Permeability Absorption (permeability) is rate 
determining and limited or no IVIVC with 
dissolution. 
IV Low Low Case by case Limited or no IVIVC is expected. 
 
 
1.7.3 Development of IVIVCs  
 
A full-time course in vivo absorption-time profile is generally the most informative way 
of evaluating formulation performance from the plasma concentration-time data (186). 
The method of choice for determination of in vivo absorption-time profiles is 
deconvolution. In this section, the different methods of deconvolution (in order to obtain 
in vivo absorption profile) and the equation of IVIVC are discussed.  
 
1.7.3.1 Deconvolution  
 
In deconvolution, three components are defined: input, weighting and response 
functions. The input function corresponds to the entry of the drug into the body, i.e. the 
in vivo dissolution- or absorption-time profiles for the oral test formulation. The 
weighting function corresponds to the time course of the drug within the body, as 
described by the plasma concentration-time profiles after administration of an oral or IV 
reference solution. Lastly, the response function is described by the plasma 
concentration-time curve for the test formulation (187).  
 
One of the commonly used methods of deconvolution of plasma profiles is the 
numerical method which is a model independent method. This method uses a simpler 
algorithm and does not require any modeling of the plasma concentration-time data in 
the assessment of the absorption profile (187). However, intravenous or oral solution 
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plasma profile of the drug (weighting function) is required for the calculation of 
absorption. Some examples of the software available for numerical deconvolution are 
PCDCON (Austin, Texas) (188) and Phoenix® Winonlin® (Phoenix, US). Numerical 
deconvolution is considered the most reliable deconvolution method (189, 190) thus it 
is implemented in this project (IV profiles for the model compounds used in this project 
were available). 
 
The integral for deconvolution is presented in Equation 3 (191): 
 ( )  ∫   (   )    ( )   
 
 
                                       Equation 3 
Where the function Cδ represents the concentration–time course that would result from 
the instantaneous absorption of a unit amount of drug. Typically, it is estimated from 
intravenous injection bolus data or reference oral solution data. In addition, c(t) is the 
plasma concentration vs time level of the tested oral formulation, rabs is drug input rate 
of the oral solid dosage form, and u is variable of integration. In simple terms, the 
relationship between these terms can be represented as Equation 4 (191): 
 ( )   ( )   ( )                                                 Equation 4 
Where Y(t) is the function which describes the plasma concentration–time curve 
following extravascular administration, G(t) is the function describing the 
concentration–time curve following bolus intravenous (or weighting function) 
administration, and X(t) is the function describing input, i.e., dissolution from the 
dosage form. 
 
1.7.4 Establish IVIVC using in vivo and in vitro dissolution data 
 
Good prediction of the dissolution properties of orally administered compounds is of 
great importance (57). A good correlation is a tool for predicting in vivo results based 
on in vitro data; if the absorption is dissolution rate limited, the optimum dissolution 
method for IVIVC is the method that best correlates with what happens in vivo (99). 
 
A linear mathematical equation with intercept (a) and gradient (b) can be applied to 
define IVIVC (Equation 5) (192): 
 
                   % absorption in vivo= b∙% dissolution in vitro + a   Equation 5 
 
where % absorption in vivo and % dissolution in vitro are the mean percentages in vivo 
absorption and in vitro dissolution respectively; a is a constant additive term that 
40 
 
accounts for a percentage delay in vivo as compared with in vitro and the gradient b is 
a transformation factor for the mean percentages. This gradient, b, compares the rate 
and extent of the in vivo absorption and in vitro dissolution. For example, if a is zero 
and b is 2, this indicates that the mean % in vivo absorption is twice as high as the 
mean % in vitro dissolution. 
 
1.7.5 IVIVCs of amorphous formulations 
 
A few successful examples of IVIVC for amorphous formulation have been reported in 
literature, for example Level A IVIVC for oxidized mesoporous silicon (pSi-ox) 
amorphous indomethacin formulations and crystalline indomethacin powder. In vitro 
dissolution profile of pSi-ox amorphous indomethacin formulation was obtained with 
USP apparatus 2 (100 rpm) in a 500 mL phosphate buffer (0.05 M, pH 7.2).  The in 
vitro dissolution data was compared directly with in vivo absorption data of a fasted rat 
(Sprague-Dawley). In vivo absorption profile of pSi-ox amorphous indomethacin 
formulation was generated from deconvolution of the corresponding plasma 
concentration profiles using the Wagner-Nelson method.  
 
Another example is the Level A IVIVC development for disintegration-controlled matrix 
tablet (DCMT) amorphous nilvadipine formulation (193) (Figure 10). Two DCMT 
amorphous nilvadipine formulations, DCMT-1 and DCMT-2 with different compositions 
of disintegrant were prepared and tested in vitro and in vivo. 
 
Figure 10. Level A IVIVCs of DCMT-1 (A) and DCMT-2 (B) amorphous nilvadipine formulation. 
The reported linear regressions were y=0.995x (A) and y=0.9512x (B)(R
2
 value was not 
reported). Reproduced with permission from (193). 
 
In vitro dissolution profile was obtained by using USP apparatus 2 (100 rpm) in 
simulated gastric fluid (pH 1.2, 37±0.5°C).  The in vitro dissolution data was directly 
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compared with in vivo absorption data of the fasted beagle dogs’ model. In vivo 
absorption profiles were calculated by means of a numerical deconvolution method 
(193). 
 
A multiple level C IVIVC correlation has been developed for poly(ethylene glycol) 
(PEG)–ritonavir amorphous solid dispersions formulations (194). In this study, In vitro 
dissolution was conducted with a USP apparatus 1 (50 rpm, 37±0.5⁰C) in 900 mL of 
0.1N hydrochloric acid. The in vivo data was obtained from sequential blood samples 
of eight beagle dogs. The multiple level C IVIVCs correlating Cmax (or AUC) and 
percentage released at 5 min (Q5min,) or at 60 min (Q60min) are shown (Figure 11). 
 
Figure 11. Multiple level C IVIVCs between Cmax (or AUC) and Q5min or Q60min of ritonavir 




1.8 Compounds selected (Amorphous state) 
 
This section describes physicochemical and pharmacokinetic properties of CA, ITR 
and CX (compounds selected for this study). 
1.8.1 Cefuroxime axetil (CA) 
 
Zinnat® was designed to be an oral dosage form of cefuroxime (Zinacef®), a second-
generation cephalosporin antibiotic previously available via IV and IM injection (195, 
196). Cefuroxime is not orally absorbed because it contains a highly polar carboxyl 
group that is ionized at intestinal pH, making transport across intestinal mucosa 
unlikely (197, 198). By masking the carboxylic acid side chains through esterification 
(199), the drug’s lipophilicity and enteral absorption were successfully increased. It can 
penetrate through the intestinal mucosa and be rapidly hydrolysed by the enzyme 
esterase in the intestinal mucosa and the portal circulation in vivo to form an active 
cefuroxime molecule. A study has shown that it is not possible to detect CA itself in the 
systemic circulation (200). The equilibrium water solubility CA is low 0.4±0.13 µg/mL 
(201). While limited by poor aqueous solubility, the lipophilicity of the compound 
renders high permeation of intestinal membranes. Therefore it is classified as a BCS 








Pharmacological category A cephalosporins group antibiotic (202) 
Molecular Weight 510.48 (202) 
pKa Neutral drug 
log P 0.25 (203) 




1.8.1.1 Bioconversion and hydrolysis of CA  
 
It was initially discovered that the bioconversion of CA to cefuroxime requires 
hydrolysis by intestinal musoca (enterocyte) esterases (197). Esterase hydrolysis leads 
to the formation of acetic acid and the unstable hydroxyethyl ester, which rapidly 
dissociates to acetaldehyde and the active cefuroxime (the microbiologically active 
form of the drug).  An in vitro study indicates that the half-life of the CA is 3.5 min in 
fresh human blood, but the in vivo hydrolysis is so rapid that the intact CA cannot be 
detected in the serum, even when a 1 g dosage was administered orally to healthy 
adults (200). Furthermore, hydrolysis of CA may proceed via a reversible base-
catalysed isomerisation. Both hydrolysis processes will remove some of the CA 
available for absorption. The result is incomplete bioavailability of the oral prodrug 
ester (204, 205).  Later studies also showed that the hydrolysis of CA could take place 




Protein binding of cefuroxime is approximately 30%. Its volume of distribution value is 
0.13 to 1.8 L/kg (207) and a Vd of 50 L was reported in healthy subjects administered a 
single oral Zinnat® 500 mg dose (208). Mean drug: creatinine clearance ratios were in 
the 1.1-1.3 range (197) which suggests that about half the drug is filtered and half is 
actively secreted by the kidney tubules. It is worth noting that a pharmacokinetic study 
has also demonstrated that cefuroxime follows linear pharmacokinetics (209).  
 
The bioavailability of cefuroxime administered as a Zinnat® 250 mg tablet was 52% 
when taken after food and 37% when taken on an empty stomach (209). The stability 
of CA is pH dependent. The rate of hydrolysis is faster in the fasted state (acidic gastric 
medium of pH 1.8) compared to the fed state (pH 4.5-5.6) (206). The inactive isomer of 
CA can also be formed under the acidic conditions and increased temperature (210). 
The optimal conditions for absorption of CA are found in the duodenum and the upper 
part of the small intestine, where pH is in the range of 4 to 6 (205). From this 
observation, it is suspected that the higher bioavailability of CA in the fed state is 
associated with the higher concentration of intact CA reaching the intestine, the main 
site of CA absorption. Many pharmacology and kinetic studies have failed to identify 
this issue and have proposed reasons such as saturable and selective absorption 
activity in the intestine (211-213). Another suggested reason for the lower 
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bioavailability in the fasted state is the rapid gastric emptying in this state. It results in 
an excessive amount of CA presented to the upper small intestine which saturates the 
absorption process leading presumably to zero-order absorption kinetics (205).  
 
1.8.2 Itraconazole (ITR) 
 
ITR is a triazole antifungal compound with a piperazine structure (214, 215). ITR has 
an extremely low solubility in water. ITR (pKa 3.7) has a strongly pH dependent 
solubility and it remains largely un-ionized in intestine secretions (pH 6.5) (216). The 
equilibrium solubility of ITR is very low (practically insoluble in water and thus is 
classified as a poorly water soluble drug (216)). The low aqueous solubility results in 
variable absorption and plasma concentration (217). While limited by poor aqueous 
solubility, the highly lipophilic nature of the compound (Table 7) allows for high 
permeation of intestinal membranes; therefore, it is classified as a BCS (48) Class 2 
compound. Some physicochemical properties of ITR are presented in Table 7. 
 
Table 7. Physicochemical properties summary of ITR  
Properties Description 
















Pharmacological category A triazoles antifungal drug (218) 
Molecular weight 705.65 (218) 
pKa 3.7 (218) 
log P 4.3 (218) 
Solubility (µg/mL) Water: 0.001 (216) 









1.8.2.1 Pharmacokinetics  
 
ITR has a long elimination half-life, ranging from 35 to 64 h (220) and it takes 15 days 
to reach a steady state in the human body. Volume of distribution of ITR is 
approximately 11 L/kg (215) and protein binding is 99% (ITR, hydroxyl-ITR) (221-223). 
 
A study of healthy volunteers evaluated the pharmacokinetics of ITR after a single 200 
mg dose and 200 mg every 12 h for 15 days (steady state). The metabolism of ITR 
occured by non-linear processes (224) as demonstrated by a fivefold greater AUC0-12h 
at steady state (22.6µg x h/mL) compared to the AUC after a single dose (3.42µg x 
h/mL) (224). Similarly in another clinical pharmacokinetic study, ITR dosage was 
increased from 100 mg and 200 mg to 400 mg daily and a non-linear increase in the 
AUC was observed (225). Other studies also have shown that administration of a 
single oral dose of ITR of 100 or 200 mg to a healthy volunteer have resulted in bi-
exponential reduction of the ITR plasma concentration with a terminal half-life of 
approximately 20 h (222). Strong evidence has shown that ITR is metabolised 
extensively in the liver, predominately by the cytochrome P450 3A4 isoenzyme system 
(222). Furthermore, ITR is both the substrate and inhibitor of the CYP3A4 enzyme 
(226, 227) and P-glycoprotein (137, 227).  
A bioavailability study has shown that milk or a meal taken together with milk could 
substantially reduce the absorption of ITR (228).  It was found that milk increased and 
prolonged the duration of gastric pH (at pH 5.6 for more than 4 h) and also acted as an 
antacid that could reduce the acidity of the stomach (229, 230). The acidity of the 
stomach is important for fast dissolution of ITR that allows a high supersaturated 
solution when entering the intestinal fluid (pH 6-pH 6.8) (231). Thus, the pH 5.6 
medium greatly reduces the ITR dissolution compared to the high and fast dissolution 
in the acidic medium (30). 
 
1.8.3 Compound X (CX) 
 
Compound X is a newly marketed compound manufactured by Hoffmann-La Roche 
(232). CX is a kinase inhibitor available as a 240 mg/tablet for oral use. CX exists in 
several polymorphic forms, with polymorphic form II being the most stable. Polymorph I 
has higher solubility and bioavailability; however, it is unstable so formulation efforts 
have been made to increase the solubility of CX (233). CX is practically insoluble in 
aqueous media across the physiological pH range (concentration less than LOQ) 
(233). While limited by poor aqueous solubility, the highly lipophilic nature of the 
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compound (log P=3.84 allows for high permeability of intestinal membranes) means it 
is classified as a BCS (48) class 2 compound (234, 235). Some physicochemical 
properties of CX are presented in Table 8. 
 






A novel small molecule selective inhibitor of the activated 
form of the BRAF serine-threonine kinase enzyme for the treatment 
of skin melanoma 
Molecular Weight 489.93 
pKa 7.9 and 11.1 
log P 3.84 (pH 7.4) 
Solubility Practically insoluble in aqueous media across the physiological pH 
range 







CX is more than 99% bound to human albumin and alpha-1 acid glycoprotein plasma 
proteins (232). The apparent volume of distribution of CX is estimated to be 106 L in 
patients with metastatic melanoma (healthy volunteer study is not available as this drug 
can increase the risk of skin cancer) (232). The population apparent clearance is 
estimated to be 31 L/day in patients with metastatic melanoma (232). The median 
elimination half-life of CX is estimated to be 57h (232). Following oral administration of 
14C-CX 960 mg in the tablet formulation, plasma samples were analysed over 48 hours 
for CX and its metabolites. Mean data showed that CX and its metabolites represented 
95% and 5% of the components in plasma, respectively. The majority of the CX in the 
body is excreted through faeces (94%) and approximately 1% is excreted through renal 
elimination (232). So far there is no bioavailability data of CX. Following oral 
administration of CX at 960 mg twice daily for 15 days to patients with metastatic 
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melanoma, the median Tmax was approximately 3h. A study has shown that a high-fat 




1.9 Aim of study 
The aim of the project was to provide a comprehensive methodology for the 
development of PBPK models and IVIVCs simulating fasted and fed states for orally 
administered amorphous formulations. In vitro dissolution of three model compounds, 
CA, ITR and CX was characterised using different dissolution apparatus (USP 
apparatus 1, 2, 4 and surface dissolution imager), setting (single stage, 2 stage, media 
and flow rate change) as well as media (compendial, biorelevant and modified media) 
to simulate the changes of pH, contents, and hydrodynamic conditions (flow rate and 
rotation speed) in the human gastrointestinal tract (fasted and fed state). The 
hypothesis of this study was that biorelevant dissolution media combined with USP 
apparatus 4 could mimic the in vivo performance of the tested formulations and 







2. Experimental Methods 
2.1 Materials 
 
Sporanox® capsules (Janssen-Cilag Ltd, Bucks, UK, batch no. 9EL5800, 100mg 
itraconazole <ITR> per capsule), Zinnat® tablets (GlaxoSmithKline, Middlesex, UK, Lot 
C420326, 250mg cefuroxime axetil <CA> per tablet) were purchased commercially. 
Compound X <CX> Formulation 4 -8 (Hoffmann-La Roche, Nutley, US, 240mg of CX 
per tablet, composition described later in Section 2.3.3), CX standard (99.6%) [Lot 
80320404R, Nutley, USA, ITR standard (98% w/w) [batch no. 097K1156, St. Louis, 
MO] and CA standard [USP Reference Standard, Lot 09822G, Rockille, MD) were 
provided by Hoffmann-La Roche, Nutley USA. 
Glyceryl monooleate (GMO, Rylo M19 Pharma®, 99.5% monoglyceride, batch number 
4011742134) was a gift from Danisco A/S, Grindsted, Denmark. Egg 
phosphatidylcholine (Lipoid E PC®, 99.1% pure) was generously donated by Lipoid 
GmbH, Ludwigshafen, Germany. Sodium oleate (lot number SZBB0110V), pepsin (lot 
number 030M1571V) and sodium chloride (NaCl) were purchased from Sigma-Aldrich 
(Dorset, UK). Sodium taurocholate (NaTC, 97% pure, batch number 2011040152) was 
purchased from Prodotti Chimici e Alimentari SpA, Basaluzzo, Italy.  
37% hydrochloric acid, maleic acid, potassium dihydrogen phosphate, sodium acetate 
trihydrate, sodium dihydrogen phosphate monohydrate and sodium hydroxide pellets 
were all of analytical grade and purchased from Fisher Scientific (Loughborough, UK).  
Ultra-heat-treated (UHT) and homogenized milk containing 3.5% fat was purchased 
from a local supermarket (Tesco, UK).  
A cellulose nitrate membrane filter 0.45µm Ø 13mm (Whatman, Dassel, Germany) and 
glass microfiber filters GFD® 2.70µm Ø 24mm (Batch no. K11670637, Whatman, 
Maidstone, England) were purchased from Fisher Scientific (UK). GF/F® 0.70µm Ø 
24mm (Whatman, Maidstone, England), glasswool (Sigma, UK) amd acetic acid 
(>99.7%, Batch no 09214CJ, Sigma, UK) and Parafilm (4x125ft, Sigma UK) were 
purchased from Sigma-Aldrich (Dorset, UK). 
Nylon membrane disc filters Ø 13mm 0.45µm (Cronus, Gloucestershire, UK) and 10µm 
direct fit UHMW polyethylene cannula filters (Labhut Ltd, Gloucestershire UK) were 
purchased from SMI-Labhut Ltd (Gloucestershire, UK). 
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Dichloromethane, acetonitrile and methanol (HPLC grade) were from Fisher Scientific 
(Loughborough, UK). The Milli-Q water was obtained from a Nanopure® Diamond UF 




A Vankel® rotating basket (USP apparatus 1) and paddle (USP apparatus 2) 
dissolution system (model 10-1200, Edison, NJ, USA) and an Erweka flow-through 
dissolution tester (USP apparatus 4, model DFZ720, Erweka GmbH, Heusenstamm, 
Germany) equipped with Ø 22.6mm cells and connected to an Erweka Piston Pump 
(model HKP720) were used. 
Sirius SDI (Surface Dissolution Imager, Sirius Analytical Instruments, East Sussex, UK) 
was used for in vitro surface UV imaging experiments.  Sirius SDI consists of a pulsed 
Xenon lamp (Perkin Elmer, Waltham, MA)  with PC interface control box , a remote UV 
camera sensor with fibre optic cable, band pass filter (wavelength 214,254, or 280 nm), 
Chemyx Fusion 200 syringe pump and a CADISS-2 dissolution cartridge. The 
CADDISS-2 comprises a 62 mm rectangular Quartz tube, Luer lock connector flow cell 
inlet and outlet and a cartridge body. 20 mL and 50 mL BD plastic buffer delivery 
syringes were used to hold the dissolution medium.  
 
A Quickset Minor® torque screwdriver (Torqueleader, M.H.H. Engineering Co. Ltd., 
England) and sample cup (316 stain steel, 2.0 mm ID 2.6 mm OD X 2.4 mm H, 
Paraytec, York) were used to prepare the drug compact for the surface UV dissolution 
experiment. The compacts were arranged on a manual press (Actipress, Paraytec, 
York).  
 
The HPLC system consisted of an Agilent 1100 Quat pump, an Agilent 1100 DAD 
spectrophotometer, an Agilent 1100 ALS autosampler and ChemStation software 
(Agilent Technologies, Santa Clara, USA).  
 
For the detection of drug compounds the following HPLC columns were used: Agilent 
Zorbax® SB-C18 (150mm× 4.6 mm, 3.5µm particle size) for CA, Water XTerra® RP18 
(250mm× 4.6 mm, 5µm particle size) for ITR and Water Sunfire® C18 (150mmx 




Centrifuge tubes (Corning Inc. New York, US) were used in the analysis process of 
milk-based media. Glass syringe 5 mL with Luer –lock Fortuna® Optima® (Poulten & 
Graf Ltd, Essex, UK) and Swinny stainless steel 13 mm filter holders (Millipore, 
Billerica, US) were used for filtration during solubility. Bent SSTM sampling cannula with 
a Luer adapter for 500 mL sampling (length: 195mm, inner diameter: 2.1mm, VanKel 
compatible, Varian, CA, US) was used for USP apparatus 1 and 2 dissolution studies 
 
Other equipments used 
Shaking water bath (model Grant SS40-2, Grant Instruments, Cambridge, UK) was 
used for solubility studies. Rotary evaporator (Buchi R-114, Buchi, Switzerland) 
equipped with a water bath (Buchi B-480, Buchi, Switzerland) and vacuum pump 
(Vacuubrand CVC 2II, Vacuubrand GMBH, Germany) was used for the preparation of 
biorelevant media. Hydrus pH meter (model 300, Fisher Scientific, UK) was used for 
adjustment of the pH of the media used for solubility and dissolution studies. Sigma 
701 tensionmeter (Attension, Biolin Scientific, Sweden) equipped with Titronic 
Universal Burette was used to measure surface tension of modified media. Sartorius 
balance (AG Gottingen, Germany) was used for all weighing. Vortex rotamixer (Hook & 
Tucker Instruments, England) was used for mixing samples. Ultrasound bath XB2 
(Grant, Cambridgeshire, England) was used for degassing of the mobile phase for 
HPLC. Finnpipettes (Fisherbrand, UK) (Volume size 1-5 mL: S/N 9066708; 100-1000 
μL: S/N 9097462; 20-200 μL: S/N 9113779) were used for standard preparations and 
treatment of precipitated samples. Ultrapure water was obtained from a NANOpure® 
DIamond UF and UV/UF Water Barnstead System (Thermo Scientific, Dubuque, US). 
Heating Magnetic Stirrer (Fisher Scientific, UK) was used for stirring the dissolution 
media. A timer (Fisherbrand) was used for timing the experiment in solubility and 




Excel 2007 (Microsoft, US) was used to process all data solubility, dissolution and 
IVIVC data. GastroPlusTM v.8 (Simulation Plus, California, US) was used for the 
development of PBPK models. ActiPixTM SDI300 application software (Paraytec and 
Sirius Analytical Instruments, East Sussex, UK) was used for the real time data capture 
and imaging, setting the integrated pump control and visualisation and dissolution 
analysis. 
 
PCDCON® 1.1 Deconvolution Utility (by Dr. Gillespie, University of Texas, Austin, TX) 
was used for numerical deconvolution of plasma concentration data after oral 
administration of CA, ITR and CX. 
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Getdata Graph Digitizer (Moscow, Russia, freely available online) was used for 
extracting data from 2D graphs. 
 
2.3 Amorphous formulation of compounds selected  
 
The marketed innovator amorphous formulation of CA, Zinnat® tablet, ITR, Sporanox® 
capsule and preclinical formulations of CX were studied in this project. These 
formulations were selected because good in vivo, IV and oral plasma concentration 
profiles are available. Studies confirmed that CA (237, 238), ITR (239) and CX 
formulations (234, 235) are of an amorphous state. The formulation characteristics of 




Zinnat® (GlaxoSmithKline) amorphous formulation of CA is formulated based on US 
Patent No 4,562,181 “Amorphous Form of Cefuroxime Ester” (238). Clinical trials of CA 
were started in 1981 with large, uncoated tablets (T). Later on, the formulation was 
improved with film coating and a reduction in size (RS). A second version, RS2 was 
released for clinical trial in 1983. In RS2, the CA tends to form a gelatinous mass when 
in contact with the aqueous media. The gelling effect is temperature dependent and 
occurs at 37°C (240). Such gelling would lead to poor dissolution of CA and hence poor 
absorption from the gastrointestinal tract. Subsequently, a revised formulation (RS3 
tablet version) was marketed in 1987 (198). Modification was done to improve the film 
coating to ensure its immediate disintegration following rupture of the film coat (241, 
242). This was achieved using croscarmellose sodium, a type of disintegrant in the 





The innovator product of ITR is the Sporanox® capsule marketed by Janssen-Cilag Ltd 
(243). During the manufacturing process hydroxypropyl methylcellulose (HPMC) which 
is a hydrophilic carrier, is added to crystalline ITR. Dichloromethane and ethanol are 
used as solvents in order to form a uniform ITR/HPMC solution with weight ratios of 
1:1.5:17.25:11.5 (ITR: HPMC:dichloromethane:ethanol) (244, 245). This solution is 
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coated on sugar beads using a fluidized bed and dried at temperatures up to 80 °C for 
2–3 days to remove any remaining dichloromethane. A thin layer of polyethylene glycol 
(PEG) 20000 is used as a non-sticking agent in order to prevent sticking of the beads. 
PEG is first dissolved in dichloromethane and ethanol (1:5.4:3.6), and the solution is 
then sprayed on the previously coated sugar beads using a fluidized-bed granulator 
which are then dried (244, 245). After drying and capsule filling of the beads, ITR 
presents in a molecularly dispersed solid solution that dissolves to give a 
supersaturated solution of the drug in the GIT (15). Dissolution of HPMC in media 
simulating the gastric environment releases supersaturated concentrations which are 
maintained before eventually undergoing precipitation. HPMC is believed to prevent 





CX is a compound with a low melting point and low organic solubility therefore 
traditional amorphous solid dispersion processing methods are not feasible. The 
formulation scientists invented is a novel amorphous solid dispersion method called 
micro-precipitated bulk powder (MBP) technology (247). The application of the MBP 
technology to CX is directly responsible for enhanced absorption of CX that allows a 
viable cancer chemotherapy that retards the further metastasis of skin cancer (233, 
248). 
 
This CX MBP formulation contains the active compound, CX and an ionic polymer type, 
hydroxypropylmethylcellulose acetate succinate (HPMCAS). The MBP technology 
involves a solvent and anti-solvent precipitation method (249, 250). The process 
utilises N,N-dimethylacetamide to dissolve CX and HPMCAS and then the solution is 
precipitated into acidified aqueous media. The precipitates are then filtered, repeatedly 
washed to remove residual acid and solvent content, dried, and milled to form the 
amorphous powder intermediate, MBP. Apart from increasing CX bioavailability, the CX 
MBP technology provides substantial physical stability. The stability of the amorphous 
dispersion is attributed to the high composite Tg, intermolecular interactions between 
the drug and polymer as well as the moisture protective effect provided by the polymer. 
CX may be molecular dispersed within a matrix formed by the polymer in its solid state 
such that the drug molecules are immobilised in its amorphous form (234, 235). The 
immobilization could prevent drug nucleation due to lack of molecule mobility within the 
polymer matrix (235). Furthermore, HPMCAS contains many substituents that are quite 
hydrophobic. As a result, even when HPMCAS becomes ionized, as it does at the pH 
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in the small intestine, the polymer is still only sparingly soluble and exists as colloidal 
polymer aggregates in aqueous solutions (251). This colloidal polymer helps to sustain 
a high free-drug concentration by replacing the free drug as it is absorbed over a 
biological membrane in vivo. Furthermore, HPMCAS is an enteric polymer that does 
not dissolve in an acidic medium but dissolves in buffers of pH greater than 4.5 and the 
exact pH value at which the polymer dissolves depends on the buffer type and ionic 
strength of the buffer (251). 
 
In this project, plasma concentration data (post IV and oral administration) of 7 
formulations (F1-F7) of CX were provided by the Hoffmann-La Roche, NJ USA (252). 
All tablets contain 240 mg of CX. The manufacturing process and parameter of these 
formulations were quite similar and only slight differ in the CX MBP particle size 
distribution (252) (Table 9). 
Table 9. Critical manufacturing variables for 8 formulations of CX 





F1 Coated - Y - 
F2 Coated 37.2 Y 295 
F3 Coated 93.8 Y - 
F4 Coated 48 Y - 
F5 Uncoated 37.2 N 341 
F6 MBP  film coated 
64.9,60.9,61.8 (A mixture of 
3 MBP lots) 
- - 
F7 MBP  film coated 62.8 - - 











2.4 Methods of Part 1: In vitro solubility and dissolution testing 
 
One of the objectives of this project is to develop in vitro dissolution methods simulating 
fast and fed states that are able to predict the in vivo performance of amorphous 
formulation. CA (Zinnat® as the amorphous formulations) and ITR (Sporanox® as the 
amorphous formulation) were chosen following an extensive literature search and CX 
(CX amorphous formulation) were provided by Roche, New Jersey, United States 
(252). In vitro dissolution using different apparatus, media and setup were performed. 
In vitro dissolution studies that stress biorelevant dissolution testing and which closely 
simulate the physiological conditions of humans (CA and ITR) and dogs (CX) were 
implemented. 
New dissolution media simulating fasted state human stomach and intestine (simulated 
gastric fluid-modified: SGF-M1, SGF-M2 and simulated intestinal fluid-modified: SIF-
M1, SIF-M2, SIF-M3, SIF-M4, SIF-M5) were developed. These modified media contain 
artificial surfactants such as SLS or HTAB at appropriate concentrations that could 
represent the more complex bile salt and lecithin surfactant system in biorelevant 
media.  
Meanwhile, the simulation of a fed state model required more complex media that 
mimic pH, viscosity, surfactants and lipolytic products. Hence milk based media such 
as FeSSGF, early FeSSGF and digested early FeSSGF as well as biorelevant fed 
state media were used. 
 
2.4.1 Chromatographic conditions 
 
The HPLC methods used for the analysis of ITR and CA are modifications of literature 
methods (253, 254). The HPLC method used for the analysis of CX is provided by 









Table 10. Parameters for the HPLC analysis  
Compound CA ITR CX 
Mobile phase Methanol and water 
45:55 (v/v) 








1 1 1 
Injection volume 
(µL) 
20 20 20 
Retention time 
(min) 
4.9 10.6 3.3 
Detection UV 
(nm) 




C18 (150mm× 4.6 





(250mm× 4.6 mm, 













15 20 40 
 
 
2.4.2 Limit of detection and limit of quantification and linearity 
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                                 Equation 7    
Where 
b is the gradient of the regression line. 
Sy/x is the standard error of estimate 
For the establishment of the linearity range, calculation of the limit of detection (LOD) 
and the limit of quantification (LOQ) of the proposed method, calibration curves were 
prepared in the following range: CA: 0.4- 50.0, ITR: 0.1- 6.0, CX: 0.2- 8.0 (unit: µg/mL). 
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2.4.3 Drug adsorption test 
 
To analyse the amount of each individual drug (CA, ITR and CX) adsorbed to the nylon 
filter (0.45 μm) the recovery of the drug in the filtered solution was determined. For 
each drug/medium combination, a sample of standard solution was withdrawn with a 
glass syringe and filtered through the nylon filter kept inside the swinny filter head 
twice. The first 1 mL of the filtrate was discarded and the concentration of the aliquot of 
the remaining filtrate was measured using HPLC. The values obtained with and without 
filtration were then compared and results reported as % recovery according to 
Equation 8 (255):  
 
           
             
           
                            Equation 8 
An+1 filtered= Area of filtered aliquot at n+1 time 
An filtered= Area of filtered aliquot at n time 
All results are reported as mean ± standard deviation, with recovery of > 95% as the 
criterion for acceptable adsorption of solute on the filter paper. 
 
2.4.4 Preparation of media 
 
The composition of each media was presented in Section 1.3, and the media used 
were: 
 
2.4.4.1 Compendial media 
 
A fasted state simulating gastric fluid without pepsin (SGF) (42), and fasted state 
simulating intestinal fluid without pancreatin (SIF) (42) were used to simulate the 
fasting GI gastric and intestinal composition, respectively (Composition of the 
compendial media presented in Table 1). 
 
2.4.4.2 Biorelevant media  
 
Simulated fasted state conditions 
FaSSGF and FaSSIF-V1 and -V2 were prepared according to the procedures of 
Vertzoni et al. (46, 94) and Jantratid et al. (57) respectively (Composition of the 




Simulated fed state conditions  
The fed state simulating gastric fluid, FeSSGF and early FeSSGF as well as the 
simulated intestinal fluids in the fed state FeSSIF-V2 were prepared according to 
Jantratid et al. (57). The digested early FeSSGF was prepared according to Fotaki et. 
al with the replacement of milk with early FeSSGF; (63) (Composition of the media 
presented in Table 2). 
 
2.4.4.3 Development of modified media 
 
Surface tension of the medium is an important factor, which affects the solubility and 
dissolution of drugs (256). Literature reports the surface tension values in the fasted 
state humans stomach range between 41.90-45.70 mN/m (83) with the levels of bio-
surfactants in vivo was confirmed to be below critical micelle concentration (CMC) 
(257). On the other hand, the surface tension value of humans intestinal fluids (HIF) 
was reported to be 33.6 mN/m (73) which is much lower that the currently established 
biorelevant media, FaSSIF-V1 (surface tension 53 mN/m (62) and FaSSIF-V2 54 
mN/m (57). Similarly the compendial media (SGF and SIF) do not include surfactants 
and therefore are less likely to simulate the solubilisation and the wetting effect that 
occur in vivo.  
 
1. SLS (anionic surfactant) based modified media 
 
Surface tension (ST) measurement 
The Du Nouy ring method was used to determine the critical micelle concentration 
(CMC) and ST of SLS (99% pure) with SGF as the dissolution medium. The 
temperature of the dissolution medium was controlled at 25 °C. Meanwhile, the 
measurement in simulated intestinal media SIF and blank FaSSIF-V2 were performed 
by Tomaszewska and Fotaki (258). Due to the precipitation of potassium from the 
phosphate salt (potassium based SIF) with lauryl sulphate from SLS, potassium salts 
were replaced with sodium phosphate salts (sodium-based SIF, Na-SIF) (259).  An 
accurate amount of SLS was titrated dropwise using a built-in automatic titrator (up to a 
total concentration of 3% SLS) into the dissolution medium, which was constantly 
stirred using a built-in magnetic stirring system. Surface tension was automatically 
measured after each addition of surfactant into the glass beaker containing medium. 
99% pure SLS was used as previous reports have shown that SLS purity could affect 




Ionic strength calculation  





∑     
  
                                    Equation 9 
Where I is ionic strength, ci is the molar concentration of the ion and zi is the charge 
number of that ion. 
 
2. HTAB (cationic surfactant) based modified media 
 
One of the model drugs used in this project, CX, is practically insoluble in aqueous 
media (249). FDA clinical pharmacology and biopharmaceutics review states that 
solubility and surfactant screening studies of CX formulation have been performed in 
media with pH 6.8 (as HPMCAS, a main component of the CX formulation, is insoluble 
in acidic media). SLS (anionic type surfactant) and HTAB (cationic type surfactant) 
were added to the phosphate buffer at pH 6.8 and the kinetic solubility of CX was 
measured and results showed that HTAB is a better surfactant for the dissolution 
testing due to the precipitation of CX in the presence of SLS (233). Similar to the SLS 
based modified media, the development of HTAB based modified media is orientated 
on a dissolution medium that could mimic the physiological surfactant system and its in 
vivo surface tension value. 
 
Surface tension (ST) measurement 
Complete ST and CMC dataset of HTAB in SGF and SIF had been presented in 
Stippler’s PhD thesis (262), therefore the reported critical micelle concentration plot of 
HTAB in SGF and SIF (262) were used in the current study. In her study, the surface 
tension measurements were performed according to the maximum bubble pressure 
method using a SitaT10 device at a 0.5 Hz bubble rate and 21°C ± 1°C. The surfactant 
solutions were prepared in a concentration range from 0% to 1% surfactant 
immediately prior to the measurements.  
 
Thus the modified media developed are listed in Table 11 (The full results and 





Table 11. Type and name of modified media used in this project 
Name Composition 
SGF-M1 Simulated gastric fluid-modified 1 (SGF+0.01%SLS) 
SGF-M2 Simulated gastric fluid-modified 2 (SGF+0.015%HTAB) 
SIF-M1 Simulated intestinal fluid-modified 1(Na-SIF+0.2%SLS) 
SIF-M2 Simulated intestinal fluid-modified 2 (blank FaSSIF-V2+0.1%SLS) 
SIF-M3 Simulated intestinal fluid-modified 3 (SIF+0.1% HTAB) 
SIF-M4 Simulated intestinal fluid-modified 4 (SIF+1% HTAB) 
SIF-M5 Simulated intestinal fluid-modified 5 (Na-SIF+1% SLS) 
 
2.4.5 Equilibrium solubility studies (Itraconazole) 
 
Saturation solubility was determined using the following method (192): Screw cap vials 
containing 20 mL of medium (FaSSGF and FaSSIF-V2) are preheated to 37°C before 
adding 2 mg (excess amount) ITR powder (n= 3). The samples were gently agitated in 
a shaking bath (100 rpm) with the temperature maintained at 37 °C. 3 mL aliquots were 
removed after 1, 4, 8 and 24 h and filtered through a 0.45µm membrane filter. The first 
1 mL of the filtrate was discarded. The filtrates were diluted with the medium (where 
appropriate) and then analysed using HPLC to determine the concentration of the drug 
in solution. 
 
2.4.6 In vitro dissolution testing with USP apparatus 1 and 2 
 
Apart from the single stage dissolution method, an alternative method to simulate the 
physiological conditions using a 2 stage dissolution experiment was performed. In this 
model, the formulation is first dissolved in simulated gastric media (FaSSGF) and the 
medium was changed to intestinal media (FaSSIF-V1 or FaSSIF-V2), under near-
physiological conditions with respect to the composition of the fluids and the gastric 
emptying time. The dissolution setup with USP apparatus 1 (for capsule) and 2 (for 
tablet) are presented below: 
Dissolution medium volume Single stage: 500 mL  
2 stage: 250 mL (0-30 min, gastric stage) then  
500 mL (30-180 min, intestinal stage) 
 




Sample volume 3 mL  
 
Sampling location From a zone midway between the surface of 
the dissolution medium and the top of the 
rotating basket or blade, not less than 1cm from 
the vessel wall (42) 
 
Sampling times Single stage: 5, 10, 15, 20, 30, 45, 60, 75, 90, 
120, 150, 180 
 2 stage: 5, 10, 15, 20, 30, 35, 40, 45, 60, 75, 
90, 120, 150, 180 
   
Number of experiments      n = 3 (triplicate) 
 
Dissolution media CA: Compendial media (SGF, SIF) Biorelevant 
media (FaSSIF-V1, FaSSIF-V2, FaSSGF, 
FeSSGF, FeSSIF-V2, digested early FeSSGF, 
early FeSSGF), 2 stage (FaSSGF/FaSSIF-V1 
and FaSSGF/FaSSIF-V2) 
ITR: Compendial media (SGF, SIF) Biorelevant 
media (FaSSIF-V2, FaSSGF, FeSSGF, 
FeSSIF-V2), 2 stage (FaSSGF/FaSSIF-V1 and 
FaSSGF/FaSSIF-V2) 
CX: Biorelevant media (FeSSGF), Modified 
media (SIF-M4 and SIF-M5), 2 stage 
(FaSSGF/FaSSIF-V1 and FaSSGF/FaSSIF-V2) 
 
Formulation tested:  CA: Zinnat® 
ITR: Sporanox® 
CX: CX formulation 8 
 
Sampling procedure (USP apparatus 1 and 2): 
 
1. Aqueous media 
3 mL samples were removed using a 5 mL Fortuna® Optima syringe fitted with a 
stainless cannula. The drawn volume was replaced with the same volume of fresh 
dissolution medium, which was kept in a separate vessel at a temperature of 370.5C. 
Each sample (apart from the milk-based media) was filtered through a Whatman 
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cellulose nitrate membrane filter 0.45μm (Whatman, Maidstone, UK) equipped in a 
stainless steel filter holder swinny style (Millipore, Billerica, USA); after discarding the 
first 1  mL, an appropriate volume of the filtrate was diluted with the dissolution medium 
and injected into the HPLC system.  
 
 
2. Milk-based media 
For the milk-based medium (FeSSGF, early FeSSGF and digested early FeSSGF) 3 
mL samples were withdrawn through a 10 µm inline polyethylene cannula filter 
connected to the end of the cannula. Since simple filtration was not applicable for these 
media, samples were subjected to a preparation step consisting of protein precipitation 
using acetonitrile and subsequent centrifugation, prior to the filtration step. The filtered 
samples were added with 1:1 (for CA) or 1:2 (for ITR and CX) of acetonitrile. The 
mixture was vortexed for 1 min and centrifuged (at 8000 rpm for 10min and at 10 ⁰C). 
The supernatant was filtered (0.45 µm nylon filter) before injecting into the HPLC. 
 
 
2.4.7 Standard curves analysis using HPLC 
 
The stock solution of CA was prepared in methanol whereas the stock solutions of ITR 
and CX were prepared in acetonitrile. A calibration curve in dissolution media was 
prepared each time prior to each experiment to ensure consistency with the dissolution 
media, mobile phase and HPLC system. Appropriate amounts of stock solution were 
transferred into volumetric flasks and were diluted with tested media in order to achieve 
the desired standard concentration. Then an adequate volume of these solutions was 
injected into the HPLC system.  
 
 
2.4.7.1 Aqueous media 
Aqueous media refer to dissolution media (used in this project) that do not contain milk 
or digested milk. The concentrations used in the calibration curve in each dissolution 






Table 12. Parameters for standard curves of aqueous media 
Drug Stock solution conc. 
(μg/mL) 
Standards conc. range 
(μg/mL) 
Standard conc. (μg/mL) 
CA 1000 10-200 10, 15, 20, 30,50, 80, 100, 
120, 140, 200 
ITR 1000 and working stock 
solution 100 
0.1-5 0.1, 0.2, 0.5, 1, 2, 3, 4, 5 
 
CX 1000 and working stock 
solution 100 
0.1-4 0.1, 0.2, 0.3, 0.4, 0.5, 
0.6,1,1.5,2,3,4 
 
The typical chromatograms of CA, ITR and CX are presented in Appendix 1. 
 
2.4.7.2 Milk-based media 
 
Milk-based media refer to dissolution media (that were used in this project) that contain 
milk (FeSSGF, early FeSSGF and digested early FeSSGF, refer to Table 2 for 
composition of media). The protein precipitation and centrifugation analysis method for 
milk-based medium, as proposed by Fotaki et al. (63) were used. In this method the 
appropriate type and volume of organic solvent were added into the milk-based 
medium and then the mixture was vortexed before centrifuging to separate the milk 
protein and aqueous phase. Furthermore, drugs can distribute into several phases of 
milk: they can bind to the milk proteins or dissolve in the oily or the aqueous phase of 
the emulsion (57). Likewise, the standard solutions in milk-based media (Table 13) 
were prepared using the following steps: in a centrifuge tube containing 2 mL of milk-
based medium, an appropriate amount of stock solution (reference standard dissolved 
in acetonitrile) was added. After vortexing for one minute, an appropriate amount of 
acetonitrile was added in order to achieve a ratio of 1:2 (Stock solution: Acetonitrile) for 
ITR and CX and a ratio of 1:1 (Stock solution: Acetonitrile) for CA (The use of higher 
ratio in ITR and CX is important to ensure no precipitation occurs in the mixture during 
analysis). After vortexing for one minute, the samples were centrifuged for 10 min at 
8000 rpm and 10 °C. The clear supernatant was then filtered using a 0.45μm nylon 




Table 13. Parameters for standard curves of milk-based media 
Drug Stock solution conc. 
(μg/mL) 
Standards conc. range 
(μg/mL) 
Standard conc. (μg/mL) 
CA 1000 10-200 10, 15, 20, 30,50, 80, 100, 
120, 140, 200 




0.1, 0.2, 0.5, 1, 2, 3, 4, 5 
CX 1000 and working stock 
solution 100 
0.1-4 0.1, 0.2, 0.3, 0.4, 0.5, 
0.6,1,1.5,2,3,4 
 
In order to study and characterise the dissolution profile of Sporanox® in the fed 
stomach, digested early FeSSIF was used to simulate the gradual digestion of the 
meal. Digested early FeSSGF was prepared by adding a pepsin solution (1.11mg/mL 
of pepsin in HCl (1.83 N, 1 mL) into solutions at 0, 15, 30, 45, 60, 75 and 90 min time 
points) into flasks pre-filled with early FeSSGF.  The solutions were mixed in a shaking 
water bath (37°C) for 60 min and a sample of 2 mL from each flask was then 
transferred into a centrifuge tube containing 4 mL of acetonitrile.  After vortexing for 1 
min, the sample was centrifuged for 10 min at 8000 rpm and 10 °C. The clear 
supernatant was then filtered using a 0.45 µm nylon filter before injecting into the 
HPLC system.  
 
In order to ensure the analytical procedure to reproducibly and accurately quantify the 
amounts of drug released in the milk-based medium the following method validation 
studies were performed.  
 
Drug recovery study (milk-based media) 
Drug recovery studies (performed in milk-based media) were also performed. Similar 
calibration curves as presented in Section 2.4.7.1 were constructed but replacing milk-
based medium with its blank media (media with the milk component replaced with 
water). The precision and accuracy occurring in spiked media with milk standards 
within this range (CA: 0.4-50, ITR: 0.1-6, CX: 0.2-8) using a standard addition method 
were evaluated (in triplicates). The recovery of tested drugs added to samples to 
determine the procedure’s accuracy was calculated as follows (Equation 10) (263): 
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Fat binding test (milk-based media) 
 
In the analysis process the milk was centrifuged to separate the precipitated protein 
with the aqueous phase. The aim of the fat binding test is to investigate the extent of 
drug (CA, ITR and CX) partition into the milk fat layer during centrifugation. Firstly, the 
control standard solutions were prepared by centrifuging the standard solutions, 
syringing out the supernatant component and then protein precipitation of the 
supernatant (through the addition of organic solvent). Thus a large amount of highly 
lipid soluble compound will be partitioned into the fat layer leaving a smaller amount of 
drug in the supernatant solution. Secondly, the tested standard solutions were 
prepared by following the normal steps of protein precipitation and then centrifugation 
whereby the standard solutions were added to organic solvent and then centrifuged.  
Percentages of drug partition into the milk fat layer are calculated using Equation 11. 
 
               
                                                                     
                               
 Equation 11 
 
 
2.4.8  Drug degradation studies (Cefuroxime axetil) 
 
CA could undergo hydrolysis to other isomers at different rates under various 
conditions as discussed in Section 1.8.1.1. Characterization of the rate and extent of 
CA hydrolysis during the dissolution test was carried out as part of the dissolution 
experiments carried out in SGF, FaSSGF, FaSSIF-V2 and SIF with USP apparatus 2. 
The dissolution testing conditions were stated in Section 2.4.8. For a more complete 
consideration of the degradation process the experiments were carried out up to at 
least 9 h (extra samples were collected at 240, 300, 360, 420, 480, 540 min). The 
concentration of CA after 120 min determined from USP apparatus 2 were plotted over 
time using Microsoft ExcelTM (the CA concentration after 120 min showed a steep 
negative curve which was evidence of drug degradation). Since the CA degradation is 
a first order process (206, 264) the CA degradation rate constant was determined 





                            Equation 12 
 
Where k is the degradation rate constant, C is the concentration at a time “t”, Ci is the 
initial concentration and t is time   
 
2.4.9 In vitro dissolution with USP apparatus 4 
 
According to the United States Pharmacopeia (USP, edition 32)  specifications a 5 
mm–size glass was positioned in the tip of the cell (22.6 mm-size) (42), 1.7 g of 1 mm–
size glass beads were added, while on the top of the cell a Whatman® GF/F and GF/D 
glass fibre filter were used. Additionally, 0.3 g of glasswool was used for CX 
formulation and Sporanox® dissolution study to enhance the filtration capacity. The 
Zinnat® and CX formulation were placed on the tablet holder whereas Sporanox® 
capsules were laid on the glass beads with inverted tablet holder to prevent the 
capsule from floating on the top of the cells (Figure 12).  
 
Figure 12. Schematic diagram of cell setup for the USP apparatus  
(a) Zinnat® and CX formulation and (b) Sporanox® capsule. 
 
The experiments were performed with sequential changes of the media and flow rates 






Table 14. The periods during which formulations were exposed to the various dissolution media 
and flow rates  
Type of medium 




(CA and ITR only) 







SGF+0.01%SLS 0-60 8 
Na-SIF+ 0.2% SLS 
60-240 (CA) 








60-600 (ITR, CX) 
4 
Modified media 
(SGF-M2/ SIF-M3) (CX only) 
SGF+0.015% HTAB 0-60 8 
SIF+0.1% HTAB 60-600 4 
Biorelevant media 
(Fasted state) 
FaSSGF 0-60 8 
FaSSIF-V1 
60-240 (CA, ITR) 
60-300 (CX) 
4 
FaSSGF 0-60 8 
FaSSIF-V2 





FeSSGF 0-120 6 
FeSSIF-V1 120-360 6 
FeSSGF 0-120 6 
FeSSIF-V2 120-360 6 
*The flow rate is defined in steps in the piston pump. Their relation is given by the 
equation: y=0.0157x+0.7842 (y: flow rate, x: steps). 
 
Sampling times:  
Every 10 min up until 240 min (fasted state studies for CA and ITR) and up until 300 
min (fasted state studies for CX) (additional sampling at every 30 min until 600 min). 






Sampling procedure (USP apparatus 4): 
The samples were collected in volumetric cylinders and an adequate volume was 
diluted with the dissolution medium (when appropriate) and injected into the HPLC 
system.  
 
For the milk-based medium, 3 mL of the collected samples were diluted with 
acetonitrile (1:1 for CA or 1:2 for ITR and CX). The mixture was vortexed for 1 min and 
centrifuged (Centrifugation 8000 rpm, 10 min at 10 ⁰C). The supernatant was filtered 
(0.45 µm nylon filter) before injecting into HPLC. 
Formulations tested were:  
1. CA: Zinnat® 
2. ITR: Sporanox® 
3. CX: CX formulations (Formulation 4, 5, 6, 7, 8, composition presented in Section 
2.3.3). The types of experiment performed for CX formulations are presented in Table 
15. 
 
Table 15. The types of experiments performed for CX formulations  
CX 
formulation 
USP apparatus 4 experiment 
F4 FaSSGF/FaSSIF-V2, FeSSGF/FeSSIF-V2 
F5 FaSSGF/FaSSIF-V2, FeSSGF/FeSSIF-V2 
F6 FaSSGF/FaSSIF-V2, FeSSGF/FeSSIF-V2 
F7 FaSSGF/FaSSIF-V2, FeSSGF/FeSSIF-V2 
F8 SGF-M1/SIF-M1, SGF-M1/SIF-M2, SGF-M1/SIF-M3, SGF-M1/SIF-M1,  
FaSSGF/FaSSIF-V1, FaSSGF/FaSSIF-V2, FeSSGF/FeSSIF-V2 
 
 
2.4.10 Drug precipitation study (Sample after media change with USP apparatus 
4) 
 
The aim of this study was to determine the drug concentration in the opaque/cloudy 
sample collected during media and flow rate change with USP apparatus 4. The results 
of the precipitation study should confirm whether the excipient or the drug precipitate 
causes the opaqueness/cloudiness. The precipitation study was performed by ITR and 
CX only because there was no precipitation observed in the dissolution experiment of 
CA. The discriminatory sample treatment methods for the opaque sample collected 




Method one (Filtered sample) 
The precipitate (or solid phase of the drug) dispersed in the medium was separated 
immediately after collection using a filtration technique. Firstly the sample collected at 
70 min was shaken well and a fraction of this sample was withdrawn using a 5 mL 
Fortuna® Optima® syringe; then the sample was filtered through cellulose nitrate 
membrane filters (0.45 μm, Whatman) fitted within 13 mm stainless steel swinny filter 
holders. The first 1 mL of filtrate was discarded. The clear eluent was analysed using 
HPLC or diluted with a dissolution medium before analysis. 
 
Method two (Methanol diluted sample) 
The precipitated sample (5 mL) was dissolved in methanol (45 mL, to dissolve any 
possible suspension of drug particles).  The mixture was shaken well and filtered using 
nylon membrane disc filters (0.45 µm) fitted with 13 mm stainless steel swinny filter 
holders. The first 1 mL of filtrate was discarded. The clear eluent was analysed using 
HPLC or diluted with the dissolution medium before analysis.  
Concentrations of both filtered and methanol diluted samples were calculated and the 
amount of drug dissolved (mg) was calculated based on the volume of the sample 
collected between 60 to 70 min. % of the dose precipitated (after media and flow rate 
change) in each cell was calculated accordingly: 
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          Equation 13 
 
* Dose of CA= 250mg, dose of ITR= 100mg, dose of CX= 240mg 
 
Mean± SD values of % dose precipitated were plotted on bar charts for each 
formulation across all dissolution media. 
 
2.4.11 Statistical analysis: Dissolution profile comparison 
 
Dissolution profile comparisons were performed with the use of difference factor f1,area 
(Equation 14) (266):
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    Equation 14
  
  





Evaluation of f1,area was considered up to the time corresponding to the first 
experimental datum after 85% of the plateau level of the reference data set. In cases 
where this datum point was not observed within the last time point of experimentation, 
f1,area was evaluated up to 4 h, to reflect the maximum physiologically reasonable small 
intestinal residence period (63). The profile comparison index calculation could be 
based on the mean data sets if the data set involved has low variability (167) (% 
coefficient of variation of data points at every sampling time less than 20%). In this 
project f1,area was applied from mean data sets and a suggested 20% average 
difference of a test from a reference data set (f1,area = 0.20) was used as the limit for 
identifying differences between the samples (266). In each dissolution profile 
comparison, one profile was chosen as the reference profile. 
 
2.4.12 Dissolution kinetics modeling 
 
Estimates for kinetic parameters were derived by fitting to the set of data in media 
simulating gastric and intestinal states. Full dissolution profiles as a whole were used 
for CA (Dissolution profile presented in Section 3.2). Meanwhile separate fitting for ITR 
and CX dissolution profile in the simulated gastric (first 1 and 2 h in simulated fasted 
and fed conditions, respectively) and intestinal phases (post 1 and 2 h in simulated 
fasted and fed conditions, respectively) were performed using first order kinetics and 
Power law models (Dissolution data presented in Sections 3.3 and 3.4). In that case, a 
model with lag time was applied whereby a lag time of 1 h and 2 h was used for 
simulated fasted and fed conditions respectively. The mathematical expressions used 
to describe the kinetics of drug release and the discernment of the dissolution and 
release mechanisms are shown in Table 16. The model used was based on the 
observation of the curve pattern and the type of formulations, for example Power law 
was applied for kinetic ITR because Sporanox® is a drug-HPMC polymeric coated 
multi-particulate formulation. Mean± SD values of the fitted parameters were 









Table 16. Dissolution kinetics model applied 
Model Equation Reference 
First order       (   
(   )) (267) 
First order with lag time       (   




     
(269) 
Power law with lag time 
  
  
  (      )
  
(270) 
Single Weibull function    (      (






First order kinetics: ft is the percentage of drug dissolved in time t. Max and c are the 
maximum cumulative percentage dissolved and first order rate constant, respectively. 
Tlag denotes the lag time.  
Power law: The Power law model is generally used to analyse the release of 
pharmaceutical polymeric dosage forms when the release mechanism is not well 
known or when more than one type of release phenomenon could be involved (271). Mt 
and M∞ are cumulative percentage of drug dissolved at time t and infinite time, 
respectively (Mt/M∞ is the percentage drug release at time t). Tlag denotes lag time and 
k is a dimensionless constant incorporating diffusion coefficient of the compound and 
geometric characteristics of the drug dosage form; n is the dimensionless diffusion 
exponent that depends on the transport mechanism and the shape of the matrix tested 
(269, 272). For swellable (a characteristic of HPMC) spherical sample, n values of 
0.43, 0.43–0.85, 0.85 and >0.85 indicates Fickian, non-Fickian (anomalous), Case II 
(zero order) and Super Case II transport (269, 273). Furthermore, Ritger and Peppas 
proposed an additional interpretation that n<0.43, diffusion controlled release; n>0.85, 
erosion controlled (polymer relaxation) release; 0.43<n<0.85, mixed mechanism (drug 
diffusion in the hydrated matrix and the polymer relaxation) (273). When pure diffusion 
is the controlling release mechanism, n = 0.5 (274). Power law is short time 
approximations of complex exact relationships and therefore its use is confined to the 
description of the first 60% of the release curve (274, 275). 
Weibull function: The Weibull function is a very versatile and commonly used model for 
fitting dissolution data of different curve shapes (272). Max is the maximum percentage 
of the drug dissolved, a is the time scale parameter, which provides information about 
the scale of dissolution process. Scale parameter (a) also represents the time interval 
necessary to dissolve or release 63.2% of the drug. b is the shape parameter [1st order 
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exponential (b = 1), sigmoid or S-shaped with upward curvature followed by a turning 
point (b > 1) or parabolic, with a higher initial gradient m and after that consistent with 
the exponential (b < 1)] (87, 271).Tlag denotes lag time which essentially is a location 
parameter which represents lag period before the actual onset of the dissolution 
process.  
2.5 Methods of Part 2: Surface UV dissolution imaging  
 
2.5.1 Experiment setup and protocol 
 
In vitro surface ultraviolet (UV) imaging experiments were performed using Sirius SDI 
(Surface Dissolution Imager, Sirius Analytical Instruments, East Sussex, UK). The 
Sirius SDI includes ActiPix™ UV area imaging technology combined with a laminar 
flow-through sample holder, integrated syringe pump and software (Schematic of 
apparatus is presented in Figure 7 in Section 1.5). The light source was a pulsed 
xenon lamp and detection was performed at 280 nm (band width 10 nm). The utilised 
CADISS-2 quartz flow cell had a light path of 4 mm. The imaging system consists of 
1280 × 1024 pixels with dimensions of 9 × 7 mm2 (total imaging area of 9 × 7 mm2), 
and each pixel can be considered as a conventional single-beam spectrophotometer. 
Output from the sensor is connected to a computer at a rate of one snapshot every 0.5 
s for processing and storage. A syringe pump (RS-232 integrated pump, Maxim 
Integrated Products, Inc, US) was used for infusion of dissolution media at constant 
and changing flow rates, with temperature controlled at 37°C using Techne DB-2D Dri-
Block® digital heater (Staffordshire, UK). Dissolution experiments themselves were 
performed using ITR and CA reference standard, Sporanox® and Zinnat® compacts, as 
described below. 
 
2.5.2 Preparation of compacts 
 
Compacts were prepared using ITR (4 mg) and CA (4 mg) reference standard powder, 
Sporanox® pellet (4 mg, the hard gelatin Sporanox capsule was removed beforehand) 
and grounded Zinnat® tablet powder (4 mg, Zinnat® tablet was grounded into fine 
powder using mortar and pestle).  Samples were transferred into a stainless steel 
cylinder sample cup (2 mm ID x 2.4 mm height). The sample cup was fitted into the 
middle plate and was accurately positioned over the compression base and beneath 
the compression rod. After powder had been placed inside the middle plate, the top 
plate was fitted. A Quickset Minor® torque screwdriver was then used to compress the 
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weighted materials at a constant torque pressure of 0.6 Nm. The compression was 
held continuously for 1 min, then the compression rod and top plate were removed to 
allow recovery of the packed sample cup. The surface to be tested was in contact with 
the bottom plate thus great care was taken in order not to touch this surface once it 
had been removed from the bottom plate. Examples of prepared compacts are 









Figure 13. Examples of Sporanox pellet (A), ITR API (B) and CA API (C) compact used for the 
surface dissolution imaging studies.  
 
2.5.3 Design of experiment  
 
2.5.3.1 Media and flow rate change  
 
The design of the experiment with flow rate change was based on the setup used in 
USP apparatus 4 (flow through cell). Due to the diameter of the sample cup (in Actipix 
SDI) being 2 mm compared to the diameter of flow through cells of 22.6mm, the flow 
rate and time for media change was scaled down by one order magnitude. For 
example in the USP apparatus 4 setup the flow rates of 8 mL/min (gastric phase) in the 
first 60 min and 4mL/min (intestinal phase) were used whereas in surface UV imaging 
setup the flow rates of 0.8mL/min (gastric phase) in the first 6 min and 0.4mL/min 
(intestinal phase) were used. 
 
2.5.3.2 Flow rate and its correlation with physiological linear velocity 
 
A linear regression of linear velocity of ActiPixTM’s flow through cell from various  flow 
rate can be made using the data presented in literature (124) (Table 17). The flow rate 
corresponding to the published nominal physiological linear velocity for stomach (2 




Table 17. Linear velocity of ActiPix
TM
’s flow through cell from various flow rates  
Flow rate ( mL/min) 0.1 0.2 0.4 0.8 1.2 
Linear velocity 0.7 1.4 2.9 5.7 8.6 
 
 
2.5.3.3 Procedure for surface UV dissolution imaging  
The procedure for surface UV dissolution imaging was as follows: 
1. For the first 10 sec period of imaging, dark values (UV light is off) are measured 
to account for the electronic noise. An average dark value is then subtracted 
from each background value to negate contributions from electronic noise. The 
subsequent 10 sec are used to collect the background intensities from the 
buffer contained within the flow cell.  
2. Dark images (I0; lamp turned off; 10 sec) and reference images (I ref; 10 sec) 
were recorded with the dissolution cell filled with the medium. During the 
reference period, a stainless steel cylinder was placed in the sample holder. 
3. After 60 sec, data collection was paused and the sample compact was then 
fitted into the sample cell before the sample cell was inserted into the 
dissolution cell. The pre-set flow program and data collection was then started. 
The pre-set flow programs consist of (1) Changing flow rate; (2) Constant flow 
rate and (3) Media and flow rate change (Table 18). UV images were therefore 















Table 18. The periods the compact was exposed to the dissolution media and the flow rate of 
each medium pumped through the cell 
Medium                                    Period (min) of each flow rate      Flow rate (mL/min) 
ITR and CA reference standard compact 
Changing flow rate 
SGF/ FaSSGF/ SIF/ FaSSIF-V1      5 or 15                        0.14, 0.28, 0.4, 0.6, 0.8, 1 
Media and flow rate change 
SGF/ FaSSGF                                  0-6                                          0.8 
SIF/ FaSSIF-V1                                7-30                                        0.4 
Sporanox
®
 pellet compact 
Constant flow rate 
SGF/ FaSSGF/ SIF/ FaSSIF-V1      5 or 15                       0.14, 0.28, 0.4, 0.6, 0.8, 1 
Media and flow rate change 
SGF/ FaSSGF                                  0-6                                                 0.8 
SIF/ FaSSIF-V1                                7-30                                               0.4 
 
4. Calibration curves were constructed by flowing drug standard solutions through 
the dissolution cell at a flow rate of 1 mL/min. Recording of UV images was 
performed while each of the standard solutions was infused for a period of 
5 min. The buffer was infused before and after the series of reference standard 
solutions for 4 min in order to detect baseline drift. The standard solutions were 
prepared using CA and ITR reference standard in FaSSGF and SGF 
respectively. The concentration range used was 5-180 µg/mL). FaSSGF was 
chosen for CA because the degradation is lowest in FaSSGF among all 
FaSSIF-V1, FaSSGF, SGF and SIF (refer to CA degradation Section 3.2.1) and 
SGF was chosen for ITR mainly due to its relatively good solubility in SGF. 
Three UV readings were made at different time points at each concentration 
and the average values were used for the calibration plot.  
 
The collected data were then used to calculate dissolution rates of tested compounds 
in the various media at 1 min intervals, using ActiPixTM D100 software version 1.5. This 
function employs absorbance values read from pixels within a designated quantification 
region of each image, located downstream from the surface of the dissolving sample 
compact. Absorbance values at each pixel row within the quantification region were 
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combined with the corresponding flow rate profile (defined by the software), together 
with the surface area of the drug compact, the molar mass and the molar absorptivity 
(extinction coefficient) of CA and ITR (determined from calibration curves), in order to 
compute drug dissolution rates. The calculated dissolution rates were subsequently 
used by the software to calculate the cumulative amount of drug dissolved. The 
calculation of the amount of dissolved drug is based on the assumption that the UV 
absorbance for each pixel reading is within the linear range (following Beer Lambert's 
law, Appendix 2). 
The absorbance of the dissolution medium is set to zero prior to the measurement of 
the samples. In the ActiPixTM D100 software the procedure for every experiment is to 
measure the reference (Iref) and the dark current (I0, electronic noise measured with the 
lamp turned off) within the first 20 s of a measurement, which are subtracted from all 
sample absorbance signals (Isig).  
 
The conversion of pixel intensities to absorbance values (A) was done using the 
ActiPixTM software based on Equation 15 (111). Absolute absorbance values were 
collected by reading each pixel intensity (mean value) during the background (or Io) 
collection and then applying the standard log formula for Absorbance. Each pixel 
records the absorbance of light by photons in the quartz cell 4 mm (width) above it. The 
same principles of Beer’s law apply to this arrangement with the exception that (b) the 
path length is 0.4 cm instead of the normal 1 cm 
      (
       
       
)          Equation 15 
Where I0, Iref, and Isig are the pixel intensity due to the dark current (electronic noise 
measured with the lamp turned off), pixel intensity measured with the dissolution 
medium in the cell (reference signal), and pixel intensity measured during the 
experiment, respectively.  
The absorbance values for each pixel in the selected viewing area create a 2-D image, 
and the images collected for the duration of the experiment were used to create a film 
(continuous images). Thus, a high resolution 2-D film of UV absorbance is captured 
that provides a detailed view of the dissolution process at the solid–liquid interface.  In 
order to extract the dissolution profiles from the UV absorbance film, the copyrighted 
software tools (ActiPixTM software) were used. 
The Limit of Quantification (LOQ) for infusion of CA and ITR reference standard 
solutions was estimated from Equation 16 (111) :  
    
 
  
            Equation 16 
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Where C, AU, and SD are the concentration of the ITR and CA reference standard 
solution, the mean UV absorbance of the selected pixels and the standard deviation of 










2.6 Methods of Part 3: Physiologically Based Pharmacokinetics (PBPK) Modeling 
 
The PBPK software used in this project is GastroPlus™. GastroPlus™ is a very useful 
modeling tool due to its broad functionalities such as predicting percentage absorbed, 
building drug-specific model, dosage formulations evaluation and design, drug 
metabolism and  pharmacokinetic model fitting, optimisation for drug-specific models 
and PSA (127, 162, 164, 277-282). The collection of mathematical models and 
correlations that were applied in GastroPlus™ mimicked the effects of a variety of 
physicochemical, physiological and formulation parameters on the absorption of drugs 
in the gastrointestinal tract (GIT) (163).  
 
The applications of GastroPlus™ to predict the absorption of three model compounds 
(CA, ITR and CX) were implemented in this study. A fundamental description of these 
mathematical models and the details of each parameter and its selection are presented 
in this section. The accuracy of the models developed using GastroPlus™ was 
validated by various published examples (126, 136, 164, 165). 
 
2.6.1 Computer hardware and software 
 
The simulations were performed on a Dell desktop station with Intel® Pentium Dual 
CPU E2160(1.80 GHz) using GastroPlus™ version 8.0 software (Simulation Plus Inc., 
Lancaster, CA). GastroPlus™ utilises the ACAT model to predict the rate and extent of 
drug absorption from the GIT (Refer to Section 1.6.2 for further details on PBPK 
modeling). It also incorporates intestinal drug efflux and metabolism in its predictions of 
pharmacokinetic parameters (163). 
 
2.6.2 Advanced Compartmental Absorption and Transit (ACAT) model 
description 
 
Input parameters in the ACAT model can be categorized into three classes: formulation 
properties (such as drug particle size distribution and density, dosage forms), 
physicochemical properties of drug substance (such as diffusion coefficient, 
lipophilicity, pKa, solubility and permeability) and pharmacokinetic parameters (such as 
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clearance, volume of distribution; Vd and fup). In addition, the ACAT model accounts for 
factors such as variation in the pH along the GIT. 
 
2.6.2.1 Compound database and dissolution model 
 
CA, ITR and CX were not included in the pre-built demo database of the GastroPlus™ 
thus a new individual compound database was built.  
 
Two main dissolution models, Johnson (283) and Wang-Flanagan (284), are available 
in GastroPlus™. In the current project, the dissolution model based on the Wang-
Flanagan model was used. 
2.6.2.2 Diffusion coefficient 
 
The diffusion coefficient (or diffusivity) is the “proportionality constant between the rate 
of change of concentration at a point and the spatial variation of the concentration at 
that point”. Theoretically, it indicates the rate of molecules in solution moving away 
from the surface of a dissolving particle into the free stream, and is a function of the 
viscosity of the surrounding fluid (163). The diffusion coefficient, γ, can be estimated 
using the Hayduk-Laudie formula whereby the VA is calculated from the molecular 
weight of the molecule (285) (Equation 17): 
 
         
     
              Equation 17 
 
Where: ηw = viscosity of water (cP) at 37°C. 
VA = Solute molal volume at its normal boiling point (cm
3/gmol). 
γ = binary diffusion coefficient at infinite dilution (cm2/s x105). 
 
 
2.6.2.3 Compound tab 
 
CA 
The physicochemical characteristics and in vivo study parameters of CA are 
summarized in Table 19. CA is a neutral compound with poor solubility and good 
permeability. The physicochemical properties (the acid dissociation constant [pKa], 
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partition coefficient [LogP]), protein binding (based on the unbound fraction in plasma 
[fu,plasma] and blood/plasma (B/P) ratio were taken from literature. The effective 
permeability (Peff) was derived from in-situ perfusion (rat) using conversion tools in 
GastroPlus™.  
Table 19. Physicochemical characteristics and in vivo study parameters of CA 
Parameters Values Comments/ references 
MW 510.48 Merck Index (286) 
logP 0.25 clogP value (203) 
Solubility (mg/mL) 0.395 (FaSSIF-V2) 
0.3719 (FeSSIF-V2) 
Kinetic solubility value measured from 
dissolution experiment with USP apparatus 2 
(Refer to Table 34 for other values used in 
solubility-based model) 
pKa - (neutral compound) Merck Index (286) 
Dose (mg) 300.27 The dose of CA corresponds to 250mg of 
Zinnat
®
 tablet used in in vivo (humans) study 
(287) 














Input as raw data as fractional % vs radius with 
total bin no. of 16 (290) 
Precipitation time 
(sec) 







 Converted value from molecular weight using 
built-in GastroPlus™ convertor. (Refer Section  





 cm/s Converted from rat in-situ perfusion permeability 






The physicochemical characteristics and in vivo study parameters of ITR are 
summarized in Table 20. 
Table 20. Physicochemical characteristics and in vivo study parameters of ITR 
Parameters ITR Comments/ references 
MW (g/mol) 705.65 (289) 









Scaled from human intestinal fluid 
data (292) using FaSSIF-V1 and 
FeSSIF-V1 solubility value (Refer to 
text for details). Refer to Table 34 for 
other values used in solubility-based 
model. 
pKa, acid/base species 3.7 (weak base) (291) 
Dose (mg) 100 (228) 
Volume of water administered 
(mL) 
100 (228) 
Particle density (g/mL) 1.2 (289) 
Mean particle radius (μm) 1 (244) 





 Converted value from molecular 
weight using built-in GastroPlus™ 
convertor (Refer to Section  2.6.2.2: 
Diffusion coefficient). 
Effective permeability, cm/s 3.46 ×10
–4
 Converted from MDCKII permeability 
value (293) (Refer to Section 2.6.3.1 
for further details). 
 
ITR: Scaling of in vitro biorelevant solubility 
As the pH of biorelevant intestinal media (FaSSIF-V1, FeSSIF-V1) and HIF is higher 
than or similar to pH 5, the solubility of ITR in these media was much lower than in 
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gastric media. In this case, the effects of mixed micelles found in human intestinal fluid 
and were reported to greatly enhance the solubility of ITR (30).  
In order to correlate the solubility of ITR in biorelevant media (fasted and fed states) 
with the human intestinal fluid, the solubility of 5 weak basic compounds in FaSSIF-V1 
vs fasted HIF as well as FeSSIF-V1 vs fed HIF were used to form the regression 
relationship (in log-log scale) (292). The solubility value of ITR in FaSSIF-V1 and 
FeSSIF-V1 (30) were then scaled using the established regression relationship 
(Appendix 3). 
In fasted HIF and in FaSSIF-V1 the regression formed is y=0.6068x+1.0272 (R2=0.80, 
log-log scale). The scaled value of FaSSIF-V1 (pH = 6.5) is 4.812x10-3 mg/mL, almost 
16 times higher compared with the solubility of ITR in FaSSIF-V1 0.34 x10-3 mg/mL 
(30). Meanwhile, in fed HIF and in FeSSIF-V1 the regression formed is 
y=0.5391x+1.4963 (R2=0.78, log-log scale). The scaled value of FeSSIF-V1 (pH = 5) is 
22.53x10-3 mg/mL, more than 30 times higher than the solubility of ITR in FeSSIF-V1, 
0.73 x10-3 mg/mL (30). 
 
CX 
The physicochemical characteristics and in vivo study parameters of CX are 
summarised in Table 21. The physicochemical properties (the acid dissociation 
constant [pKa], partition coefficient [LogP]), protein binding (based on the unbound 
fraction in plasma [fu,plasma], blood/plasma (B/P) ratio were taken from literature and a 
drug review published by the Center for Drug Evaluation and Research of FDA (in vivo 
studies conducted in humans) (233). The effective permeability (Peff) was derived from 












Table 21. Physicochemical characteristics and in vivo study parameters of CX 
Parameters CX Reference 
MW 489.93 (233, 249) 
Partition coefficient, 
logP (neutral, water) 
3.0 (233, 249) 
Solubility (mg/mL at 
pH=5) 
0.37 From solubility experiment in FeSSIF (at 2 h using 
shake flask method, (252)) (Refer to Table 34 for 
other values used in Solubility-based model). 
Dissociation 
constant pKa 




Dose/tablet (mg) 240 The dose used in in vivo (dog) study (252) 
Volume of water 
administered (mL) 











9000 Estimated value postulated from literature value 







 Predicted value from molecular weight using built 
in GastroPlus™ convertor (Refer to Section  





 cm/s Converted to Peff (dog) using built-in GastroPlus™ 
permeability convertor (Refer to Section 2.6.3.1). 
 
 
CX: Scaling of in vitro biorelevant solubility 
 
Similar to ITR, in order to correlate the solubility of CX in biorelevant media (fasted and 
fed states) with the human intestinal fluid, the solubility of 6 weak acidic compounds in 
FaSSIF-V1 vs fasted HIF as well as FeSSIF-V1 vs fed HIF were used to form the 
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regression relationship (in log-log scale) (292). The solubility values of CX in FaSSIF-
V1 and FeSSIF-V1 (252) were then scaled using the established regression 
relationship (Appendix 3).  
In fasted HIF and in FaSSIF-V1 the regression formed is y=0.7933x+0.8385 (R2=0.958, 
log-log scale). The scaled value of FaSSIF-V1 (pH = 6.5) is 0.11mg/mL, almost three 
times higher than the solubility of CX in FaSSIF-V1 0.04 mg/mL (252). Meanwhile, in 
fed HIF and in FeSSIF-V1 the regression formed is y=1.04x+0.4093 (R2=0.9572, log-
log scale). The scaled value of FeSSIF-V1 (pH = 5) is 1.08 mg/mL, almost three times 
the solubility of CX in FaSSIF-V1, 0.37mg/mL (252). 
 
2.6.2.4 Particle size distribution  
 
The particle radius was normally kept constant in equations. Using GastroPlus™, the 
particle radius could be modelled by monodisperse (all particles have the same radius) 
or polydisperse (contains a mixture of different size particles) particle size distributions.  
CA: Particle size distribution was entered as raw data as a fractional percentage vs 
particle size with total bin number of 16 (Figure 14). The initial mass of undissolved 
drug corresponding to each bin was calculated automatically by GastroPlus™ using  
the previously published data (290) (Figure 14). 
Figure 14. Particle size distribution of amorphous CA. Redrawn based on data available from 
PhD thesis by Ghazal (290). 
 
ITR and CX: Due to the lack of particle size distribution of the raw material of 
Sporanox® and CX formulations, mean particle size was used. The mean particle size 
















Particle size (µm) 
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2.6.3 Effective permeability (Peff)  
GastroPlus™ provides a logD model, which scales regional permeability so that 
effective permeability decreases as the ionised fraction of a compound increases. The 
default Opt logD model, SA/V 6.1 model and four coefficients, C1–C4, were used in the 
current study. All the physiology parameters were the default values in GastroPlus™.  
 
The absorption rate coefficient ka(i) for each compartment is the product of the effective 
permeability value for the absorption and the compartment scale factor (α) for the 
compartment (Equation 18). 
  ( )             Equation 18 
 
In GastroPlusTM, Peff was inserted on the Compound tab and equations of the 
Optimisable log D model were applied to adjust the absorption scale factor for each of 
the other compartments of the small intestine and colon. The absorption scale factors 
justify changes in passive transcellular permeability primarily due to changes in 
ionisation and the distribution coefficient.  
 
2.6.3.1 Conversion of the intestinal permeability  
 
In the absence of a measured Peff, an estimated value can be used in the simulation. 
Estimated Peff can come from an in silico prediction using software or from in vitro 
measurements. The programme also provides a convenient Peff converter to input 
experimental permeability data from any source for a number of BCS reference 
compounds and the Peff converter will generate a set of correlation models to estimate 
human Peff. For interspecies conversion, GastroPlus™ incorporates an allometric 
model to estimate human Peff from rat or dog Peff  measurements and vice versa 
To the author’s best knowledge, the actual measured Peff values in humans for CA, ITR 
and CX are not available. Therefore, in this project, data from Caco-2 (CX) or MDCK 
cell cultures (ITR) and from a rat gut perfusion study (CA) were used. This was 
achieved by developing a correlation between Peff in humans and the experimental 
models (163). 
 
The “convert permeability” from user data function in GastroPlus™ (with “user 
permeability data” file extensions) was used to create a correlation function between 
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human Peff and user-supplied data for permeability (Caco-2, rat gut perfusion and 
MDCK II).  
CA 
 
The apparent permeability coefficient of CA measured using Caco-2 cell monolayer 
(apical to basolateral direction, pH 6 buffer solution) following the application of 1.0 mM 
CA was 3.43 (±SD 0.15) x10-7cm/s (295). The apparent permeability coefficient was 
transformed using the built-in GastroPlus™ Caco-2 permeability conversion model 
(Caco-2 model convertor, the values are presented in Appendix 4) to an estimate of 
human Peff value, 0.55 ±0.21x10
-4 cm/s. This value had underestimated the in vivo 
value because the CA concentration in the reservoir of Caco-2 was far lower than the 
in vivo condition and CA degradation was high in the phosphate buffer at pH 6 (206). 
On the other hand, Peff of CA in rats measured using the in situ perfusion study was 
reported as 0.3332x10-4± 0.16 x10-4 cm/s (290). 
These values were scaled to human Peff, 0.9682x10
-4 cm/s using a built-in model in 
GastroPlus™. This model correlates the in situ rat permeability values with human Peff 
values using a regression relationship derived from example compounds where 
permeability values for such compounds were measured using both techniques for the 
same compounds (built-in data were not disclosed in the software) (163). The scaled 
values calculated from the GastroPlus™ model are very close to the value calculated 
from the conversion of Peff,man= 3.6*Peff,rat+0.03x10
-4 (R2 = 1.00), 1.2477x10-4 cm/s, 
reported by Fagerholm et al. (296). This value (1.2477x10-4 cm/s) was chosen and 
used in the CA model because the reported conditions of the experiment (where the 




Monolayer efflux studies with multidrug resistance and MDR1-MDCKII cell permeability 
studies were available for 9 reference compounds and in the same study the Papp value 
of ITR was also reported, 0.571±0.0261 x10-4 cm/s (293, 297). A regression 
relationship that correlates the Papp permeability values of the 9 compounds with 
human Peff values (built-in confidential GastroPlus™ data) was then established using 
the GastroPlus™ permeability convertor function. Thus, using this regression 








Peff of CX measured using the Caco-2 cell monolayer (basolateral-to-apical direction) 
was reported as 2.9x10-6 cm/s (252). These values were converted to human Peff, 
1.1565x10-4cm/s using a built-in model in the GastroPlus™ Caco-2 permeability 
conversion model. This model correlates the Caco-2 cell permeability values with 
human Peff values using a regression relationship derived from example compounds 
where permeability values for such compounds were measured using both techniques 
for the same compounds (163). Using the built-in GastroPlus™ convertor this value 
was then converted to Peff (dog), 2.801x10
-4cm/s. 
 
2.6.4 The pharmacokinetic model 
 
Plasma concentration profiles after IV administration of CA, ITR and CX (profiles 
presented in Appendix 5) were analysed using PKPlus™ to obtain the systemic 
clearance, Vd and distribution constants between central and peripheral compartments. 
Fitting of empirical PK models were performed using 1, 2 and 3 compartmental models.  
R2 and Akaike information criterion (AIC) was used to select the best fitted 
compartmental model which were subsequently used in simulations. 
 
CA 
The plasma profiles of cefuroxime with IV administration were reported by Finn et al. 
(209). In that particular study 12 healthy male volunteers were given a single dose of 
500mg cefuroxime IV injection and the reported mean cefuroxime plasma 
concentration profile was used in the compartmental analysis. Results of the 
compartmental analysis show cefuroxime IV profile was best represented by two 







Table 22. Compartmental analysis (1, 2 and 3 compartmental models) of cefuroxime in humans 
after administration of 500mg cefuroxime IV bolus (209) 
Parameter 1 compartmental 2 compartmental 3 compartmental 
Vd (central compartment)(L) 15.23 7.28 4.56 
Vd (2
nd
 compartment)(L) - 3.27 7.66 
Vd (3
rd 
compartment)(L) - - 37.09 
Clearance (L/h) 6.76 7.63 7.51 
K10 (1/h) 0.44 0.71 1.65 
K12 (1/h) - 0.08 5.26 
K21 (1/h) - 0.17 3.13 
K13 (1/h) - - 0.30 
K31 (1/h) - - 0.04 
Cmax (μg/mL) 33.00 46.50 109.50 
R
2
 0.68 0.99 0.91 
AIC -21.74 -68.63 -58.43 
 
Subsequently, the disposition model (of CA in GastroPlusTM) was constructed by using 
parameters from the fitted 2 compartmental model (best fitted compartmental model). 
Meanwhile, other IV pharmacokinetic parameters from the literature also were applied 
in the model: fup [67% (197)]; simulation time [24h (287, 288)]; body weight [70kg (287, 
288)] and blood to plasma concentration ratio [0.6315 (298)].  
 
ITR 
The results of the compartmental pharmacokinetic data analysis for 100mg ITR post 1 











Table 23. Compartmental analysis (1, 2 and 3 compartmental models) of ITR in humans after 
administration of 100mg ITR IV infusion (1 h) (291) 
Parameter 1 compartmental 2 compartmental 3 compartmental 
Clearance (L/h) 9.74 21.98 20.95 
Vd (L) 
(central compartment) 





- 5.43 162.83 
Vd (L) 
(3rd compartment) 












K21 (1/h) - 0.07 0.32 
K13 (1/h) - - 0.14 
K31 (1/h) - - 0.05 
R
2
 0.72 0.94 1.00 
AIC -17.74 -45.75 -69.79 
 
The results shows that the ITR IV concentration vs time curves were best fitted to 3 
compartment model (R2: 1.00, AIC:-69.79). Subsequently, the disposition model (of ITR 
in GastroPlusTM) was constructed by using parameters from the fitted 3 compartmental 
model. Meanwhile, other IV pharmacokinetic parameters from the literature also were 













Table 24. Reported IV pharmacokinetic parameters of ITR applied in ITR model 
Parameter Value Reference 
fup (%) 0.2 (291) 
Simulation time (h) 96 (228) 
Body weight (kg) 74.77 (291) 
Blood to plasma concentration 
ratio 
0.58 (291) 
Absolute bioavailability, F (%) 30 (fast) 
25 (fed) 
Observed values (fasted state) (299) and fed 
state (228) 
Cmax (µg/mL) 0.112 
(fast) 
0.083 (fed) 
Tmax (h) 3 (fast) 
4.47 (fed) 






Following the oral administration of a single dose of 1 mg/kg of intravenous CX to four 
healthy beagle dogs, blood samples were collected to determine plasma concentration 
of CX (252). Besides linear pharmacokinetics compartmental analysis, non-linear 
pharmacokinetics compartmental analysis of IV CX administration was also performed. 
This is because there are no reported in vitro results of CX metabolism by Cytochrome 
P450 enzyme and P-gp and results of CX non-linear compartmental analysis could be 
used to determine Vmax and Km of enzyme and transporter metabolism. The fitted 







Table 25. Mean± SD IV pharmacokinetics parameters of CX 240mg tablet orally in dogs using 
linear pharmacokinetic compartmental analysis 
Parameter 1 compartmental 2 compartmental 3 compartmental 
Vd (L)(Steady state) 5.59 5.59 4.31 
Clearance (L/h) 1.64 1.36 1.51 
K10 (1/h) 0.29 0.24 0.35 
K12 (1/h) - 0.05 2.02 
K21 (1/h) - 2.78x10
-6
 5.87 
K13 (1/h) - - 0.038 





 0.96 0.96 0.96 
AIC -35.33 -31.33 -32.01 
 
Table 26. Mean± SD IV pharmacokinetic parameters of CX 240mg tablet orally in dogs using 
non-linear pharmacokinetic compartmental analysis 
Parameter 1 compartment 2 compartment 3 compartment 
Vd (L)(Steady state) 6.05 5.64 5.59 
K12 (1/h) - 0.02 1.71 
K21 (1/h) - 0.03 3.02 
K13 (1/h) - - 0.04 
K31 (1/h) - - 0.07 





Km (µg/mL) 63230.00 4.91 0.89 
Cmax (µg/mL) 0.18 0.19 0.25 
R
2
 0.87 0.90 0.96 
AIC -39.04 -63.57 -70.11 
 
The results show that the CX IV concentration vs time curves were best fitted to 3 
compartment non-linear model (R2: 0.96, AIC:-70.11). Subsequently, the disposition 
model (of CX in GastroPlusTM) was constructed by using parameters from the fitted 3 
compartment non-linear model. Meanwhile, other IV pharmacokinetic parameters from 





Table 27. Reported IV pharmacokinetic parameters of CX applied in CX model 
Parameter Value Reference 
fup (%) 0.2 (in vivo humans 
study) 
(233) 
Simulation time (h) 24 In vivo (dog) study (252) 
Body weight (kg) 9.85±0.65 In vivo (dog) study (n=4, 
(252)) 
Blood to plasma concentration 
ratio 




2.6.5 Enzyme and transporter metabolism 
 
The sophisticated mathematical model that has been developed for the Metabolism 
and Transporter Module in GastroPlus™ accounts for the important interactions among 
transit, release, dissolution, absorption/ exsorption, metabolism, transport, plasma 
protein binding and pharmacokinetic parameters in the humans or animals. The model 
had been tested extensively with a variety of drugs that had undergone various 
combinations of saturable metabolism and transport that had been found to be in 
excellent agreement with published observations in humans for the compounds tested 
(136, 278, 300). The contribution of efflux transport by P-gp (P-glycoprotein) on the 
absorption rate was also accounted for in building the GI absorption model, where the 
in vitro values of Km and Vmax for P-gp (various model compounds) were obtained from 




2.6.5.1 Saturable gut and liver metabolism 
 
The ACAT model in GastroPlus™ accounts for the relative distribution of P-gp based 
on studies describing experimental distribution in human tissues (as shown in Table 
21-23). The contribution of passive diffusion and efflux transport were integrated 
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together to account for the total rate of absorption from the lumen to enterocytes. The 
contribution of the intestinal metabolism was also considered in the simulation by 
GastroPlus™ to calculate the gut metabolism rate by using the in vitro Km and Vmax 
values for CYPs. The distribution of P-gp in the GIT was not uniform, as it was shown 
by many studies in both animals and humans that the relative distribution of P-gp 
increases when approaching closer to the colon (302, 303). In contrast to P-gp, the 
distribution of CYP450 decreases when approaching closer to the colon. The relative 
distribution of CYP450 was also included in the calculation of the gut metabolism rate 
in each compartment (as shown in Tables 28-30). It is important to note that gut 
metabolism and apical membrane efflux will affect free drug concentration in the 
enterocyte, and the dynamic changes in concentration gradient will affect the rate of 
drug transport both into and out of the enterocytes to the intestinal lumen and portal 
vein.  
Meanwhile in GastroPlusTM gut metabolism was assumed to follow Michaelis-Menten 
kinetics. The enzyme kinetic constants for each gut metabolising enzyme were entered 
into the “Enzyme Table” with the location "Gut". Since the GIT was split into distinct 
compartments and each of these compartments could contain different amounts of 
enzyme, the regional distribution of the enzymes was required to calculate the rate of 
metabolic process in each compartment. When the enzyme already existed in the 
selected physiology, the column would hold the stored scale factor profile (as shown in 
Table 30-32).  
2.6.5.2 Enzyme metabolism  
 
Values for the maximum metabolic velocity, Vmax, and the Michaelis-Menten constant, 
Km) were inserted into the “Metabolism and Transporter Module” to calculate saturable 
metabolism. The Enzymes table shows the database table that stores the values of 
Vmax and Km for each drug record (163). Different distribution profiles of enzymes had 
been built into the GastroPlus™ programme (301) as shown in Table 28-30.  As with 
gut enzymes, GastroPlus™ will load the corresponding distribution factors for each 
compartment from the selected physiology into the “Physiology tab” for any transporter 
with Gut Location (Gut-Apical or Gut-Basolateral). 
 
It must be stressed that the default enzyme distribution factors represent the relative 
amount of the enzyme in each intestinal compartment to the amount of that enzyme in 
the liver; the default transporter distribution factors represent only relative expression 
levels of that transporter across different intestinal compartments. These values are not 




In fact, GastroPlus™ is the first commercial compartmental absorption and transit 
model to incorporate saturable gut and liver metabolism. In the “Physiology tab”, 





Enzyme and transporter effects were not applied in the CA models because linear 
relationships between the dose of CA and both Cmax and AUC were demonstrated in 
the bioavaibility study designed to evaluate the dose proportionality of four oral doses 
of CA (125, 250, 500, and 1,000 mg) (209).   
ITR 
 
Studies have reported that oral absorption and bioavailability of ITR are a function of 
dose (304-307). For example, after oral doses of 50, 100 and 200 mg, increases in the 
AUC and Cmax follow nonlinear kinetics, suggesting a saturation of the first-pass 
metabolism process in the liver and the intestine. Furthermore, consistent with 
concentration, dose and time nonlinearity, the elimination of ITR was found to follow 
Michaelis–Menten kinetics and it was suggested that ITR and/or its metabolites 
saturate intestinal and hepatic CYP3A4 and thus their own CYP3A4-mediated 
elimination (224, 226). Based on all the clinical evidences, the nonlinear metabolism in 
the liver and the gut was included in the PBPK model. 
 
The in vitro Vmax and Km of ITR were obtained from literature where the cDNA-
expressed CYP3A4 (supersomes)-mediated metabolism of ITR was used (226). From 
this study, the reported in vitro value of Vmax was 270 pmol/min/nmol CYP3A4 protein 
(226). However, this reported in vitro Vmax value was unrealistically large because its 
corresponding intrinsic unbound clearance value (CLint(u)) is 69.3 mL/min/nmol CYP3A4 
protein which was equal to an unreasonable total drug clearance of 33858 L/h 
(calculated using built-in “Enzyme and transporter convertor”). Thus it was necessary 
to scale the in vitro Vmax value to a corresponding in vivo ITR clearance value of 20.95 
L/h (determined using compartmental analysis with ITR IV profile) (291). Thus, a linear 
regression of in vitro Vmax vs in vivo intrinsic clearance of ITR was established by 
generating ten in vitro Vmax data using the metabolism and transporter units convertor 
(built-in GastroPlusTM software) with values of intrinsic clearance that were close to the 
real in vivo ITR clearance value (20.95 L/h). Using linear regression (y=0.095x+0.0001, 
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R2=1), the scaling of the in vitro Vmax value was performed and the scaled in vitro Vmax 
value of 2.095x10-2pmol/min/mg protein was found (Figure 15).  
 
Figure 15. In vitro Vmax (x10
-2
pmol/min/mg protein) as a function of in vivo intrinsic clearance 
(L/h). 
The scaled in vitro Vmax value was converted to the equivalent in vivo values using the 
built-in “Enzyme and transporter convertor”. After conversion, an in vivo Vmax value of 
1.685x10-5 mg/s was obtained and applied in the hepatic metabolism of ITR models. 
Meanwhile, the Km value for the hepatic metabolism of ITR by CYP3A4 is 0.00275 
µg/mL (226). This Km value was taken from the same study as above by Isoherranen et 
al. where cDNA-expressed CYP3A4 (supersomes)-mediated metabolism of ITR was 
tested.  
Likewise the Vmax and Km parameters of ITR due to gut metabolism of ITR by CYP3A4 
also were taken from the same study by Isoherranen et al. (226). As recommended by 
literature (278), the same Km value for the hepatic metabolism (0.00275 µg/mL) could 
be used for gut metabolism but the in vivo Vmax value for hepatic metabolism should be 
scaled with a scaling factor of two, giving an  in vivo Vmax gut metabolism value as 





It has been known that the major intestinal CYP3A isozyme is CYP3A4 for humans and 
CYP3A12 for dogs (308) and preliminary studies have indicated that the CYP3A12 is 
the major isozyme responsible for the metabolism of CX in dogs (233). Study also had 
shown that saturation of the first-pass metabolism process of CX occured in the liver 
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and the intestine of the beagle dog (139). Based on these information, nonlinear 
metabolism of CX in the liver and the gut are included in the PBPK model (beagle dog). 
Vmax and Km of both liver and gut metabolism were determined from nonlinear kinetics 
compartmental analysis of in vivo (beagle dog) IV studies (252). Vmax and Km values 
obtained from the fitting were 0.00069 mg/s and 0.894 mg/L respectively. 
 
2.6.5.3 P-glycoprotein transporter metabolism  
ITR 
 
The in vitro Vmax and Km values for P-gp were obtained from literature (137). P-gp 
transporter could be located in the “gut-apical” (at the apical enterocyte membrane) 
and “gut-basolateral” (at the basolateral enterocyte membrane) and an in vitro study 
using ITR determined that only efflux P-gp at the apical enterocyte membrane was 
responsive to ITR metabolism (137) thus the “efflux and gut-apical option” was 
selected in the GastroPlus™ model of ITR. The reported ATP hydrolysis (a parameter 
to determine the activity of P-gp) in the presence of ITR showed a Vmax of 69.1±1.5 
nmol/min/mg (137). As recommended by literature (278), scaling of in vitro Vmax for P-
gp metabolism is necessary before it can be used in PBPK modeling. It is because the 
ACAT model in GastroPlus™ uses the simulated concentration in the cytoplasm of the 
enterocyte for interaction with the binding site of P-gp (163). If the in vitro Vmax value 
was not scaled then the ACAT model predicted a very low drug concentration because 
of the rapid efflux of the substrates in the enterocyte (278).  
In order to perform the scaling, a correlation between in vivo intrinsic clearance and in 
vivo Vmax was established. Firstly, in vitro Vmax of the four model compounds reported 
in the study by Adachi et al. (309) was converted to its equivalent in vivo Vmax using 
built-in GastroPlus™ metabolism and transporter unit convertor. Basically, the 
convertor converted the value from in vitro unit of (nmol /min/mg protein) to in vivo unit 
of mg/s. Then, the in vivo intrinsic clearance for the four model compounds was 
calculated using Vmax and Km of P-gp kinetics as reported in a study by Adachi et al. 
(309) (Note: Vmax divided by Km is equal to intrinsic clearance). Using the same 
equation, the in vivo intrinsic ITR clearance by P-gp was calculated using Vmax and Km 
value obtained from literature (137). Figure 16 shows that there is a good correlation 
between in vivo Vmax (log scale) and in vivo clearance [logY=-2.22x10-2X+1.57, 
R2=0.97]. Using this linear regression function and the in vivo intrinsic ITR clearance by 
P-gp, the in vivo ITR Vmax (P-gp) of 2.2658x10





Figure 16. In vivo Vmax (mg/s) as a function of in vivo intrinsic clearance (x10
3
 L/h). The 
correlation line and correlation function between both parameters are indicated. 
Meanwhile, the reported ATP hydrolysis in the presence of ITR showed an apparent 
Km of 0.8±0.2 µM (137). Considering the fraction unbound of ITR is 0.002, these values 
were inserted into the built-in GastroPlus™ metabolism and transporter unit convertor: 
the calculated in vivo unbound Km was 0.5642± 0.1411 mg/L. 
It must be noted that the expression of P-gp in enterocytes exhibits similar intra and 
interpatient variability as seen with CYP3A4 and is not under synchronised regulation 
of CYP3A4 expression in the liver (310). Therefore, the Km of the P-gp and CYP3A4 of 
ITR in humans might differ. Subsequently, these kinetic parameters for CYP3A4 and P-
gp were then integrated into the ACAT model. The ACAT model assumed that P-gp 
and CYP3A4 were present in the same forms with similar intrinsic activity in all parts of 
the GIT; therefore any change in the rate of flux by P-gp or metabolism by CYP3A4 




In vitro studies conducted in transfected Madin-Darby canine kidney II (MDCK II) cells 
showed that the intracellular accumulation of CX was significantly restricted because of 
active efflux by P-gp (ABCB1/MDR1). Bidirectional flux studies indicated greater 
transport in the basolateral-to-apical direction than the apical-to-basolateral direction 
because of active efflux by P-gp. The P-gp inhibitor decreased the flux ratio by more 
than 50% thus the result strongly suggested that CX is a P-gp substrate (139). Similar 
y = -0.0222x + 1.5658 


























In vivo intrinsic clearance x103 (L/s) 
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to CYP3A12, Vmax and Km of gut efflux transportation by MDR-1 was determined using 
nonlinear kinetics compartmental analysis of in vivo (dog) IV studies (252), thus the 
same values of V (0.00069 mg/s) and Km (0.894 mg/L) were applied in the CX models. 
The kinetic parameters for CYP3A4 and P-gp were then integrated into the “Physiology 
tab” of the ACAT model.  
 
2.6.6 Physiology tab 
 
The GastroPlusTM contains built-in physiology models that can be selected. Each 
physiology model contains pH values, transit times, and geometric parameters 
(lengths, radii, volumes) that are appropriate to the selected physiology. For the fed-
state models, the physiology input parameters for food-induced changes to GI 
physiology such as increased gastric residence, increased splanchnic blood flow, lower 
GI motility, bile salt/lecithin micellar solubilisation are considered and incorporated into 
the built-in database of the GastroPlus™ programme. 
In this project, the default physiology models for the fasted (“Humans Physiological 
Fasted”) and fed state (“Humans Physiological Fed”) in humans were used for CA and 
ITR (humans in vivo data available). The default physiology models for the fasted 
(“Beagle Physiological Fast”) and fed state (“Beagle Physiological Fed”) in beagle dogs 
were used for CX (in vivo data available in beagle dogs). 
CA and ITR (Human physiology model) 
 
The default value of the parameter set in “Human physiological fast” and “Human 
physiological fed” is used for all CA and ITR models (fasted and fed states accordingly) 









Table 28. ACAT physiological model parameters for simulation of CA and ITR (fasted state 
humans) 
Compartment data (CA and ITR) Enzyme and transporter 
regional distributions 
(ITR) 


















Stomach 0.0 1.30 0.25 
 
49.32 29.37 9.91 0.0 0.0 
Duodenum 2.730 6.00 0.26 45.21 14.67 1.57 0.538 1.96x10
-3
 
Jejunum 1 2.675 6.20 0.94 169.3 60.63 1.49 0.645 3.10x10
-3
 
Jejunum 2 2.669 6.40 0.74 132.8 60.63 1.32 0.723 3.08x10
-3
 
Ileum 1 2.623 6.60 0.58 103.6 60.63 1.17 0.77 9.75x10
-4
 
Ileum 2 2.591 6.90 0.42 76.36 60.63 1.00 0.838 9.78x10
-4
 
Ileum 3 2.521 7.40 0.29 54.37 60.63 0.84 0.908 9.8x10
-4
 
Caecum 54.67 6.40 4.39 51.10 13.56 3.46 1.000 2.96x10
-4
 





Table 29. ACAT physiological model parameters for simulation of CA and ITR (fed state 
humans) 
Compartment data (CA and ITR) Enzyme and transporter 
regional distributions 
(ITR) 


















Stomach 0.0 4.90 1.00
 
986.4 29.37 9.91 0.0 0.0 
Duodenum 2.730 5.40 0.26 45.21 14.67 1.57 0.538 1.96x10
-3
 
Jejunum 1 2.675 5.40 0.94 169.3 60.63 1.49 0.645 3.10x10
-3
 
Jejunum 2 2.669 6.00 0.74 132.8 60.63 1.32 0.723 3.08x10
-3
 
Ileum 1 2.623 6.60 0.58 103.6 60.63 1.17 0.77 9.75x10
-4
 
Ileum 2 2.591 6.90 0.42 76.36 60.63 1.00 0.838 9.78x10
-4
 
Ileum 3 2.521 7.40 0.29 54.37 60.63 0.84 0.908 9.8x10
-4
 
Caecum 54.67 6.40 4.39 51.10 13.56 3.46 1.000 2.96x10
-4
 






CX (Dog physiology model) 
In the physiology tab, the default values (Beagle - Physiological – Fed) were used and 
the enzyme and transporter regional distribution were taken from literature (311) (Table 
30). 
Table 30. Physiological parameters for CX model (fed state) 
Compartment data Enzyme and transporter 
regional distributions 
















Stomach 0.0 5.00 1.50 1000.0 15.00 1.00 0.0 0.0 
Duodenum 11.23 6.20 0.28 6.083 12.43 0.62 3.0x10
-4
 0.410 
Jejunum 1 12.66 6.20 0.85 18.58 66.64 0.47 3.0x10
-4
 0.530 
Jejunum 2 10.38 6.20 0.63 13.74 66.64 0.41 2.0x10
-4
 0.660 
Ileum 1 7.103 6.40 0.02 0.389 1.43 0.47 2.0x10
-4
 0.880 
Ileum 2 6.960 6.60 0.02 0.396 1.43 0.47 3.0x10
-4
 0.990 
Ileum 3 6.815 7.05 0.02 0.403 1.43 0.47 4.0x10
-4
 1.030 
Caecum 9.147 7.50 3.81 0.538 1.99 0.93 4.0x10
-4
 0.530 




2.6.7 Intestinal first-pass effect and chemical degradation (CA) 
 
Following oral administration, CA was absorbed from the GIT and was rapidly 
hydrolysed by non-specific esterases in the intestinal mucosa and blood, to cefuroxime 
(312). The loss in extent of the unabsorbed parent drug (CA) is the main reason for its 
moderate bioavailability (199, 313). Numerous investigations have focused on the 
effect of intestinal esterases in the hydrolysis of CA to the poorly absorbed cefuroxime 
in the GIT before CA is absorbed (212, 213, 313-315). For example, an in vitro study 
performed on the intestine of rats showed 21.44% CA hydrolysis (212).  
 
 
2.6.7.1 Luminal degradation (CA) 
The hydrolysis rate changes according to the pH environment of the GI lumen and was 
incorporated into the model as chemical degradation rate vs pH data. The chemical 
degradation data is presented in Table 31. 
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Table 31. Chemical degradation rate vs pH data: Hydrolysis rate of CA in physiological pH 
environment measured with USP apparatus 2 (50rpm, 500mL, 37⁰C, n=3) 
Dissolution medium 
pH 




FaSSGF, pH 1.6 
1.60 
3960.00±1005.42 
FaSSIF-V2, pH 6.5 
6.50 
1823.68±104.40 




Luminal degradation (chemical or metabolic) was modelled by interpolating from an 
input table of degradation rate as half-life (h) vs pH. At any time point in any 
compartment, the degradation rate constant was determined for the local pH while the 
loss of drug concentration through chemical degradation was calculated in 
GastroPlus™ using the degradation rate constant multiplied by the amount of dissolved 
material in the compartment. 
 
In this study intestinal extraction of 46.8% was obtained using data from a degradation 
study performed on fasted state human intestinal fluid (264). Meanwhile, a CA food 
effect study found that 64% and 48% of CA was not absorbed in fasted state and fed 
state, respectively (209). The degradation of CA followed first order kinetics (264) thus 
the intestinal extraction in fed state could be postulated using the ratio of intestinal 
extraction and the % of CA not absorbed in fasted and fed states (Equation 19) 
                      (         )  
                    (            )                        (            ) 
                     (         )
                 Equation 19 
From the calculation using Equation 19, the intestinal extraction of CA in fed state was 
35.1%. The fixed intestinal extraction input in GastroPlus™ gave a fixed percentage of 
the absorbed drug to be extracted before it reached the portal vein. This intestinal 
extraction % was constant at all times and all concentrations during a simulation.  
 
2.6.8 Approach and design of simulation 
 
In this project, prediction of in vivo performance based on PBPK models for Zinnat® 
(CA), Sporanox® (ITR) and CX formulation were performed using (i) solubility-based 
model and (ii) solubility combined with dissolution based model. 
102 
 
2.6.8.1 Solubility-based model 
 
In the solubility-based model (Table 32), the solubility of the drug within the luminal 
contents was taken into account for absorption simulation. The absorption rate was 
restricted to the maximum possible luminal drug concentration based on the local (pH-
dependent) solubility of the simulated compound calculated according to the 
Henderson–Hasselbalch equation (163). For the solubility based model, the IR tablet 
(CA, CX) and IR capsule (ITR) dosage forms in GastroPlus™ were selected for 
simulations. IR formulations begin dissolving in the stomach as soon as the dose is 
administered.  
Table 32. Simulations using solubility-based model 
Studies Media used 
Input as an individual 
solubility and pH 
(reference solubility) 
CA: 
Experimental solubility data in simulated fasted state media :SGF, 
SIF, FaSSGF, FaSSIF-V2 and in simulated fed state media : 
FeSSGF and FeSSIF-V2 
ITR: 
Solubility data using SGF, SIF, FaSSGF, FaSSIF-V1 and human 
gastric fluid, human intestinal fluid reported in literature (30) and 
scaled FaSSIF-V1 and FeSSIF-V1 values (Details in Section 
2.6.2.3) were used. 
CX: 
Solubility data using FaSSIF-V1 and FeSSIF-V1 (252) and scaled 
FaSSIF-V1 and scaled FeSSIF-V1 values (Details in Section 
2.6.2.3) were used. 
Input as a solubility 
over a pH range 
CA: 
Experimental solubility-pH data in simulated fasted state media 
:SGF and SIF; FaSSGF and FaSSIF-V2 and in simulated fed state 
media : FeSSGF and FeSSIF-V2 
ITR: 
Solubility-pH data using SGF and SIF; FaSSGF and FaSSIF-V1 
(30) were used. 
CX: 
Solubility data using aqueous buffer (pH3) and FeSSIF-V1 (252) 






2.6.8.2 Solubility combined with dissolution based model 
 
The dissolution profile determined using an in vitro dissolution method was inserted 
into the GastroPlus™ as a table of time and % dissolved. Simulations were performed 
using the Controlled Release (CR): Dispersed option (Table 33). In this CR: Dispersed 
option, unreleased material disperses by way of transit at the same rates as solid 
particles or drug in solution (used for other dosage forms such as oral suspension). 
This is especially applicable for Sporanox which consists of a capsule that releases 
coated pellets which then disperse throughout the GIT compartments (163). 
 
Table 33. Simulation design using solubility combined with dissolution-based models 
Study Solubility used Dissolution profile from Media used 
CA FaSSIF-V2 (fasted state);  
FeSSIF-V2 (fed state) 
a. USP apparatus 2 
b. USP apparatus 4 
Compendial and 
biorelevant media 
ITR Scaled FaSSIF-V1 (fasted 
state);  
Scaled FeSSIF-V1 (fed state) 
a. USP apparatus 1 
b. USP apparatus 4 
Compendial and 
biorelevant media 
CX FeSSIF-V1 (fed state) a. USP apparatus 2 




There is no recommended dissolution medium simulating gastric and intestinal fluids of 
beagle dogs up to the time the dissolution experiment was conducted. Thus the 
modified media and biorelevant media (fasted and fed state) simulating human GI 
conditions were used for the study of CX (in vivo study performed on beagle dog) since 
literature had suggested that beagle dog GI conditions are close to humans (316). 
Thus dissolution profiles in simulated biorelevant media in fed state as well as fasted 
state were also inserted into the GastroPlus™ CX fed state model to test if these 
profiles could produce a predictive absorption model.  
With GastroPlusTM, a four-parameter single Weibull function (Equation 20) or an eight-
parameter double Weibull function (Equation 21) (163) could be used for fitting the 
dissolution profiles.  
               (     (
 (      )
 
 
))          Equation 20 
               (          (
 (       )
  
  
       (
 (       )
  
  
)) Equation 21 
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Where Max is the % of maximum release, Tlag is the lag time, a is the scale factor, and 
b is the shape factor.  
Due to the parabolic curve shape of the dissolution profiles in 2 stage dissolution 
experiments, instead of fitting with a Weibull function the dissolution profiles were 
inserted as raw dissolution data (CX). The single Weibull function was used for CA and 
CX but the double Weibull function was used for ITR due to the more complex nature 
of its dissolution curve shape. It is noteworthy that the use of Weibull distribution which 
does not have a physiological meaning was mainly due to its versatility to fit most curve 
shapes (sigmoidal or parabolic). 
 
2.6.9 Prediction of in vivo performance based on PBPK models 
 
In order to verify the capability of each PBPK model to predict accurately the in vivo 
profiles, the simulated profiles were compared with the observed in vivo profiles 
reported in literature. 
CA 
The observed in vivo plasma concentration–time data of CA in fasted and fed states 
were reported by Rojanasthien et al.(287) and Donn et al. (288) respectively. The in 
vivo plasma concentration–time profiles were obtained from the published graphs by 
digitalisation with a software tool (GetData® Graph Digitizer version 2.24). 
In the fasted state study, a single immediate release (IR) Zinnat® 250mg/tablet 
(GlaxoSmithKline, Durham, UK) was given to 12 healthy volunteers together with 
200mL of water. In the fed state study, a single immediate release (IR) Zinnat® 250mg/ 
tablet was given to 24 healthy male volunteers together with 100mL of water after a 




In vivo plasma concentration–time profiles of Sporanox® (Janssen-Cilag, High 
Wycombe, UK) tablets were taken from the study of Yun et al. (228) (fed state). In the 
fasted state study, 12 healthy volunteers were given a single dose of Sporanox® 
containing 100mg of ITR/capsule. The dose was administered with 100 mL of water. In 
the fed state study, 80 healthy male volunteers were administered a single dose of 
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Sporanox® containing 100mg of ITR/capsule. The dose was administered 5 min after a 
standard bread meal (150g) recommended by FDA plus 150mL of low fat milk.  
 
CX 
The observed in vivo plasma concentration–time data of CX were obtained from an 
interim company report (252) in which 7 formulations (F1, F2, F3, F4, F5, F6 and F7) of 
CX formulation 240mg/tablet was given separately to 4 healthy beagle dogs 1 h post 
meal (fed state) with 15mL of water (as a slurry mixture). The plasma concentration–
time profiles are presented in Figure 17.  
Figure 17. Mean (±SD) plasma concentration vs time profiles of CX in beagle dogs (n=4) after a 
single administration of F1, F2, F3, F4, F5, F6 and F7 of CX (252).
 
As only F4, F5, F6 and F7 were available for in vitro dissolution testing, the average 
plasma concentrations of these four formulations (n=16) were used as reference 
profiles in the model validation study.  
 
2.6.10 Parameter sensitivity analysis 
  
Parameter sensitivity analysis (PSA) was performed to analyse the effect of selected 
parameters on the predicted amount absorbed, Cmax and AUC of simulated profiles. 
Three types of parameters were tested for sensitivity analysis. The first group was 
related to the absorption process and included parameters such as Peff and dose of the 
drug given. The second group consisted of parameters that describe the 
physicochemical properties of the drug such as solubility, particle size distribution 
(PSD) and precipitation (prec) time. The third group related to physiological 
parameters, such as gastric emptying time, percentage of drug having undergone first 








































During this analysis, one parameter was changed gradually within a realistic range. 
The parameter ranges used for the PSA are presented in Tables 34-36. 
Table 34. The range of parameters used for the PSA of CA: simulating fasted state (A) and fed 
state (B) conditions. 
A % Gut first pass extraction Ref solubility (mg/mL) Prec time (s) 
Baseline 46.8 0.443 900 
Lower limit 23.4 0.044 90 











Gut 1st pass 
extraction % 
Baseline 0.372 900 0 1.247 35.1 
Lower 
limit 0.037 90 0 0.624 17.55 
Upper 
limit 3.719 9000 10 2.494 70.2 
 
Table 35. The range of parameters used for the PSA of ITR; simulating fasted state (A) and fed 
















Baseline 900 0.00481 3.46 1 100 6 1.3 
Lower 
limit 90 0.000481 1.73 0.1 10 0.5 
0.5 
Upper 



















Baseline 0.023 900 3.46 0 100 4.9 5.4 
Lower 
limit 0.00225 90 1.73 0 10 0.5 0.5 
Upper 
limit 0.225 9000 6.92 10 1000 8 8 
 
Table 36. The range of parameters used for the PSA of CX; simulating fed state condition. 
 
Ref solubility (mg/mL) Dose (mg) PSD (µm) Prec time (s) Peff (cm/s) 
Baseline 0.37 240 1.5 9000 0.641 
Lower Limit 0.037 24 0.15 900 1.282 




PSA was performed using the “solubility combined with dissolution based model” that 
showed the closest simulated profiles with the in vivo profiles (based on the simulated 
results performed in this study, Table 37).  
Table 37. The solubility value and dissolution profiles used for PSA 
 Simulating state Solubility value Dissolution profile 
CA 
Fasted FaSSIF-V2 FaSSGF/FaSSIF-V2 
 
Fed FeSSIF-V2 FeSSGF/FeSSIF-V2 
ITR 
Fasted Scaled FaSSIF-V1 FaSSGF/FaSSIF-V1 
 
Fed Scaled FeSSIF-V1 FeSSGF/FeSSIF-V2 
CX* 
Fed FeSSIF-V1 FeSSGF/FeSSIF-V2 
*For CX, only PSA for fed state was performed because only in vivo data in fed state is 
available. 
 
2.6.11  Analysis and comparison of plasma concentration vs time data 
 
Differences in the simulated vs the observed profiles were assessed using the model-
independent approach based on the similarity factor (f1) as follows (Equation 22) (43) 
                                        
∑ |     |
 
   
∑   
 
   
                                         Equation 22 
where n is the sample number, and Rj and Tj are the drug plasma concentration of the 
reference and test profiles, respectively, at different time intervals j. f1 value increases 
proportionally due to the dissimilarity between the two dissolution profiles. 
The observed plasma concentration time data were used as a reference data set. 
Predicted profiles were compared in this manner so the equivalent time points to 
reference profiles could be selected for comparison. Entire profiles were taken into 
account. 20% average difference of a test from a reference data set was set as the 
limit for identifying differences between the profiles. The 20% is in agreement with the 
FDA guidance for industries where the difference in predicted means of Cmax and AUC 




2.7 Methods of Part 4: Deconvolution and development of In vitro-in vivo 
correlation 
 
2.7.1 Deconvolution analysis 
 
Essentially in numerical deconvolution, drug plasma data from oral formulations are 
used as a response and IV profile as a weighting function to estimate the in vivo drug 
absorption profiles. 
 
In the current study, numerical deconvolution was performed using the PCDCON 
software (188). PCDCON enables the provision of absorption rate plots vs time and the 
cumulative amount absorbed over time as part of the output. An interpolating cubic 
spline was used to fit the serum concentration data for the intravenous formulation (as 
weighting function). Input rate function was the plasma concentration vs time profile 
following oral administration of CA, ITR and CX formulations (Refer to Section 2.3.3: 
CX formulations). The deconvolution result is expressed in terms of the cumulative 
percentage absorbed (%) and absorption rate (mg/h). Meanwhile, the input response 
was from the plasma concentration vs time profile following oral administration of the 
tested marketed amorphous formulations (Table 38).   
 
Table 38. Input response used in the deconvolution  
Drug Formulation Sample/Subject 
CA Zinnat
®
 (Glaxo Wellcome) 250 mg/ tablet, 
fasted state (287) and fed state (288) 
Humans (mean data, fasted state 
and fed state n=10) 
ITR Sporanox
®
 (Jassen) 100mg/ capsule, fasted 
state (299) and fed state (228) 
Humans (mean data, fasted state 
n=12, fed state n=80) 
CX 240mg/tablet, fed state (252) Dog (mean data, n=4) 
 
For CA the plasma concentration profile of IV injection data (dose=500mg, mean data 
of n=12 healthy male volunteers, age 21-27 years, mean weight 80 kg) reported by 
Finn et al. was used as a weighting function for deconvolution (209).  
 
For ITR, due to the unavailability of IV bolus profiles in the literature, an IV infusion 
(over 1 h, dose=100mg, mean data of n=6 health male volunteers) profile reported by 
Heykants et al. was used (291). PK parameters derived from compartmental analysis 
of this profile were used to construct a biexponential function (317). The concentration 
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time course for ITR administered as 1 h IV infusion (100mg) was fitted with the 
following bi-exponential equation (Equation 23): 
 
                     (    ⁄ )                                     Equation 23 
The parameters of biexponential Equation 23 were then used as the weighting 
function.  
 
For CX the data after an IV injection (1mg/kg) were obtained from a crossover study in 
4 healthy beagle dogs (252). The mentioned individual plasma concentration profiles 
post IV doses (weighting function) were entered as raw data and an interpolating cubic 
spline was used as a weighting function for deconvolution. The IV profile corresponding 
to each dog was used and then the mean deconvoluted profile was calculated. The 
calculated cumulative amount then was used to compare the critical manufacturing 
variables (CMV) of CX formulation such as the particle size of API and tableting 
strength. 
 
2.7.2 Development of IVIVC  
 
The percentage of in vivo absorption obtained with deconvolution (Section 2.7.1) was 
compared directly with the percentage of in vitro dissolution determined from in vitro 
dissolution experiments. 
 
The Level A IVIVC (Point-to-point IVIVC) model was developed using a direct 
comparison method: % in vivo absorption (from deconvolution) vs % in vitro dissolved 
at time. Linear interpolation was used in cases where % in vitro dissolved was at 
different time points with % in vivo absorption. Linear regressions were used to develop 
a single time IVIVC model using data in each experimental in vitro dissolution profile. A 
linear mathematical equation (Equation 24) with intercept (a) and gradient (b) was 
applied to define the IVIVC model (192). 
 
%absorption in vivo= b∙% dissolution in vitro+ a          Equation 24 
where % absorption in vivo and % dissolution in vitro are the mean percentage in vivo 
absorption and in vitro dissolution respectively; a is a constant additive term that 
accounts for a percentage delay in vivo as compared with in vitro and the gradient b is 
a transformation factor for the mean percentages. This gradient, b, compares the rate 
of the in vivo absorption and in vitro dissolution.  
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3. Results and discussion 
3.1 Results and discussion of Part 1: In vitro solubility and dissolution testing 
3.1.1 Validation of chromatographic methods 
3.1.1.1 Calibration curve linear range 
 
Linear calibration curves for the three drugs were obtained throughout the 
concentration range studied. Regression analysis was performed for the area of the 
peak vs drug concentration and the results are presented in Table 39 and Table 40.  
 
Table 39. Analytical parameters of calibration curve in aqueous media. 
 
Table 40. Analytical parameters of calibration curve in milk-based media. 
 
3.1.1.2 Limit of detection (LOD) and limit of quantification (LOQ) 
Based on the LOD and LOQ equations and calibration curves, LOD and LOQ values 
for the investigated drugs in aqueous media (Table 41) and milk-based media (Table 





Drug Concentration  range (µg/mL) R
2
 
CA 10-200 0.999 
ITR 0.1-5 0.999 
CX 0.1-4 0.999 
Drug Concentration range (µg/mL) R
2
 
CA (FeSSGF) 0.4-50 1.00 
ITR (FeSSGF) 0.1-6 1.00 
ITR (Early FeSSGF) 0.2-6 0.999 
ITR (Digested early FeSSGF) 0.2-5 0.999 
CX (FeSSGF) 0.2-8 1.00 
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Table 41. LOQ and LOD (μg/mL) for the investigated drugs in aqueous media 
Drug LOD (μg/mL) LOQ (μg/mL) 
CA 0.04 0.10 
ITR 0.03 0.09 
CX 0.03 0.07 
 
Table 42. LOQ and LOD (μg/mL) for the investigated drugs in milk-based media 
Drug (Milk based media) LOD (μg/mL) LOQ (μg/mL) 
CX (FeSSGF) 0.06 0.18 
ITR (FeSSGF) 0.03 0.09 
ITR (Early FeSSGF) 0.049 0.149 
ITR (Digested early FeSSGF) 0.064 0.197 




Accuracy of the developed method was examined by recovery studies at various 
concentration values. These results are summarised in Table 43. Recovery data were 
determined as ratios of drug concentration in standard solutions prepared in FeSSGF 
compared to the standard solution in blank FeSSGF (acetate buffer). An estimation of 
the recovery of the method can also be obtained using the standard addition method.  
 
Table 43. Mean± SD of % recovery of the three investigated drugs 
Drug (Milk based 
media) 
Calculated using ratio of 
concentration 
Calculated using standard 
addition method 
CX (FeSSGF) 94.41±-0.87 to 99.52±0.65 97.51±-1.1 to 103.41±1.19 
ITR (FeSSGF) 96.77±0.32 to 103.01±2.07 100.21±0.78 to 104.76±0.081 
ITR (Early FeSSGF) 95.73±1.48 to 101.89±1.97 98.83±0.16 to 103.51±0.41 
ITR (Digested 
early FeSSGF) 
94.73±4.74 to 105.56±1.47 106.26±0.15 to 115.45±0.45 







3.1.1.4 Fat binding test 
 
The binding of the drug to the fat content was clearly related to the hydrophobicity of 
the drug (Table 44). This agrees with a previous study which showed correlation 
between increasing octanol–water partition coefficient (log P) and increasing affinity of 
drug to fat in milk (318).  
Table 44. Mean± SD of % fat partition of the three investigated drugs 
Drug (Milk based media) Log P % fat partition ± SD 
CX (FeSSGF) 3.84 51.49 ±2.30 
ITR (FeSSGF) 4.3 45.23 ±2.72 
ITR (Early FeSSGF) 4.3 35.12±4.23 
ITR (Digested early FeSSGF) 4.3 4.33±1.70 
CA (FeSSGF) -1.4 11.60 ±0.99 
 
3.1.1.5 Filter adsorption studies (Milk-based media) 
The results showed that the drugs adsorption to the nylon filter was low and was within 
the accepted value (>95%) (Table 45). Therefore, this filter type was used. 
Table 45. % recovery ± SD from filtrate for filter adsorption studies 
Drug 1st filtration 2nd filtration 
CX 95.12±0.092 100.84±0.604 
ITR 95.12±1.86 95.19±1.86 
CA 100.30±0.71 100.29±4.83 
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3.1.2 Development of modified media 
 
In the current study, the addition of SLS (anionic surfactant) and HTAB (cationic 
surfactant) in the compendia media (SGF, SIF) and blank FaSSIF-V2 (FaSSIF-V2 
without bile salt and lecithin) has been proposed to mimic the presence of bile salts in 
vivo, as in biorelevant media. These newly proposed modified media may be used for 
initial screening as an alternative to the BDM which are costly and time consuming to 
prepare (319).  
 
3.1.2.1 SLS-based modified media 
 
Surface tension (ST) measurement 
Endogenous surfactants such as bile salts and lecithin reduce the ST of GI fluids and 
affect the solubilisation of poorly water-soluble drugs (62, 320). Literature has shown 
that blank (without bile salt and lecithin) FaSSIF-V1 plus surfactant had a similar ST to 
FaSSIF-V1 and produced similar dissolution profiles (319). To mimic the surface 
tension in gastric fluid, SLS is included in SGF to reduce the ST of the medium to 
physiological values of 41.9-45.7 mN/m (73). The linear regression plot of ST in 
different concentrations of SLS in SGF showed that 0.01% SLS in SGF has an ST 
equivalent to the ST in fasted stomach fluid (Figure 18). Furthermore, in this study, 
critical micelle concentration (CMC) of different surfactants was estimated by 
identifying the concentration corresponding to the bend in the curve of ST plotted 
against surfactant concentration. This is determined graphically from the intersection of 
the two linear portions of the ST and concentration plot and the value determined from 
the graph is 0.103% SLS. As observed in the graph, the ST of the solution does not 
decrease further with an increase in surfactant concentration at concentrations greater 
than the CMC (321).  
 
Figure 18. Surface tension vs log SLS concentration (mM) (CMC determination of SLS) in SGF 
at 25°C (data obtained in this project). 
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Therefore, a modified compendial medium simulating the contents in the stomach 
under fasted state conditions (SGF-M1) was proposed. It contains 0.2% NaCl and 
0.01% (w/v) SLS with its pH adjusted to 1.2 with 1M hydrochloric acid. It achieved 
similar physicochemical properties to fasted state human gastric fluid (e.g. ST, ionic 
strength, pH value and osmolality) (Table 46).  
 
Table 46. Comparison of physicochemical properties between modified compendial medium for 
the fasted stomach and fasted state human gastric fluid. 
 Medium 
Property Fasted state human gastric fluid SGF-M1 (SGF +0.01% SLS) 
Surface tension 
(mN/m) 
41.9-45.7 (73) 42.8 
Ionic strength (M) 0.1 (72) (Detailed calculation 
presented in Appendix 6) 
0.136 (Detailed calculation 
presented in Appendix 6) 
pH 1.7 (73) 1.2 
Osmolality 
(mOsm/kg) 
98.0 (Median value) (73) ~103.3* 
* Calculated using NaCl equivalence method (322):0.2% NaCl (from SGF) plus 0.125% 
NaCl (Equivalent value of 0.01% SLS) 
 
Meanwhile, simulated intestinal fluid-modified 1 and 2 (SIF-M1 and SIF-M2) were 
developed by Tomaszewska and Fotaki (258), composed of 50mM sodium phosphate 
buffer plus 0.2% SLS (SIF-M1) and 19.12mM maleate buffer plus 0.1% SLS (SIF-M1), 
both at pH 6.8.  
 
SIF-M5 consists of 1% SLS in 50mM phosphate buffer, pH6.8. The medium is used 
mainly as a controlled medium for SIF-M4 (1% HTAB in 50mM phosphate buffer, pH 
6.8) to compare the effect of anionic and cationic surfactant. Due to its high surfactant 
content, this medium is regarded as being for quality control purposes for complete 
dissolution of test formulation. 
 
It is important to note that the surfactant, when present at levels below the CMC, 
enhances the dissolution rate of low water soluble drug products, probably by 
increasing the wetting and lowering the interfacial tension (320). Since CMC in the 
other dissolution media is lower than that in water, more surfactants form micelles 
rather than moving to the surface. This will increase the solubility of the drug rather 
than just reducing the surface tension or wettability (323). For example, the SLS 
concentration in SGFSLS is 8.67 mM and the CMC of SLS in SGFSLS is 1.75 mM (54). If 
the concentration of SLS in the media is greater than its CMC, the potential for 
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overestimation of solubility exists due to the presence of an additional 6.92mM SLS in 
SGFSLS (58). 
Another reason for not having the surfactant exceeding the CMC concentration is that 
the natural surfactant in the stomach, pepsin, is not known to form micelles (58). The 
lower gastric ST has also been attributed to bile salts due to reflux. According to the 
literature (58), the concentration of bile salts found in the stomach is in an order of 
magnitude lower than the reported CMC values of bile salts (e.g. 20 mM, 18 mM, 13 
mM, and 17mM for sodium cholate, sodium taurocholate, sodium deoxycholate and 
sodium taurodeoxycholate, respectively). Hence, one would not expect any significant 
bile salt micellar solubilisation in the stomach. 
3.1.2.2 HTAB-based modified media 
 
Unlike studies with SLS, the complete ST and CMC dataset of HTAB in SGF and SIF 
was presented in Stippler’s PhD thesis (262). Therefore, the reported CMC plot of 
HTAB in SGF and SIF was used in this study (262) (Figure 19). 
 
 
Figure 19. Mean± SD surface tension vs HTAB concentration (%) in SGF and potassium 
phosphate buffer (n=6) [values were extracted from a graph presented in Stippler’s PhD thesis 
(262)]. 
Literature had reported that the ST in the human stomach and duodenum (fasted state) 
is 41.90-45.70 mNm-1 and 33.30-46.00 mNm-1 (83), respectively. Using the same 
principle as mentioned in SLS-based modified media, three new HTAB-based modified 
media were developed in this study.  
 
Simulated gastric fluid-modified 2 (SGF-M2), consists of 0.015% HTAB in 2% sodium 






























corresponding to an ST of 43.99. Since the reported CMC of HTAB in SGF was 0.02%, 
at a concentration of 0.015% HTAB, it was expected that no HTAB micelle is formed, a 
condition also found in the human stomach.  
 
Simulated intestinal fluid-modified 3 (SIF-M3), composed of 0.1% HTAB in 50mM 
phosphate buffer pH 6.8, corresponds to an ST of 36.7 mNm-1, within the reported in 
vivo surface tension range of 33.30-46.00 mNm-1 (83). As this concentration is the 
CMC value of HTAB (262), the HTAB micelle can be formed in agreement with the in 
vivo condition (83). 
 
Lastly, simulated intestinal fluid-modified 4 (SIF-M4), composed of 1.0% HTAB in a 
50mM phosphate buffer pH 6.8, has a concentration 100 times higher than its CMC. A 
study has shown that 1% HTAB provided a sink condition for CX dissolution and it is 
the recommended dissolution medium for the CX specification as suggested by the 




3.2 Results and Discussion of Part 1: In vitro dissolution testing (Cefuroxime 
axetil) 
 
3.2.1 Degradation study of cefuroxime axetil 
 
As part of the characterisation of the in vitro dissolution behaviour, it is crucial to 
determine the experimental degradation during dissolution. In particular the first 4 h of 
the experiment, the same reaction could take place in vivo and the degradation could 
adversely reduce the amount of CA for absorption. The results of the degradation study 
are presented in Figure 20. 
 
 
Figure 20. The relationship between the pH of the dissolution medium and the mean± SD 
degradation rate constant, K (n=3). 
Based on Figure 20 which presents the degradation rate constant vs pH, a “U” shape 
curve indicates CA degradation is very pH dependent to the CA and it is most stable at 
pH3.5-5.5 (324). CA degradation is highest in the phosphate buffer at pH 6.8 (18.40 
x10-4 min-1), followed by in acidic medium, SGF (6.62 x10-4 min-1), FaSSIF-V2 (3.825 
x10-4 min-1) and FaSSGF (1.733 x10-4 min-1). 
 
It is noteworthy that for FaSSIF-V2 (pH 6.5), a maleate buffer is used. From a chemical 
point of view, two reactions (Michael addition) could occur between a primary amine 
group of the CA molecules and maleic acid: one undergoes nucleophilic attack at the 
carbonyl carbon with 1, 2-addition, and the other attacks at the β- carbon with 1, 4-
addition. Michael addition is a common reaction mechanism in API–salt interaction 






















3.2.2 Dissolution testing in USP apparatus 2 
Simulated fasted state conditions 
 
The cumulative % CA dissolved from Zinnat® in various media with USP apparatus 2 is 
presented in Figure 21. 
 
Figure 21. Mean± SD % cumulative CA dissolved from Zinnat
®
 tablets in various media using 
the USP apparatus 2 (500mL, 50rpm, 37ºC, n=3). 
Studies have shown that the solubility of CA, which is a cephalosporin ester molecule, 
is highest at low pH values (SGF: pH 1.2 and FaSSGF: pH 1.6) and it reduces at 
higher pH (205). Meanwhile, CA was degraded at a higher rate in SIF therefore greatly 
reduced the amount of CA available for dissolution. As a result, dissolution profiles 
SGF vs SIF were different by 41% (f1,area: 0.41). At pH 6.8, a considerable amount of 
croscarmellose sodium (anionic type disintegrant) forms sticky cellulose leading to 
coning effects that affect the CA dissolution (238). It is notable that biorelevant media 
produce very similar profiles (FaSSGF vs FaSSIF-V2: f1area 0.03 or FaSSIF-V2 vs 


































Simulated fed state conditions 
 
The cumulative % CA from Zinnat® in FeSSGF and FeSSIF-V2 with USP apparatus 2 
are presented in Figure 22.  
 
Figure 22. Mean± SD  %  CA dissolved from  250mg Zinnat
®
 tablet in  FeSSGF and FeSSIF-V2 
with USP apparatus 2 (500 mL medium,37°C,50rpm). 
The CA dissolution profiles showed that the rate and the extent of dissolution was 
faster and higher in FeSSGF compared to FeSSIF-V2 (FeSSGF vs FeSSIF-V2; f1,area: 
0.48). This is probably due to glyceryl monooleate and sodium oleate in FeSSIF-V2 
forming a glutinous aggregate with the croscarmellous sodium in Zinnat® tablet causing 
excessive gelling and cones at the bottom of the vessel. 
 
Dissolution kinetics of profiles with USP apparatus 2 
 
The dissolution profiles of the CA tablet were fitted well with first order and single 
Weibull kinetics models. The fitted parameters in the fasted state and fed state 































Table 47. Mean± SD  dissolution kinetic parameters of CA  dissolved from Zinnat
®
  tablet in 
simulated fasted and fed states media with USP apparatus 2 (n=3). 
 First order kinetics 



















































































































According to first order kinetics, CA dissolution was higher but the dissolution rate was 
lower in SGF than SIF. Similarly, the same scenario was observed between FaSSGF 
and FaSSIF-V2. The higher dissolution is probably due to the higher equilibrium 
solubility of CA in SGF and FaSSGF than SIF and FaSSIF-V2— as in a closed 
dissolution system the dissolution of a poorly soluble drug is limited by the equilibrium 
solubility of the drug. Meanwhile, the first order kinetics showed that the maximum % 
dissolved and the dissolution rate between FaSSIF-V1 and FaSSIF-V2 are very similar; 
whereas, FeSSIF-V2 has a lower rate and extent of dissolution. The disparity is mainly 
due to the heavy coning effect observed in FeSSIF-V2 with USP apparatus 2.  
The dissolution kinetics of CA from the amorphous formulation Zinnat®, was also 
analysed by the application of a single Weibull function. The shape factor (b) reveals 
that all media (simulating fasted and fed state) have a parabolic curve shape. Literally, 
the dissolution profiles show a steep initial dissolution and then plateau out at the 
maximum dissolution level. It is important to note that the time scale of the dissolution 
process for CA follows the sequence of FaSSGF (0.62 h), FaSSIF-V2 (0.67 h), SGF 
(0.75 h) and SIF (0.76 h) which is in agreement with the sequence of rate of CA 
degradation measured in vitro (results presented in Section 3.2.1). This seems to 
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indicate that the Weibull function could be a good fitting method to forecast the CA 






3.2.3 2 stage dissolution studies 
 
The cumulative % of dissolved CA from Zinnat® in 2 stage dissolution experiments with 
USP apparatus 2 are presented in Figure 23.  
 
Figure 23. Mean± SD  % CA dissolved from 2 stage dissolution, 250 mL FaSSGF for 30min/500 
mL FaSSIF-V1 or -V2 with USP apparatus 2 (37°C,50rpm). Blue arrow indicates time with 
media change. Gap after media change indicates short pause of paddle rotation. 
 
The results of the 2 stage dissolution model in the simulated gastric phase compared 
to the conventional USP apparatus 2 (using FaSSGF) showed that the dissolution was 
lower, probably limited by the smaller volume of medium used (250mL) in the first 30 
min of the experiment. The results showed that higher and faster CA dissolution 
occurring in FaSSIF-V1 (Max 78.03%, first order rate constant 3.31h-1 vs 45.08% and 
2.73h-1  in FaSSIF-V2, respectively) could be due to FaSSIF-V1 containing almost four 





3.2.4 Dissolution testing in USP apparatus 4 (with sequential change of media 
and flow rate) 
 
Simulated fasted state conditions 
 
The cumulative % of dissolved CA from Zinnat® in various media with USP apparatus 4 
are presented in Figure 24.  
 
Figure 24. Mean± SD % cumulative CA dissolved from Zinnat
®
  tablet in (A) SGF-M1(8mL/min; 
1h) then SIF-M1 and M2 (4mL/min; 5h) SGF (8mL/min;1h) then SIF (4mL/min; 5h) (B) 
FaSSGF(8mL/min; 1h) then FaSSIF-V1 and V2 (4mL/min; 3h) using the USP apparatus 4 
(n=3). Blue arrows indicate time with media and flow rate change. 
The dissolution curves indicated that CA remained solubilised when it was transferred 
from simulated gastric media into simulated intestinal media with USP apparatus 4. 
This condition was probably due to the solubility of CA in simulated gastric media being 
close to the simulated intestinal media. Therefore the issue of recrystallisation was not 
apparent in the dissolution of Zinnat® tablet.  
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The presence of SLS (part of the excipient of the tablet) caused more than 50% CA 
dissolution across all five experiments presented in Figure 24. The dissolution profiles 
comparison showed that the difference between the dissolution profiles of SGF-
M1/SIF-M1 and SGF/SIF was 17% (f1area: 0.17) whereas the profiles between SGF-
M1/SIF-M2 and FaSSGF/FaSSIF-V2 were very similar (f1area: 0.05). 
 
The dissolution curve of CA in SIF-M1 reached a plateau in 2 h compared to the 
dissolution curve of SIF. This was because the type of buffer and its pH can change 
the rate of degradation of CA (206, 326). Even though both SIF and SIF-M1 were 
prepared using a phosphate buffer, lower dissolution was observed in SGF-M1/SIF-
M1. The lower dissolution was an artifact due to the higher degradation of CA in the 
presence of SLS (324).  
From the dissolution results, a few critical factors affecting CA dissolution were 
identified: 
1. Effect of extent of disintegration and agglomeration/aggregation of tablet 
content 
During the dissolution study of FaSSGF/FaSSIF-V1, one particular tablet formed a 
gelatinous mass that prevented free penetration of medium into the mass. Literature 
had demonstrated that the gelling effect of CA could affect its dissolution (241). 
Furthermore, mass formation also was shown to lead to a lower rate and extent of 
dissolution (59). Furthermore, it was observed during dissolution experiments with USP 
apparatus 4 that hard lumps were formed with SIF-M1 as a dissolution medium 
compared to compendial media where most of the tablet was dissolved. The reduced 
surface area decreased the dissolution of CA. As reported by Rohrs et al., the changes 
in the disintegration/deaggregation behavior can cause occlusion of the drug in the 
aggregate that did not disperse during testing. The extent of dissolution would then be 
limited by the lack of drug surface exposed to the dissolution medium (327).  
 
2. Effect of CA degradation on dissolution profile  
A study reported that the degradation rate of CA was influenced by the type of buffer 
and its concentration (328). Its degradation rate was highest in phosphate (SIF, 
FaSSIF-V1) compared to acetate and carbonate and formate buffer (206). 
During the experiment with modified media containing SLS, the colour of the powder in 
the cell was white. After changing media, the color of the powder turned yellowish 
gradually, indicating delta-3-isomers of CA had been formed (Delta-3-isomers of CA is 
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a clumpy tan or yellowish coarse powder). The clumpy powder increased clustering 
and agglomeration of the drug powder and affected the CA dissolution.  
Simulated fed state conditions 
 
The cumulative percentage and mean amount of dissolved CA from Zinnat® in 
FeSSGF/FeSSIF-V2 and FeSSGF/FeSSIF-V1 with USP apparatus 4 are presented in 
Figure 25.  
 
Figure 25. Mean± SD % CA dissolved from Zinnat
®
 tablet in fed state FeSSGF(6mL/min; 
2h)/FeSSIF-V1 and-V2 (6mL/min; 4 h) using the USP apparatus 4 (n=3). Blue arrow indicates 
time with media change. 
The results of the dissolution test with USP apparatus 4 showed that the FeSSIF-V2 
enhanced the dissolution of CA with 80% dissolved, compared to 70% in FeSSIF-V1. 
This was probably due to the presence of GMO and high concentrations of sodium 
oleate in FeSSIF-V2 increasing the dissolution of CA under the open dissolution setup. 
 
Dissolution kinetics of profiles with USP apparatus 4 
The dissolution profiles of CA tablet were all fitted well with first order kinetics model. 
The maximum % dissolved (Max) and rate constants in fasted state and fed state are 










Table 48. Mean± SD  dissolution kinetic parameters of CA  dissolved from Zinnat
®
 tablet in 















First order kinetics 








































































































As described in Section 3.2.1, the dissolution of CA was affected by the types of buffer, 
surfactant, pH and hydrodynamics of the system and the effect of degradation. These 
cumulative effects were shown in the Max (%) and dissolution rate of the applied 
models. The application of first order and single Weibull kinetic models in the analysis 
of dissolution data (simulating fasted state) showed that the mean values of Max 
(maximum percentage dissolved) followed the sequence of FaSSGF/FaSSIF-V2> 
SGF/SIF> SGF-M1/SIF-M2> SGF-M1/SIF-M1> FaSSGF/FaSSIF-V1. 
Similarly, application of first order and single Weibull kinetic models in the analysis of 
dissolution data (simulating fed state) shows that the mean values of Max (maximum 
percentage dissolved) in FeSSGF/FeSSIF-V2 is higher than in FeSSGF/FeSSIF-V1. 
From the perspective of CA dissolution rate, the first order rate constant and time scale 
parameter of single Weibull function (simulating fasted state) followed the rank order of 
FaSSGF/FaSSIF-V1> SGF-M1/SIF-M2> SGF-M1/SIF-M1> FaSSGF/FaSSIF-V2> 
SGF/SIF. The results clearly showed that the rate of dissolution is higher in media 
containing a surfactant (Table 48). Meanwhile, in the simulated fed state experiments, 
a higher amount of lecithin in FeSSIF-V1 caused almost twice the increment of 
dissolution rate compared with FeSSIF-V2.  
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Comparing the first order rate constant of dissolution profiles of CA with USP 
apparatus 2 and 4 (Table 47 vs Table 48), the rate constant was at least 10 times 
higher in experiments with USP apparatus 2 (closed system) than the experiments with 
USP apparatus 4 (open system). It is appropriate to state that the dissolution process 
in dissolution experiments with USP apparatus 4 had mimicked the in vivo condition 
closer when compared with the dissolution profiles with USP apparatus 2 which 
showed a sharp rise to plateau in 5-10 min. Considering this factor, biorelevant media 
with USP apparatus 4 seem to be a good dissolution setup to characterise dissolution 
of CA formulation. 
 
3.3 Results and Discussion of Part 1: In vitro solubility and dissolution testing 
(ITR) 
3.3.1 Equilibrium solubility studies 
 
Solubility values (measuring solubility up to 72 h) of ITR API in FaSSGF and FaSSIF-
V2 measured by the shake flask method (37°C) are shown in Figure 26.  
 
 
Figure 26. Equilibrium solubility (µg/mL, Mean± SD) of ITR in FaSSGF and FaSSIF-V2 
 
Solubility of ITR in FaSSGF 
 
ITR is a weak base (pKa 3.7). After the 1st h the solubility was enhanced mainly 
because ITR exists as an ionised (cationic) form in pH 1.6 medium. The concentration 
was reduced to 0.92µg/mL, 0.62µg/mL and 0.10µg/mL subsequently. The rapid 
precipitation of ITR in FaSSGF could be due to the acid-base reaction between the 
sodium taurocholate (329, 330) and weak base ITR leading to the charge neutralisation 
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of ITR that facilitate the nucleation of ITR. In the beginning of the experiment, the 
dissolution of the ITR molecules into the bulk solution probably exceeded the 
equilibrium solubility of the ITR in FaSSGF. This excess concentration or chemical 
potential, called the supersaturation, was the driving force for nucleation and crystal 
growth of ITR (36, 331). 
 
Solubility of ITR in FaSSIF-V2 
 
In FaSSIF-V2 ITR mainly exist in an unionised form. The dissolution profile of ITR in 
the presence of FaSSIF-V2 compared to FaSSGF showed a very slow and steady 
dissolution; after the supersaturation state at 24 h the ITR slowly reached the 
equilibrium solubility of 0.02±0.0023 µg/mL at 48 h. The supersaturated solution of ITR 
at 24h could be due to the micellar solubilisation effect of mixed micelles as a 
combination of bile salt and lecithin. The bile components exert their effect on solubility 
by forming different colloidal phases that could solubilise the ITR molecule better. The 
mixed micelle produced a transient higher solubility than FaSSGF before slowly 
nucleating and precipitating at 48 h.  
 
3.3.2 Dissolution testing in USP apparatus 1 
 
Simulated fasted state conditions 
The cumulative % of ITR dissolved from Sporanox® in SGF, FaSSGF and FaSSIF-V2 
with USP apparatus 1 is presented in Figure 27. 
 
 
Figure 27. Mean± SD % ITR dissolved from Sporanox
®
 capsule with USP apparatus 1 (500mL, 




The Sporanox® capsule is a floating capsule therefore the basket apparatus (USP 
apparatus 1) is a better option compared with USP apparatus 2. Essentially, all 
dissolution profiles were very different depending on the pH of the dissolution media. 
As a weak base (pKa 3.7) (216, 219) the decrease in solubility in media above pH 3 
confirms the changes in pH profoundly influenced both solubility and dissolution. 
Dissolution of ITR from Sporanox® was enhanced as the equilibrium solubility of ITR in 
SGF (3.9 µg/mL)(219 3.9 µg/mL) could only bring about 2% dissolution  (Figure 27). It 
is due to Sporanox® being a solid dispersion formulation with molecular dispersion of 
ITR in HPMC. HPMC is an amorphous carrier that could form a high apparent 
concentration supersaturated solution of ITR and increases the solubilisation of ITR 
(332, 333). In agreement with the literature (30, 231) the supersaturation effect has 
been shown in this study (Figure 28).  
 
  
Figure 28. Mean± SD ITR concentration yielded from 100mg Sporanox
®
 capsule with USP 
apparatus 1 (500mL SGF: A and FaSSGF: B, 37⁰C, 75rpm) [Dashed line indicates the ITR 
equilibrium solubility in the medium (219)] 
 
The dissolution data profile showed that the initial burst in FaSSGF was larger than in 
SGF with 14.2% dissolved in FaSSGF compared to 9.7% dissolved in SGF at 0.5 h.  
In the ITR dissolution study with USP apparatus 1 (closed dissolution system) a 
supersaturated solution of ITR was produced in FaSSGF and it is significantly higher in 
SGF (almost 90% of ITR dissolved in SGF and 16% of ITR dissolved in FaSSGF) 
(SGF vs FaSSGF; f1,area=0.76) The tendency to achieve supersaturation is higher in 
closed dissolution systems such as USP apparatus 1. This is due to the fact that poorly 



























































Simulated fed state conditions 
 
The cumulative % of ITR dissolved from Sporanox® in FeSSIF-V2, FeSSGF, early 
FeSSGF and digested early FeSSGF with USP apparatus 1 are presented in Figure 
29.  
 
    
Figure 29. Mean± SD % ITR dissolved from 100mg Sporanox
®
 capsule with FeSSIF-V2, 
FeSSGF, early FeSSGF and digested early FeSSGF with USP apparatus 1 (500mL medium, 
37°C, 75rpm, n=3).  
In FeSSGF (pH 5) ITR mainly exists as unionised form. Compared with FaSSGF the 
dissolution rate in FeSSGF is slower. It is noted that the initial slow dissolution could be 
partially contributed by the fact that milk (a major component of early, digested early 
FeSSGF and FeSSGF is milk) influences disintegration of drug products and the 
formulation disintegration was more than five times longer in milk than in fasted state 
simulated gastric media (335). 
 
In this study, gastric secretions in the fed stomach were simulated using digested early 
FeSSGF. Meanwhile, the dissolution experiment in early FeSSGF served as a control 
study. In the digested milk ITR exists mainly in an ionised (cationic) form (pH of 
medium reduces due to the pepsin solution added into the medium throughout the 
experiment) and has better solubility in digested early FeSSGF. The observed larger 
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variability in digested early FeSSGF compared to FeSSGF and digested early FeSSGF 
is probably due to the highly viscous digested milk formed when pepsin was added 
causing non-uniformity of drug concentration distribution. The f1,area value for the 
comparison of dissolution data profiles of Sporanox® in digested and undigested early 
FeSSGF using the USP apparatus 1 is 0.52. The results show that milk digestion (pH 
and digested protein) could lead to about 50% difference in in vitro dissolution studies. 
 
On the other hand, the presence of lecithin and sodium taurocholate in FeSSIF-V2 
produced a greater dissolution in the first 1 h of the experiment compared with 
FeSSGF (FeSSGF vs FeSSIF-V2, f1,area=0.85). The bile components exert their effect 
on solubility by forming different colloidal phases that could solubilise lipophilic drugs. 
In vivo, food stimulates the release of bile salts and phospholipids; this highlights the 
importance of the fed state in solubilising this lipophilic compound. 
 
3.3.3 2 stage dissolution studies 
 
In this section the biorelevant 2 stage dissolution model with composition and volume 
of the fluids that have a closer simulation of the in vivo conditions is discussed. The 
cumulative % of dissolved ITR from Sporanox® in 2 stage dissolution experiments with 
USP apparatus 1 are presented in Figure 30.  
 
 
Figure 30. Mean± SD % ITR dissolved from 100mg Sporanox
®
 capsule from 2 stage 
dissolution, 250 mL FaSSGF for 30 min/500mL FaSSIF-V1 or -V2 with USP apparatus 1 
(37°C,75 rpm). Blue arrow indicates time with media change. Gap after media change indicates 
short pause of paddle rotation. 
 
This experimental setup using closed system optimises dissolution conditions for the 
ITR because the simulated gastric medium FaSSGF enables a potentially higher 
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amount of ITR to dissolve prior to the simulated intestinal medium, FaSSIF-V1 and –V2 
which has a physiological relevant amount of bile salts and lecithin. 
 
In the first 0.5 h FaSSGF was used and close to 5% and 8% ITR dissolution were 
recorded. Then FaSSIF-V1 and FaSSIF-V2, the biorelevant dissolution media 
simulating the physiological conditions in the small intestine in the fasted state were 
used in two separate 2 stage dissolution experiments. Dissolution experiments resulted 
in a maximum dissolution of approximately 14% in FaSSGF/FaSSIF-V2 and 6% in 
FaSSGF/FaSSIF-V1. It was observed that the level of ITR dissolved was maintained 
better in FaSSIF-V1 compared to FaSSIF-V2 mainly due to a lower supersaturation 
and better solubility of ITR in FaSSIF-V1. 
 
In the two stage dissolution, highly supersaturated ITR solution in FaSSIF-V2 was 
produced after medium change and maintained up to 3h-4h. The combination of high 
concentration of ITR in FaSSGF and micellar solubilisation of ITR by the mixed micelle 
in FaSSIF-V2 provided the high “spring effect” (29) and the HPMC acts as a 
precipitation inhibitor to sustain the “parachute effect”, preventing the nucleation and 







Dissolution kinetics of profiles with USP apparatus 1 
 
The dissolution profiles of Sporanox® capsule were fitted with first order, single Weibull 
and Power law kinetics models. The fitted parameters in the fasted state and fed state 
experiments are presented in Table 49. 
Table 49. Mean± SD  dissolution kinetic parameters of ITR dissolved from Sporanox
®
 100mg 
capsule in simulated fasted and fed states media using the USP apparatus 1 (n=3)  
 Simulating fasted state Simulating fed state 
First order kinetic 































































































































































*the model could not fit the data satisfactorily 
 
A study has shown that the release mechanisms of ITR from Sporanox® were 
controlled by diffusion, swelling, and/or erosion which depends on the HPMC:ITR ratio. 
For example, in the beginning of the experiment the weight ratio of HPMC:ITR was 
1.15:1 and as the experiment progressed, the ratio increased or decreased depending 
on the rate of HPMC swelling and ITR diffusion to the bulk media (336). Meanwhile, the 
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surfactant used in dissolution (bile salt, lecithin, SLS) can assist in transferring the drug 
molecules out of the diffusional layer.  
 
The application of Power law in the analysis of dissolution data showed that the values 
of kinetic constant are very different in the simulated fasted state conditions compared 
to the values of 0.57-3.31 in the simulated fed state conditions. The kinetic modeling 
using Power law  also shows that the dissolution of ITR from Sporanox® with USP 
apparatus 1 is associated with an erosion controlled mechanism (exponent >0.85, 
except FeSSIF-V1 at borderline of 0.82). Studies have shown that for a swellable (a 
characteristic of HPMC) spherical sample, the values of n of more than 0.85 indicate 
Super Case II transport (erosion controlled and polymer relaxation release 
mechanisms) (269, 273). This was due to the increase in HPMC matrix erosion, which 
can be attributed to slow relaxation of HPMC after exposure to the in vitro USP 
apparatus 1 system. Furthermore, the erosion mechanism is predominant because of 
the much different hydrodynamics inside the USP apparatus 1 vessel (Reynolds 
number of more than 1500) compared with in USP apparatus 4 (Reynolds number 
approximately 10) (337). 
 
On the other hand, application of first order and single Weibull kinetic models in the 
analysis of dissolution data shows that the mean values of maximum % dissolved 
(Max) in SGF is higher than in FaSSGF. However, the time scale parameter of Weibull 
function and first order rate constant shows that the ITR dissolution rate with FaSSGF 
is at least 5 times higher than in SGF. It indicates that the use of lecithin and bile salt, 
even at below the CMC value is still able to increase the ITR dissolution rate 
considerably. Similarly, the time scale parameter of Weibull function and first order rate 
constant show that the rate of ITR dissolution with digested early FeSSGF is much 
greater than the early FeSSGF and FeSSGF. For instance, the first order rate constant 
with digested early FeSSGF is almost 5 times higher than early FeSSGF and FeSSGF. 







3.3.4 Dissolution testing in USP apparatus 4 
Simulated fasted state conditions 
 
The cumulative % of ITR dissolved from Sporanox® in various simulated fasted state 





Figure 31. Mean ±SD % ITR dissolved from Sporanox
®
 capsules in (A) SGF-M1(8mL/min; 1h) 
then SIF-M1 and M2 (4mL/min; 5h) SGF (8mL/min;1h) then SIF (4mL/min; 5h) (B) FaSSGF 
(8mL/min; 1h) then FaSSIF-V1 and V2 (4mL/min; 3h) using the USP apparatus 4 (n=3). Blue 
arrows indicate time with media change. 
 
ITR is a weak base and it is important to test the formulation of ITR with change of 
media that reflect the human GI system to characterise the degree of supersaturation 
and dissolution behaviour. One of the main dissolution setups with sequential change 
of media and flow rate that is accepted by the regulatory agency such as FDA and 
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EMA is USP apparatus 4. Firstly, in order to characterise the dissolution of ITR from 
Sporanox® in compendial media, experiments with media change using SGF/SIF were 
conducted. Figure 31A demonstrates that % dissolved in SGF was far greater than the 
% dissolved in SIF which reflects also in the solubility of ITR in both media (solubility of 
ITR in SGF and SIF are 3.9 µg/mL and 0.003 µg/mL respectively) (219). As a result, 
the dissolution of ITR in SGF (8mL/min) was relatively fast initially but slowed down 
after conditions changed to SIF (Figure 31A).   
 
Secondly, in order to characterise the dissolution of ITR from Sporanox® using 
biorelevant media, experiments with media change using FaSSGF/FaSSIF-V1 and 
FaSSGF/FaSSIF-V2 were conducted. The results clearly show that the presence of 
lecithin and sodium taurocholate produced an enhancement in dissolution compared 
with the compendial media. It is important to note that FaSSIF-V1 which contains more 
bile salts and lecithin may give a false impression that it has better dissolution of ITR 
than FaSSIF-V2. This is mainly attributed to the fact that approximately 8% more 
dissolution in the gastric phase of FaSSGF/FaSSIF-V1 compared to gastric phase of 
FaSSGF/FaSSIF-V2.  
 
There are a few possible mechanisms of the observed supersaturation and dissolution 
behavior of ITR from Sporanox®. A comprehensive explanation for the mechanism of 
stabilisation of supersaturated ITR solutions has not been reported (338). Several 
studies had suggested the factors related to the improved supersaturation of ITR: (1) 
through incorporating polymers to solutions is the result of intermolecular interactions 
in solution (hydrogen bonding) (338); (2) steric hindrance of recrystallisation (338); (3) 
viscosity that influence the stability of supersaturation (338); (4) the effect of elevated 
glass transition temperature (Tg) of the binary system (the incorporation of the drug 
and the polymer) which would slow down the molecular mobility rendering greater 
physical stability (37). Related to that, it was observed that ITR concentration levels 
increased sharply to above 80.8 µg/mL (FaSSIF-V1) and 60.9 µg/mL (FaSSIF-V2). 
This phenomenon of a higher level of supersaturation tends to cause greater driving 
force for ITR precipitation (51, 339). Upon media change to intestinal media, the ITR 
concentration reduced immediately and slowly decreased over the next 3 h of the 
experiment.  
 
It is noteworthy that when the media was changed to simulated intestinal media, the 
solution in the cells turned opaque which was a strong indicator that the ITR 







Figure 32. Proposed dissolution and precipitation mechanisms of ITR dissolved from 
Sporanox
®
. The capsule dissolved in dissolution medium in flow-through cell (A), the 
pellet/beads dissolving in the medium flushing through (B), the coating dissolving with the 
polymer carried away by medium causing phase separation, exposing the ITR molecules which 
eventually leads to nucleation/crystallisation and precipitation (C, D). 
 
A study has found that the ITR dissolution from Sporanox® was controlled by the 
dissolution of its HPMC matrix (341). The spray-dried layers of HPMC and ITR solid 
dispersion dissolved along with the erosion process. HPMC, the hydrophilic carrier of 
Sporanox® in this case acted as a precipitation inhibitor and prevented the plasticizer 
effect of the water molecules. Other studies also have shown that once the phase 
separation between HPMC and ITR occurred the nucleation and precipitation of ITR 
occur almost immediately (338, 339). In the event of phase separation, a colloidal 
dispersion of ITR in the aqueous dissolution medium was generated (observed as an 






Simulated fed state conditions 
 
The cumulative % ITR dissolved from Sporanox® in FeSSGF/FeSSIF-V2 and 
FeSSGF/FeSSIF-V1 with USP apparatus 4 are presented in Figure 33. 
 
 
Figure 33. Mean± SD % ITR dissolved from Sporanox
®
 capsule in fed state media FeSSGF/ 




; 4h) using the USP apparatus 4 
(n=3). Blue arrow indicates time with media change. 
 
In FeSSGF, designed to simulate the fed state conditions in the small intestine, the 
percentage of ITR dissolved is considerably low, with dissolution of the drug in the first 
2 h of up to 1.83%.  The observed slow and delayed ITR dissolution in FeSSGF could 
be due to the milk albumin or drug binding mechanism. The albumin could interact with 
ITR through hydrophobic and electrostatic interaction (342) as in the case with human 
serum albumin where ITR exhibited significant protein binding in vivo (99.8%) (343). 
There was a faster dissolution of ITR in FeSSIF-V2 compared with FeSSIF-V1. Also, 
the initial burst in FeSSIF-V2 was far greater than in FeSSIF-V1 (Figure 33) (f1,area: 
0.42). Apparently, the presence of 5mM of glyceryl monooleate in FeSSIF-V2 produced 
an enhancement in dissolution rate even though FeSSIF-V1 contains up to 50% more 
bile salts and lecithin than FeSSIF-V2. It is noteworthy that the high variation was 
observed in the FeSSGF/FeSSIF-V1 mainly due to one of the triplicate experiments 





Dissolution kinetics of profiles with USP apparatus 4 
Simulated fasted state conditions 
 
Swelling facilitates drug release and dissolution through Fickian diffusion, whereas 
erosion results in anomalous diffusion (co-dominated by both diffusion and polymer 
erosion in the release mechanism), and these have been reported as Case 1 (Higuchi 
model) and Case 2 transport (zero-order release) (274).  A study has shown that the 
erosion process and diffusion through the gel layer (transfer of drug molecules into 
solution) are the main mechanisms that control the dissolution and release rate from 
coated beads (344). The ITR coated pellet is in the amorphous state before the 
dissolution experiment (244). To investigate the mechanism involved in the drug 
diffusion process (Fickian, non-Fickian, Case II or Super Case II transport), the 
dissolution data in simulating gastric and intestinal phases was fitted to the Power law 
equation (269) (Table 50). Similarly, the dissolution data in simulating gastric and 
intestinal phases was fitted with first order kinetic model and the whole profile was 



















Table 50. Mean± SD  dissolution kinetic parameters of ITR dissolved from Sporanox
®
 100mg 
capsule in simulating fasted state media using the USP apparatus 4 (n=3) 









First order kinetics (Gastric phase at first 1 h) 
 






































First order kinetics (Intestinal phase post 1 h) 
 





















































































































































The first 60min of the dissolution curve (in fasted state simulating gastric condition) 
obeyed the Power law model. The analysis of the release mechanism in SGF, FaSSGF 
and SGF-M1 followed Super Case II transport (n>0.85) which implied that ITR 
dissolution in these media could have occurred by a combination of several processes 
like diffusion, swelling of HPMC component (polymer relaxation), and erosion of the 
HPMC matrix.  
 
The Power law kinetic constants (k) (Table 50) show that initial dissolution rates occur 
in the following sequence: FaSSGF> SGF> SGF-M1 (simulating gastric state with USP 
4 apparatus) and SIF-M1> FaSSIF-V1> SIF-M2> FaSSIF-V2> SIF (simulating intestine 
state with USP apparatus 4). The trends are in agreement with the concept that the 
kinetics constant increases with increasing total solubility of the matrix (269). 
 
In Fickian diffusion the solvent diffusion rate is slower than the polymer relaxation rate 
and the increase of kinetics constant (k) reflects the decrease of the disorder of the 
medium (274). The sequential change of medium and flow rate simulating intestinal 
conditions after 60min with USP apparatus 4 lead to dissolution associated with 
diffusion controlled release in SIF and FaSSIF-V1 and -V2 (n, exponent <0.43, Fickian 
diffusion). The kinetic modeling also shows that the dissolution mechanism 
transformed to Fickian diffusion of ITR through the HPMC matrix upon changing to SIF 
and FaSSIF-V1 and -V2 concurrently, with a reduction in flow rate from 8 mL/min to 4 
mL/min. It indicated that the amorphous matrix had transformed to a rubbery state. 
This was due to the fact that the polymer is in a rubbery state and polymer chains have 
a higher mobility that allows easier penetration of the solvent. Furthermore, water acts 
as a plasticizer, and its presence has caused a decrease of the polymer glass 
transition temperature (Tg) (345). The exponent, n, increases as the solubilisation 
capacity of the surfactant/micelle increases (Table 50). This may be attributed to the 
fact that as the HPMC and drug matrix swelled, the soluble drug was also removed by 
the micelle systems, thus decreasing the resistance of the gel layer to diffusion of the 
drug (269). These findings suggest that the nature of the soluble fraction of the tablet is 
as important a factor as the drug loading (269). On the other hand, the exponent 
constant (n) data indicated mixed mechanism of diffusion and erosion controlled 
release (0.43< exponent< 0.85; non-Fickian) in SIF-M1 and SIF-M2. In the dissolution 
of the polymeric system the polymer chains are not sufficiently mobile to permit 
immediate penetration of the solvent into the polymer core. This could lead to a non-
Fickian diffusion process which also includes anomalous diffusion whereby the rate of 




Meanwhile, application of first order kinetic models in the analysis of dissolution data 
(simulating gastric phase) shows that the mean first order rate constant is in the 
following sequence: SGF-M1/SIF-M2> SGF-M1/SIF-M1> FaSSGF/FaSSIF-V2> 
FaSSGF/FaSSIF -V1> SGF/SIF. This is strongly supportive of the effect of SLS (in 
SGF-M1) and bile salt and lecithin (in FaSSGF). Likewise, the mean first order rate 
constant (simulating intestinal phase) is in the following sequence: SGF-M1/SIF-M2> 
SGF/SIF> SGF-M1/SIF-M1> FaSSGF/FaSSIF-V2> FaSSGF/FaSSIF-V1. It shows that 
SIF-M2 could allow faster ITR dissolution compared to other media.  
 
Simulated fed state conditions 
 
The dissolution profiles of ITR from Sporanox® 100mg capsule in simulating fed state 
media using the USP apparatus 4 were fitted well with Power law, first order, and 
single Weibull kinetics models. The fitted parameters are presented in Table 51 and 
52. 
Table 51. Mean± SD dissolution kinetic parameters (first order and Power law with gastric and 
intestinal phase) of ITR from Sporanox
®
  









First order kinetics 









 0.36±0.34 1.89±0.17 
R
2
 0.93±0.06 0.98±0.01 1.00±0.00 1.00±0.00 
Power law kinetics 
Rate (unit-less) 0.28±0.04 0.78±0.04 5.00±3.02 11.94±1.80 
Exponential 
(unit-less) 
1.96±0.62 1.25±0.14 0.82±0.07 0.64±0.03 
R
2
 1.00±0.00 1.00±0.00 0.99±0.00 0.96±0.01 










Table 52. Mean± SD dissolution kinetic parameters (single Weibull with whole curve) of ITR 
dissolved from Sporanox  
 FeSSGF/FeSSIF-V1 FeSSGF/FeSSIF-V2 
Single Weibull function 
Max (%) 14.51±1.84 11.65±3.64 
a (h) 264.76±142.06 63.79±9.93 
b 5.60±0.63 3.05±0.59 
R
2
 1.00±0.00 1.00±0.00 
 
The dissolution data in simulating gastric and intestinal condition was fitted to the 
Power law equation (269). The dissolution profiles obeyed the Power law model. The 
kinetic constants show that ITR initial dissolution rates in FeSSIF-V2 are higher than in 
FeSSIF-V1 (simulating intestinal stage with USP 4 apparatus). 
 
The mean value of n changed from 1.96± 0.62 (in FeSSGF) to 0.82± 0.07 (in FeSSIF-
V1) and from 1.25± 0.14 (in FeSSGF) to 0.64± 0.03 (in FeSSIF-V2). It indicates that 
with the change of medium and hydrodynamics, release mechanism shifted from Super 
Case 2 release (n>0.85) to non-Fickian release (0.43<n<0.85). 
 
Interestingly, the dissolution of ITR in FeSSIF-V1 with USP apparatus 4 at 6 mL/min is 
very close to zero order kinetic (mean, n=3, Power law exponent parameter is 0.82± 
0.07). From a kinetic viewpoint, the term “zero-order release” occurs when the 
transport of a drug is sustained at a constant thermodynamic activity gradient across 
the diffusional layer for an extended period of time (under steady state conditions) 
(346). Furthermore, Korsmeyer et al. suggested that zero order kinetic (Case 2 
transport)  is a case of anomalous (non Fickian) diffusion, in which a solvent front 
penetrates the initially glassy polymer at a constant velocity (269). At high coating 
levels the drug is forced to diffuse through the membrane. The coating layers 
effectively seal the pores and channels in the coating. Hence dissolution of the drug 
from coated beads exhibits zero release.  
 
The dissolution mechanism is more erosion driven in FeSSIF-V1 because the Power 
law exponential (n) is 0.82±0.07 and closer to Super Case II transport compared with 
more diffusion driven in FeSSIF-V2 (n: 0.64± 0.03). It is proposed that the higher 
concentration of lecithin and bile salt in FeSSIF-V1 affects also the characteristic of the 
144 
 
HPMC system found in the Sporanox® pellet. The high viscosity in the pellets retards 
the diffusion of the drug at the early stages of release in FeSSIF-V1. At the later stages 
of release the polymer solution becomes dissipated and resistance to diffusion is 
decreased. The net effect of this process is a decrease in release rate, which is 
normally observed as the drug concentration in the drug content within the flow through 
the cell decreases (269).  
 
The role of a polymer such as HPMC in controlling drug release is determined by its 
hydration, swelling and dissolution. The latter process involves steps including 
absorption or adsorption of water at the most accessible sites on the polymer, breaking 
of polymer–polymer bonds via the creation of water–polymer bonds, separation of the 
polymer chains and finally dispersion of the polymer chains in the dissolution media 
(345). It seems that the polymer relaxation (swelling of HPMC) was less complete after 
2 h (at 6mL/min) in viscous colloidal solution (FeSSGF; Table 51) than 1 h in FaSSGF 
solution (at 4mL/min; results as shown in Table 50). Therefore kinetic fitting using the 
Power law shows that drug release and dissolution of ITR from Sporanox® are affected 
by the rate of dissolution of the API, the diffusion through the coating polymer as well 
as gelling, swelling and erosion of the coating polymer.  
 
In this study, first order and single Weibull kinetic models were also applied to analyse 
the ITR dissolution data (simulating fed state). From the perspective of the ITR 
dissolution rate, the first order rate constant and time scale parameter of a single 
Weibull function showed that a higher rate was achieved in FeSSGF/FeSSIF-V2 
compared to FeSSGF/FeSSIF-V1. Furthermore, the shape factor of the Weibull 
function also implies that the curve shape of FeSSGF/FeSSIF-V2 is steeper (in terms 
of sigmoidal curve) than FeSSGF/FeSSIF-V1. The results indicate that FeSSIF-V2 
which contains lipolytic products caused at least 4 times the increment of the 
dissolution rate compared to FeSSIF-V1.  
 
3.3.5 Simulation of physiological relevant in vivo precipitation  
 
It is generally believed that the drug precipitation in the GIT affects the drug absorption. 
This is especially true for weakly basic drugs that have a high solubility in the gastric 
medium but low solubility at high pH values (347). ITR, a weak base has shown a high 
solubility and dissolution rate in the acidic environment of the stomach (Figure 34). It is 
possible that as it moves down the GIT and the pH rises, its solubility and dissolution 
rate decreases and it may precipitate out. This possible in vivo precipitation was 
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investigated using a drug precipitation study design with USP apparatus 4, in which the 
drug precipitation was calculated when the media was changed from simulated gastric 
to simulated intestinal media.  
 
The % of dose and sample precipitated after media change with USP apparatus 4 are 
shown in Figure 34.  
Figure 34. (A) Mean± SD % dose precipitation of ITR from Sporanox
®
 with various media with 
USP apparatus 4; (B) Sample precipitation at 70 min. 
The solubility of ITR is 3.9 µg/mL in SGF in contrast to 0.003 µg/mL in SIF (219). 
Precipitation of the ITR occurred during a change of media from 1.2 to 6.8. The 
precipitation level is mainly controlled by two factors, the solubility of ITR in the gastric 
and intestinal phase and the composition of the medium simulating intestinal phase. 
The better solubility of ITR with SIF-M1 and SIF-M2 caused lower precipitation of ITR 
from the Sporanox® capsule. Interestingly, the higher solubility of ITR in SGF leading to 
lower precipitation in SIF and the lower solubility of ITR in FaSSGF compared to the 
one in SGF caused higher precipitation even though both FaSSIF-V1 and FaSSIF-V2 

















































pH is the more dominant factor influencing the precipitation compared with the micellar 




3.4 Results and Discussion of Part 1: In vitro dissolution testing (CX) 
 
3.4.1 Dissolution testing in USP apparatus 2 
 
Compound X (CX) is a highly lipophilic, poorly soluble compound. CX has weak acidic 
(pKa 10) functional groups and its pKa at 10 renders it essentially neutral under the GI 
physiological pH range. Due to its high lipophilicity (log P= 5.42) its solubility is very low 
(less than 5 μg/mL in water and SGF and 40 μg/mL in FaSSIF-V1) (252). Owing to the 
extremely low solubility and dissolution of CX in media such as FaSSGF, FaSSIF-V2 
analysis with USP apparatus 2 (a closed dissolution system) was not performed. In this 
case the use of a surfactant is necessary in order to facilitate the characterisation of 
the CX dissolution profile. 
 
The cumulative % of dissolved CX from CX F8 in FeSSGF and SIF-M4 and –M5 with 
USP apparatus 2 are presented in Figure 35.  
 
Figure 35. Mean± SD % CX dissolved from CX formulation (F8) with various media with USP 
apparatus 2 (500 mL medium, 37°C, 75 rpm). 
Dissolution of CX from CX formulation (F8) in FeSSGF, which is the acetate buffer 
solution containing 50% milk, is 4.7% at 2 h. Considering that the dissolution was 
almost zero in SGF and SIF under the same conditions (Figure 35), the composition of 
milk seems better able to solubilise this highly lipophilic compound compared to SGF 
and SIF. Shono et al. proposed that poorly water soluble drugs could possibly be 
incorporated into casein micelles (55).  However, it must be noted that casein micelles 


























isoelectric point (IEP; the pH at which the protein is least soluble and is precipitated) of 
casein is approximately 4.6 (348) a value very close to the pH of FeSSGF (pH 5.0). 
Therefore it is highly probable that the casein precipitated in FeSSGF and hence the 
main mechanism of the solubilisation of CX in milk is through emulsification by milk 
lipids and fat globules. This is supported by the dissolution profile closely following a 




3.4.2  2 stage dissolution studies 
 
The cumulative % of dissolved CX from CX formulation (F8) with 2 stage dissolution 
experiments with USP apparatus 2 are presented in Figure 36.  
                         
Figure 36. Mean± SD  % CX dissolved from CX formulation (F8) using 2 stage dissolution, 250 
mL FaSSGF for 30min/500 mL FaSSIF-V1 or -V2 with USP apparatus 2 (500 mL medium, 37 
°C, 75 rpm). Blue arrow indicates time with media change. Gap after media change indicates 
short pause of paddle rotation. 
A high percentage of CX was dissolved after medium change and maintained up to 1 h 
before the precipitation rate exceeded the dissolution rate of CX, leading to a fast 
descending dissolution curve. This solid dispersion formulation exhibited the so-called 
“spring” and “parachute” dissolution profile (29). The amorphous compound served as 
the “spring” that brings the dissolved drug concentration above the equilibrium solubility 
and the polymer (precipitation inhibitor) served as a “parachute”, slowly settling down 
the concentration to the equilibrium solubility.  
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Dissolution of CX in FaSSGF (in the first 0.5 h) was almost zero (Figure 62).  Upon the 
medium change to FaSSIF-V1 or FaSSIF-V2 a marked increase in dissolution 
occurred. The extent and rate of dissolution was much higher in FaSSIF-V2 than in 
FaSSIF-V1. This is mainly due to the change of the properties and capacity of the 
lecithin/bile salt micelle which is influenced by the ionic strength of the medium (349).  
 
3.4.3 Dissolution testing in USP apparatus 4  
Simulated fasted state conditions 
 
The cumulative % of dissolved CX from CX formulation in modified media (F8), 
FaSSGF/FaSSIF-V1 (F8) and FaSSGF/FaSSIF-V2 (F4-F8) are presented in Figure 37. 
Formulation 8 of CX was tested in all conditions (modified media, FaSSGF/FaSSIF-V1 
and FaSSGF/FaSSIF-V2) to characterise its dissolution profiles in these media. 
Furthermore, formulation 4, 5, 6 and 7 of CX were also tested in FaSSGF/FaSSIF-V2 
to study the formulation effects on dissolution of CX. 
 
                              
Figure 37. Mean± SD % CX dissolved from CX formulations (A): modified media (B):F4-F8 with 
FaSSGF/FaSSIF-V2 and F8 with FaSSGF/FaSSIF-V1 (8 mL/min; 1 h; 4 mL/min; 4h) using the 
USP apparatus 4 (n=3). Blue arrow indicates time with media change. 
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The dissolution of CX in simulated gastric media was extremely poor mainly due to the 
fact that the polymer used in CX solid dispersion formulation is HPMCAS, which does 
not dissolve in an acidic medium. On the other hand, when media were changed to 
simulated intestinal fluids (SIF-M3, FaSSIF-V1 and FaSSIF-V2), the dissolution of CX 
increased gradually with the modified media with 0.1% HTAB (SIF-M3) yielding 16.73% 
CX dissolved; whereas, in FaSSIF-V1 and V2 less than 10% and 5% of CX were 
dissolved at 5 h, respectively.  
Immediately after the medium change to simulated intestinal media with a physiological 
amount of SLS (SIF-M1 and SIF-M2), the presence of SLS micelle with high 
solubilisation capacity was able to solubilise CX molecules available in the system 
thereby producing a sudden increase of dissolution. Due to twice higher the content of 
SLS in SIF-M1 (0.2%) than in SIF-M2 (0.1%) the dissolution of CX is almost double in 
the SIF-M1 compared to SIF-M2. 
Comparing FaSSGF/FaSSIF-V1 and FaSSGF/FaSSIF-V2 (F8), it is obvious that 
FaSSIF-V1 solubilises CX better than FaSSIF-V2. A sharper rise in the FaSSIF-V1 
phase seems to suggest that a mixed micelle of bile salt and lecithin in FaSSIF-V1 has 
a better solubilisation capacity. The lower ratio of bile salt: lecithin (4:1) in FaSSIF-V1 
vs 15:1 in FaSSIF-V2 proved to be superior for dissolution of this poorly soluble 
compound with USP apparatus 4 (open system). In the open dissolution system, fresh 
FaSSIF-V1 containing mixed micelle of bile salt and lecithin was able to solubilise the 
drug molecules and 9.5% of the drug was dissolved after 5h. Profile comparison 
among different CX formulations (F4, F5, F6, F7 and F8) with FaSSGF/FaSSIF-V2 
shows that these profiles are similar (f1,area=F4: 0.08 F5:0.06, F6:0.07, F7:0.08, F8 as 
reference formulation). It must be stressed that a medium with a non-physiological 
surfactant such as HTAB could potentially mask supersaturation of the amorphous 
form especially under non-sink conditions (350). Supersaturation of the CX from its 
amorphous formulation was clearly observed in FaSSIF-V1 that was not apparent in 
SIF-M3 (CX solubility in SIF-M3 of 480 µg/mL (233) is not shown in Figure 38 due to 
the high scale value for clarity in the graph). Therefore, FaSSIF-V1 is superior for 
characterising the dissolution profile of CX. Literature has also suggested that FaSSIF-





Figure 38. Mean± SD % CX concentration yielded from CX formulation in post media change 
(SGF-M2/SIF-M3, FaSSGF/FaSSIF-V1 (8mL/min 1 h then 4 mL/min; 4 h) using the USP 
apparatus 4 (dissolution profiles were presented in Figure 38). Equilibrium solubility of each 
media is shown except SIF-M3, 480 µg/mL. Blue arrow indicates time with media change. 
 
Simulated fed state conditions 
 
The cumulative percentage dissolved of CX from CX formulation (F4-F8) in 
FeSSGF/FeSSIF-V2 and FeSSGF/FeSSIF-V1 with USP apparatus 4 is presented in 
Figure 39. 
  
Figure 39. Mean± SD % of CX dissolved from CX tablet in fed state media FeSSGF (6 mL/min; 
2 h)/ FeSSIF-V1 or -V2 (6 mL/min; 4 h) using the USP apparatus 4 (n=3). Blue arrow indicates 
time with media change. 
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Drug solubility and dissolution can be considerably enhanced in the mixed micelles 
found in GIT and especially fatty substances and products of fat digestion (lipolytic 
product) such as monoglycerides and fatty acids (57). Studies have confirmed that the 
combination of bile salt and monoglycerides in the medium could increase the 
dissolution and capacity for supersaturation for a poorly soluble compound (351). 
Furthermore, partitioning of poorly soluble drugs between the different colloidal phases 
(mixed micelles and vesicles) formed in aqueous media containing bile acids and 
phosphatidylcholine with the addition of monoglycerides and free fatty acids could also 
greatly increase drug dissolution (352). 
Similar to the FaSSGF/FaSSIF-V1 and -V2 dissolution profile, immediately after the 
medium change to simulate fed state intestinal media, there is an apparent increase of 
CX dissolution. These results again indicate that the bile salt, lecithin and lipolytic 
products found in FeSSIF-V2 have a significant effect on CX dissolution. It is 
interesting to note that the percentage of CX dissolved in FeSSIF-V2 is 15% higher 
than in FeSSIF-V1, a pattern that was observed also in the ITR dissolution profile 
(another model drug used in this project). For the purposes of profile comparison, in 
agreement with the comparison in FaSSGF/FaSSIF-V2,  for the dissolution studies with 
different formulations (F4, F5, F6, F7 and F8) the profiles are deemed to be similar 
(f1,area=F4:0.14, F5:0.0.13, F6:0.09, F7: 0.10, F8 as a reference compound). 
 
Dissolution kinetics of profiles with USP apparatus 4 
Simulated fasted state conditions 
HPMCAS (an enteric polymer) consists of more than 50% of the bulk content of the CX 
tablet (235). It must be noted that due to its high polymer content, the dissolution 
behaviour tend to be influenced and affected by the polymer (HPMCAS) used. When 
placed in medium with a pH greater than 4, HPMCAS would dissolve and act as the 
water-filled pores (251). A study has also shown that drug molecules diffuse through 
pores and channels in the membrane according to first order kinetics (251). In 
agreement with that, the dissolution profiles of CX formulations all fitted well with a first 
order kinetics model. For comparison purposes, the dissolution profiles were also fitted 
with a single Weibull function. The fitted parameters of CX dissolved from CX 
formulations in simulated fasted state media using the USP apparatus 4 (n=3) are 





Table 53. Mean± SD dissolution kinetic parameters (first order with intestinal phase and single 



















First order (Intestinal phase post 1 h)* 
Max 
(%) 
4.74± 0.21 6.20± 0.84 4.25±0.54 4.99±1.25 10.43±1.48 4.47±0.36 
c (/h) 0.25± 0.01 0.21±0.04 0.30±0.05 0.29±0.10 0.61± 0.05 0.33±0.03 
R
2
 1.00± 0.00 1.00± 0.00 1.00± 0.00 1.00±0.00 0.99± 0.00 1.00±0.00 
Single Weibull function 
Max 
(%) 
3.05±0.11 3.40±0.16 2.98±0.16 3.27±0.23 9.06±0.94 3.23±0.17 
a (h) 12.95±0.88 15.93±0.93 11.30±0.74 12.45±3.28 9.26±2.28 11.33±0.88 
b 2.30±0.16 2.52±0.04 2.20±0.07 2.31±0.19 2.58±0.31 2.31±0.06 
R
2
 0.99±0.00 1.00±0.00 0.99±0.00 0.99±0.00 0.99±0.01 1.00± 0.00 
 
Table 54. Mean± SD dissolution kinetic parameters (first order with intestinal phase and single 
Weibull function) of CX from CX formulations with modified media 
 SGF-M1/SIF-M1 SGF-M1/SIF-M2 SGF-M2/SIF-M3 
First order kinetics (Intestinal phase post 1 h)* 
Max (%) 11.69± 8.19 3.21± 0.16 71.71± 28.69 
c (/h) 0.08± 0.05 0.18± 0.05 0.07± 0.06 
R
2
 1.00± 0.00 0.98± 0.01 1.00± 0.00 
Single Weibull function 
Max (%) 4.12±0.43 2.79±0.38 59.08±37.32 
a (h) 8.33±3.17 9.11±1.84 27.97±16.09 
b 5.78±1.76 5.28±0.66 1.43±0.13 
R
2
 0.97±0.00 0.98±0.00 1.00± 0.00 
(*Due to the extremely low dissolution (less than 2%) of CX formulation in the simulated gastric 
phase (SGF-M1, SGF-M2 and FaSSGF) only the dissolution profiles in the simulated intestinal 
phase were characterised) 
The application of a first order kinetics and single Weibull model in the analysis of 
dissolution data shows that the mean values of maximum percentage dissolved (Max) 
followed the sequence of SGF-M2/SIF-M3>SGF-M1/SIF-M1 >FaSSGF/FaSSIF-V1 > 
FaSSGF/FaSSIF-V2> SGF-M1/SIF-M2. This indicates that HTAB-based modified 
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media (SGF-M2/SIF-M3) have greater solubility capacity for CX than SLS-based 
modified media and biorelevant media.  
According to the first order kinetic model, the first order rate constant suggested that 
the dissolution rates are FaSSGF/FaSSIF-V1> FaSSGF/FaSSIF-V2> SGF-M1/SIF-
M2> SGF-M1/SIF-M1> SGF-M2/SIF-M3. The results clearly show that FaSSIF-V1 and 
FaSSIF-V2 which contain physiological surfactants (bile salt and lecithin) gave a faster 
dissolution rate. However, the biorelevant micelle system has less solubilisation 
capacity compared to an artificial surfactant such as SLS and HTAB.  
 
The dissolution profiles of CX formulations (F4, F5, F6, F7 and F8) in 
FaSSGF/FaSSIF-V2 show quite similar first order rate constant and maximum 
percentage dissolution. Likewise, the Weibull fitting also shows a very similar value of 
time scale and shape factor parameters. For example, the shape factor parameters (b) 
range from 2.20-2.58. This can be attributed to the fact that the CX formulations tested 
(F4-F8) do not vary much in the critical manufacturing attributes thus it is expected that 
the dissolution profiles would be very similar. The Max values show the same rank 
order according to the particle size distribution of CX proprietary microprecipitated bulk 
powder (MBP). The radius of MBP in the formulation of CX is F5 (37.2 µm) >F4 (48 
µm)> F6 (60.9-64.9 µm) (Compositions presented in Section 2.3.3).  It is generally 
accepted that the dissolution rate is proportional to the particle size of the powder (353, 
354), indicating the importance of particle size as a critical manufacturing variable that 
indirectly affects the absorption of poorly soluble drugs. However, the rank order of 
Max does not translate into the ranking of first order rate constant between F4, F5 and 
F6. This could be due to the fact that the difference in particle size is too small to be 
discriminated in an in vitro experiment. For instance, literature indicates that the 
dissolution rate for a micronised particle would not be affected even by changing the 
stirring conditions because the thickness of the boundary layer is too small (355). 
Furthermore during dissolution, the volume of a particle decreases at a faster rate than 
the surface area. Thus, surface area is one of the critical factors affecting dissolution 
especially for relatively small particle sizes like the MBP for CX (249). 
 
Simulated fed state conditions 
 
Similar to the dissolution profiles of CX from CX formulations (F4-F8) of the simulated 
fasted state conditions, the dissolution profiles of the simulated fed state conditions 
were fitted well with a first order kinetic and single Weibull model. The fitted parameters 
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of CX dissolved from CX formulations in simulated fed state media using the USP 
apparatus 4 (n=3) are presented in Table 55.  
Table 55. Mean± SD dissolution kinetic parameters (first order with gastric and intestinal phase 































































































































































Like the FaSSGF/FaSSIF-V2 dissolution profiles of CX formulations (F4, F5, F6, F7 
and F8), FeSSGF/FeSSIF-V2 show a fairly consistent time scale parameter of single 
Weibull function and maximal percentage dissolution apart from the one tested using 
Formulation 5. Higher dissolution rate and extent achieved in Formulation 5 could be 
due to its smaller PSD of 37.2 µm compared to other formulations that range from 
48.0- 64.9 µm. Likewise, the Weibull fitting also shows a very similar time scale and 
shape factor parameters. For example, the shape factor parameters (b) range from 
3.06-3.97 except 5.19 from Formulation 5. This shows that FeSSGF/FeSSIF-V2 is a 
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more discriminating testing media compared to FaSSGF/FaSSIF-V2 because 
FeSSGF/FeSSIF-V2 could differentiate Formulation 5 with other formulations.  
The Max values show the same rank order according to the particle size distribution of 
CX proprietary microprecipitated bulk powder (MBP). The radius of MBP in the 
formulation of CX is F5 >F4> F6 (Compositions presented in Section 2.3.3). The 
application of a first order kinetics and single Weibull function in the analysis of this 
dissolution data showed that the mean values of Max in FeSSGF/FeSSIF-V2 is higher 
than in FeSSGF/FeSSIF-V1. On the same note, the dissolution rate fitted using first 
order and Weibull model (in the intestinal phase) is almost 3 times higher in 
FeSSGF/FeSSIF-V2 compared to FeSSGF/FeSSIF-V1. 
 
3.4.4 Simulation of physiological relevant in vivo precipitation  
 
CX has shown a very low solubility and dissolution rate across the physiological pH in 
the GIT, reflected also in the drug precipitation after media change. In vitro precipitation 
was observed due to the properties of the compound and its formulation effect. The 
whole dissolution setups are designed based on the physiological conditions (pH, 
media and hydrodynamics used); thus, similar in vivo precipitation could also be 
observed. The percentage of dose precipitation after media change with USP 
apparatus 4 is shown in Figure 40.  
 
Figure 40. Mean± SD % precipitation (A: sample precipitated; B: dose precipitated) of CX from 
its formulations in various media with USP apparatus 4. Graphs C and D show precipitation 
from FaSSGF/FaSSIF-V2 (FF: FaSSGF/FaSSIF; SS: SGF-M1/SIF). 
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Drug precipitation after media and flow rate change ranged from 20% to 90% in the 
sample collected, which accounted for less than 1% of the dose tested (240 mg of CX 
per tablet). Relatively higher dose precipitation was observed after change of medium 
using modified compendial media with SLS and less with HTAB. This is in agreement 
with the dissolution results of the modified media with SLS, that reported fast 
precipitation compared to media with HTAB (Figure 40). The high variability observed 
in some experiments was mainly due to the difference in the dispersion of the content 
inside the flow through cells especially during media change, which led to a difference 
in drug dissolution. Furthermore, there was no significant difference in the percentage 
dose precipitation among the various formulations (F4, F5, F6, F7 and F8) and 
dissolution media of FaSSIF-V1 and FaSSIF-V2, which show that these formulations 
are very similar in terms of their critical manufacturing variables.  
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3.5 Results and Discussion of Part 2: Surface UV dissolution imaging  
3.5.1 Calibration curves  
 
Calibration curves for ITR and CA were constructed and the quantitative performance 
of the UV imager was verified before conducting the in vitro release experiments. For 
this purpose, the phosphate buffer followed by a series of ITR and CA reference 
standard standard solutions were flowed through the laminar flow cell (2 mL/ min) with 
continuous image data collection. In this project the area selected for imaging was 
9.0 mm × 4.3 mm as suggested in the literature (111). In principle, 4× 4 pixel binning 
was applied and produced approximately 5 x 104 individual UV spectrophotometers.  
 
From the gradients of calibration curves (Figure 41), the molar absorption coefficient 




Figure 41. Mean absorbance values as a function of concentration for pixel subselection 
obtained by flowing ITR and CA standard solutions through the laminar flow cell. Insert shows 
the UV absorbance vs time profile obtained by flowing ITR standard solutions through the cell. 
The UV imaging ITR and CA reference standard calibration curve at 280 nm was 
considered linear within the investigated range. The LOQ was estimated to be 2.4x 




3.5.2 In vitro surface UV dissolution imaging studies 
 
In the current study, two particular low flow rates of 0.14mL/min and 0.28 mL/min are 
chosen based on the linear regression of linear velocity and flow rate (Figure 42). The 
results of linear velocity (cm/min) of ActiPix™’s laminar flow cell at various flow rates 
and in the human stomach and intestine have been reported in the literature (124, 
276).  Without taking into account the cross-sectional water loss, the flow rates of 
ActiPix™’s flow cell that correspond to the linear velocity reflecting the human stomach 
and intestinal section are 0.28 mL/min and 0.14 mL/min respectively. Based on the 
facts that both ActiPix™’s flow cell and USP apparatus 4’s flow through cell provided 
unilateral laminar flow and the former generates lower hydrodynamics, a  one-order 
magnitude scale-down of the current project’s USP apparatus 4 setup was used. 
Hence, flow rates of 0.8mL/min and 0.4mL/min reflecting the human stomach and 
intestine respectively were used in the experiment with media and flow rate change.  
 





First, it must be noted that an initial dissolution test using Zinnat® (amorphous 
formulation of CA) compact was not satisfactory because the high loading of super-
disintegrant croscarmellose sodium  in Zinnat® became a dense layer after being 
exposed to the dissolution medium (Figure 43). This layer caused physical blocking of 
the light and yielded a large amount of debris that clogged the flow cell thus preventing 
further testing.  
y = 7.17x - 0.0135 


































Figure 43. Dense layer formed immediately after Zinnat
®
 compact exposure to dissolution 
medium.  
The intrinsic dissolution rate (IDR) was calculated using the built-in programme 
available in the ActiPix™ software using the absorbance values from the quantification 
region during dissolution of drug compacts. The calculation program integrates 
information such as the absorbance reading, the molar absorptivity calculated from the 
calibration curves of each drug, the surface area of compacts and the flow rate profile 





Single medium and flow rate study 
 
IDRs of CA API in compendial and biorelevant media vs time profiles with single media 





Figure 44. Mean± SD IDR  of CA  from its API compact in compendial and biorelevant media. 
The impact of reducing the flow rate from 1mL/min to 0.14mL/min on the CA IDR 
profiles was evident (Figure 44). The dissolution experiment setup with FaSSIF-V1 
showed a clear stepwise IDR reduction in tandem with flow rate decrease from 
1mL/min (0.097 mg/min/cm2) to 0.14mL/min (0.018 mg/min/cm2 at 5min). In contrast, 
the IDR profiles in SGF, SIF and FaSSGF showed a very dense IDR profile pattern 


























































































A compilation of all measured IDR results vs flow rate is shown in Figure 45. The graph 
profiles formed in SGF, FaSSGF and SIF are almost straight and suggest that the 
dissolution mechanism is predominantly swelling or erosion; whereas, with the FaSSIF-
V1 profiles the graph profile shows an apparent gradient which indicates dissolution in 
convective flow as the main dissolution mechanism. The difference is a good indicator 
for the effect of mixed micelles that facilitate and enhance the dissolution of a poorly 





Figure 45. Mean± SD IDR and amount of CA dissolved at 5 min from its API compact with 
compendial and biorelevant media (n=3, except FaSSGF n=2). 
All IDR profiles, regardless of the media used, yielded a plateau IDR vs time profile 
which clearly showed zero order dissolution kinetic. This verified that sink conditions for 
CA dissolution possibly exist in the channel flow cell and literature has suggested that 
this sink condition is an important factor in the simulation of the human in vivo condition 
(117, 124). 
 
Media and flow rate change study 
 
Dissolution behaviour of CA was monitored by the surface UV dissolution imager with 
SGF (0.8 mL/min;6 min)/ SIF (0.4 mL/min;18 min). The UV images of absorbance 
maps of dissolved CA at different selected time points are shown in Figure 46. A 
contour concentration line is presented in the concentration scale bar. The measured 
concentrations in the UV map shown were all within the linear range of the calibration 
curve (below 35 µg/mL). It can be observed that the dissolution layer is thin with a wide 
















































Figure 46. UV concentration maps of CA dissolved from API compacts with SGF (0.8 mL/min;6 
min)/ SIF (0.4 mL/min;18 min) using surface UV imaging apparatus (Time point: 2,4,6,8,10,12 
and 18 min). Colour-concentration banding: red 62.07; orange  49.64; green  37.21; light blue 
24.77; dark blue 12.34 µg/mL. 
The results point out that soon after media and flow rate change the drug concentration 
peak at 8 min forms a supersaturated solution and then gradually reduces.  As 
indicated by the arrow in Figure 46, there was an apparent turbulent pattern contour 
which could probably imply a dispersion of the recrystallised particle at 8 and 10 min 
corresponding to the crystal growth post supersaturation.  
The dissolution layer thickness at the surface is approximately 0.05mm to 0.1mm 
under both flow rate at 0.8mL/min and 0.4mL/min, whereas the boundary layer 
thickness is 4.34 x10-3 mm (0.8mL/min) and 8.66x10-3 mm (0.4mL/min), respectively. 
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The boundary layer thickness is calculated based on the CA diffusion coefficient value 
of 5.776x10-6 cm2/s (calculated value based on molecular weight using GastroPlusTM). 
The measured values using surface UV imaging apparatus is far higher than the value 
projected using a diffusion coefficient. According to the literature (116), this 
phenomenon suggests that CA dissolved from the surface as aggregate, initially 
forming a supersaturated solution; this is in agreement with the observed IDR and 
amount of CA dissolved from its API compact with media and flow rate change from 
SGF (0.8 mL/min) to SIF (0.4 mL/min) (Figure 47). Figure 47 indicates that there are 
two supersaturated solutions formed in SGF and SIF before particle precipitation and 
decrease of IDR.   
 
Figure 47. Mean± SD IDR of CA dissolved from its API compact with SGF (0.8 mL/min; 6 min)/ 








Single medium and flow rate study 
 
IDR of ITR from ITR API and Sporanox® in compendial and biorelevant media vs time 
profiles are presented in Figure 48.
165 
 
Medium ITR API compact (reference standard) Sporanox
®












Legend:Flow rate  
Figure 48. Mean± SD IDR of ITR from its API compact and Sporanox
®
 compact in compendial 









































































































































































A stepwise decrease in dissolution rate corresponding to the stepwise reduction in flow 
rate was obtained from the imaging data (Figure 48). This trend was expected 
according to the convective diffusion theory (357). The impact of reducing the flow rate 
from 1 mL/min to 0.14 mL/min on the IDR profiles was evident in ITR API in the 
compendial and biorelevant media and Sporanox® formulations with SGF and FaSSIF-
V1. In Sporanox®, the IDR profiles in FaSSGF and SIF showed no obvious rank order, 
probably due to the interference of surface dissolution characterisation in the presence 
of excipients and polymers, such as HPMC and PEG.  
In order to determine the dissolution mechanism of ITR from both compacts, the same 
IDR results were plotted against flow rate (Figure 49).  
 
ITR API compact (n=2 except SGF n=3) Sporanox
®
 pellet compact (n=3) 
  
Legend  
Figure 49. Mean± SD IDR and amount of ITR dissolved at 5 min from its API compact and 
Sporanox
®
 compact with compendial and biorelevant media. 
Literature has suggested that the flat and gradient IDR profiles indicate that the 
dissolution mechanism is predominantly erosional (swelling) and convectional, 
respectively (116). The dissolution mechanism of ITR from Sporanox® (SIF and 
FaSSIF-V1 at 1mL/min) showed a higher gradient curve than from the ITR API, 
denoting a higher convectional dissolution of ITR from the HPMC gel matrix. This is in 
agreement with the dissolution kinetic of ITR characterised with USP apparatus 4 
showing that the dissolution in convective flow is the main process determining the 
dissolution of ITR formulated as a solid dispersion coating pellet. The IDR trends with 
biorelevant media did not reveal the advantage of the surfactants in terms of enhancing 
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whereby bile salt was shown to potentially undergo an acid-base reaction with ITR 
molecules leading to slower ITR dissolution (329, 330).  
 
The content of HPMC in Sporanox® pellet coating is 60% w/w (ratio of 1:1.5 ITR to 
HPMC), thus at this high concentration the release of ITR is controlled by HPMC. The 
multiparticulate drug coated Sporanox® pellet was also coated with the PEG membrane 
at its outer most layer. The rate of ITR dissolution in convective flow to the dissolution 
media is dependent not only on the thickness of the membrane but also on the 
composite of the HPMC-ITR solid solution matrix itself which sustains the dissolution. 
Furthermore, HPMC has a gelling property upon hydration which has been identified as 
a variable affecting drug dissolution (358). Hence, the dissolution of ITR from 
Sporanox® compact was delayed due to drug particles having to diffuse out from the 
HPMC matrix before undergoing dissolution.  
Due to the poor solubility of ITR in SIF and without the interference of bile salt and 
lecithin, SIF was able to discriminate Sporanox® formulation (amorphous formulation) 
and ITR API (crystalline compact). For example, the IDR of Sporanox® pellet in SIF 
was nearly 10 times higher than the same measurement in the ITR API compact. The 
results seem to suggest that this experiment setup and conditions could be used to 
discriminate critical manufacturing variables of such formulations.  
 
 
Media and flow rate change study 
 
Dissolution behaviour of ITR from its API and Sporanox® compacts were monitored by 
the surface UV dissolution apparatus with SGF (0.8 mL/min;6 min)/ SIF (0.4 mL/min;18 
min) and FaSSGF (0.8 mL/min;6 min)/ FaSSIF-V1(0.4 mL/min;18 min). IDR and 




Figure 50. Mean± SD IDR and amount of ITR dissolved from its API and Sporanox
®
 compact 
with SGF(0.8 mL/min;6 min)/ SIF (0.4 mL/min;18 min) and FaSSGF(0.8 mL/min;6 min)/ FaSSIF-
V1(0.4 mL/min;18 min, n=3) 
Compared to the graphs in individual media such as FaSSGF, FaSSIF-V1, SGF and 
SIF (Figure 50) that showed a flat and linear graph, the curve experiments with media 
change have exhibited their own characteristic gradient. The dissolution profiles of 
experiments with media change using surface UV imaging resembled those of USP 
apparatus 4. For example, the biphasic curve was apparent, with a sudden increment 
after media change from simulated gastric medium to simulated intestinal medium. 
Similar to USP apparatus 4, due to media change to FaSSIF-V1 with micellar 
solubilisation, higher supersaturation could be observed with the media change from 
FaSSGF to FaSSIF-V1. The same dissolution rate enhancement was observed in the 
Sporanox® pellet compact with FaSSGF/FaSSIF-V1 also but not in SGF/SIF.  
 
The IDR profile of ITR API compact in SGF/SIF and FaSSGF/FaSSIF-V1 also showed 
that after medium and flow rate changes from simulating gastric condition to simulating 
intestinal condition the IDR and amount dissolved increased significantly forming a 
transient supersaturated solution of ITR. After 5 to 8 min the supersaturation ratio 
reduced steadily toward the equilibrium dissolution rate of 0.128 mg/min/cm2 in 
FaSSIF-V1 and 0.051 mg/min/cm2 in SIF yielding a total amount of ITR dissolved of 98 
µg and 51µg respectively. 
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The IDR of ITR from its API and amorphous formulation (Sporanox®) showed that the 
IDR and amount dissolved were twice as high in the ITR API compact than Sporanox® 
compact (Figure 50). This does not reflect the fact that amorphous formulation 
generally has a higher dissolution. The results were probably due to the interaction of 
bile salt (found in FaSSIF-V1) and potassium salt (found in SIF) with PEG which had 
been proposed in the literature (359). The PEG coating was used in Sporanox® pellet 
to prevent agglomeration which in surface UV imaging hindered the ITR dissolution. 
The effect of PEG on the surface UV imaging was also shown in the individual 
Sporanox® dissolution test using FaSSGF and FaSSIF-V1 (Figure 50). Probably for the 
aforementioned reason, the supersaturated solution produced from FaSSGF/FaSSIF-
V1 was less obvious with a peak IDR of 0.103 mg/min/cm2 compared with the 
equilibrium rate of 0.086 mg/min/cm2 which yields a total of 48 µg of ITR dissolved.  
The concentration curves of ITR dissolved from ITR API compact and Sporanox® pellet 
compact relative to the compact surface axis are presented as concentration contours 
within the UV absorbance maps of ITR dissolved at different selected time points 
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Legend: Concentration colour indicator for ITR  
 
Figure 51. UV concentration maps of ITR dissolved from API and Sporanox
®
 pellet compacts 
with SGF (0.8 mL/min;6 min)/ SIF (0.4 mL/min;18 min) and FaSSGF (0.8 mL/min;6 min)/ 
FaSSIF-V1 (0.4 mL/min;18 min) using surface UV imaging apparatus (Time point: 2,4,6,8,10,12 
and 18 min). 
The area in blue shows the background (without drug solute) absorbance and tense 
light colour indicates high absorbance at the lower right corner. The sample compact 
was located at the bottom of each image and the contours represent curves with the 
same concentration. The absorbance map in each image indicates the spatial 
concentration distribution of the dissolved ITR in the flow cell at the recording time, 
which was affected by the flow rate and diffusion coefficient of ITR.  
Generally, the contours based on concentration bands show that laminar flow 
conditions are obvious in the flow cell. However, when approaching downstream, the 
more turbulent flow was observed due to the hydrodynamic boundary layer built up, 
leading to slowing down of more drug and fluid molecules. The contours of Sporanox® 
pellet compacts (Figure 51) showed that density gradients in the proximity of compact 
surface affect the concentration distribution of the surrounding solutions. Accumulation 
of dissolved ITR was slightly skewed toward the left part of the contour images for the 
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sample due to a higher density of the HPMC and PEG gel matrix as compared to the 
solvent (Figure 51). This is in agreement with the previous results showing that the ITR 
dissolution from the Sporanox® compact was affected by the PEG gelling layer and 
HPMC matrix thus showing a steady convectional and erosional dissolution pattern.  
On the other hand the contour in ITR API compact has contour lines that show a flat 
and broad laminar layer. ITR API compact with FaSSGF/FaSSIF-V1 form the least 
concentrated solution in the dissolution layer compared with the experiments in 
SGF/SIF, Sporanox® compact with SGF/SIF and FaSSGF/FaSSIF-V1. There was a 
clear upward movement of the dissolved ITR into the bulk buffer solution as the 
downstream distance increases to form a stable dissolution layer. Furthermore, it is 
observed that a distorted curve and abnormal shifting of contour lines strongly 
indicated ITR dissolution followed by recrystallisation of the ITR particle at the compact 
surface (black bold arrow in Figure 51).  
For ITR with compendial media, although a thicker dissolution layer was observed 
throughout the whole experiment, the size of the dissolution layer quickly dissipated to 
the minimum layer at 18 min. Likewise for the ITR compact with biorelevant media, 
there was a significant decrease in the dissolution layer after 10 min of the dissolution 
test that slowly relaxed at a low concentration layer. It is safe to conclude that the fast 
supersaturation formed on the surface after media change drastically increased the 
recrystallisation of ITR on the surfaces of the compacts which could also lead to crystal 















3.6 Results and Discussion of Part 3: PBPK modeling (CA) 
 
3.6.1 Prediction of in vivo performance based on PBPK models 
 
In the first part of this section, the PBPK predictions of the in vivo behaviour of the 
amorphous CA formulation (Zinnat®) using GastroPlus® are presented. Profile 
comparison was performed using plasma concentration vs time profile obtained in 
clinical in vivo study. 
 
Firstly, the predictions were made based on solubility based models in which the 
results showed that these models were not able to simulate closely the observed in 
vivo profile (results presented in Appendix 7). Secondly, the predictions were made 
based on the solubility combined with the dissolution based model whereby in vitro 
drug dissolution profiles obtained with USP apparatus 2 and 4 were included.  
 
3.6.1.1 Solubility combined with dissolution based model 
Simulated fasted state condition 
 
The plasma concentration-time of simulated (solubility and dissolution-based model) 
and observed (human) profiles after an oral administration of Zinnat® in fasted state 
with USP apparatus 2 are presented in Figure 52 (single stage dissolution models) and 
Figure 53 (2 stage dissolution models). 
 
a) USP apparatus 2  
 
Figure 52. Simulation (line) of oral Zinnat
®
 profiles in humans with various media with USP 
apparatus 2 and reference solubility in FaSSIF-V2 compared to the observed in vivo profile 











































Figure 53. Simulation (line) of oral Zinnat
®
 profiles in humans with various media with USP 
apparatus 2 and reference solubility in FaSSIF-V2 compared to the observed in vivo profile 




b) USP apparatus 4 
The plasma concentration-time of simulated (solubility and dissolution-based model) 
and observed (human) profiles after an oral administration of Zinnat® in fasted state 
with USP apparatus 4 are presented in Figure 54. 
 
 
Figure 54. Simulation (line) of oral Zinnat
®
 profiles in humans with various media with USP 
apparatus 4 and reference solubility in FaSSIF-V2 compared to the observed in vivo profile 











































































In the case of CA, plasma concentration–time profiles of the immediate release tablet 
could be predicted after integrating the corresponding dissolution functions into the 
model. The simulated profiles’ curve characteristics mimicked the in vivo profiles well, 
except the dissolution profile in 2 stage-V1 (FaSSGF/FaSSIF-V1) with USP apparatus 
1. The dissolution profile of CA in FaSSGF/FaSSIF-V2 closely simulated the in vivo 
(human) data with almost identical plasma concentration–time profiles compared with 
the other dissolution profiles (f1 FaSSGF/FaSSIF-V2:12.28, f1 SGF/SIF:18.19, f1 
FaSSGF/FaSSIF-V1: 22.70). This shows that physiological relevant hydrodynamics 
and medium change with USP apparatus 4 combined with solubility value in FaSSIF-
V2 could be used to develop a predictive human absorption model. 
 
Simulated fed state condition 
 
The plasma concentration-time of simulated (Solubility combined with dissolution-
based model) and observed (human) profiles after an oral administration of Zinnat® in 
fed state are presented in Figure 55 (USP apparatus 2) and Figure 56 (USP apparatus 
4). 
 
a) USP apparatus 2 
 
Figure 55. Simulation (line) of oral Zinnat
®
 profiles in humans using reference solubility in 
FeSSIF-V2 and dissolution profiles measured in FeSSGF and FeSSIF-V2 with USP apparatus 2 
compared to  observed in vivo (human, fed; ■) (288). 
In the FeSSGF model, a higher simulated peak concentration was observed. 
Nevertheless, the curve was well characterised by FeSSGF. As seen in Figure 55, the 
simulation using dissolution profile with FeSSGF overestimated the in vivo profile while 
the dissolution profile with FeSSIF-V2 shows a much closer simulation (f1 FeSSGF: 







































b) USP apparatus 4 
 
 
Figure 56. Simulation (line) of oral Zinnat
®
 profiles in humans using reference solubility in 
FeSSIF-V2 and dissolution profiles measured in FeSSGF/FeSSIF-V1 and FeSSGF/FeSSIF-V2 
with USP apparatus 4 compared to the observed in vivo profile (human, fed; ■) (288). 
 
The simulated profiles show that plasma concentration–time profiles of the Zinnat® 
could be predicted after integrating the corresponding dissolution profiles. 
FeSSGF/FeSSIF-V2 closely simulated the in vivo (human) data with almost identical 
plasma concentration–time profiles compared with other dissolution profiles (f1 
FeSSGF/FeSSIF-V2: 11.98, f1 FeSSGF/FeSSIF-V1: 7.79).  
 
In this project, robust and validated PBPK models for fasted and fed states were 
developed. These models incorporate in vitro degradation, particle size distribution of 
CA, in vitro solubility and in vitro dissolution data. The inclusion of these elements into 
PBPK models proved their capability to predict accurately in vivo dissolution in terms of 













































3.6.2 Parameter sensitivity analysis 
 
Parameter sensitivity analysis (PSA) is useful for continuous improvement of 
formulation development. In the scenario that the effect of changing certain parameters 
is uncertain, the PSA could be used for forecasting the impact of changes in key 
properties than to make precise quantitative experimental study. 
Simulated fasted state conditions 







Figure 57. PSA of absorption and pharmacokinetic parameters of CA (fasted state) 
The results of PSA show that the precipitation time and percentage of gut first pass 
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This is in agreement with in vitro dissolution testing where no precipitation occurred 
during media change from simulated gastric media to simulated intestinal media. The 
range of CA solubility analysed in this study was 0.044-4.43 mg/mL. The wide range of 
solubility applied was based on the consideration that the solubility of CA in the 
biorelevant media and aqueous media were different. The PSA results show that 
increasing CA solubility from 0.044 to 0.572 mg/mL (rank order 1 to 6) would have 
greater effects on the Cmax, AUC and Tmax (Figure 57). However, if the CA solubility is 
increased beyond 0.572 mg/mL, no effect on the pharmacokinetics of cefuroxime is 
observed. It seems to suggest that 0.527 mg/mL is the maximum solubility that might 
limit the absorption of CA. Furthermore, an increase in percentage of gut extraction of 
CA (from 23.4- 93.6 %) primarily caused by chemical degradation of CA would greatly 






Simulated fed state conditions 
 








Figure 58. PSA of absorption and pharmacokinetic parameters of CA (fed state). 
Parameter sensitivity analysis (PSA) using built-in GastroPlusTM software showed that 
the oral absorption of CA is very sensitive to solubility changes (Figure 58). For 
example, if the solubility increased from 0.037 to 0.48 mg/mL, the Cmax would increase 
from 1.98 to 3.65 mg/L before it plateaued out. Likewise, the amount absorbed also 
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it plateaued out when solubility of CA increased from 0.037 to 0.48 mg/mL.  
Interestingly, when the same range of solubility was tested, the Tmax fluctuated around 
3.28-3.44 h and then from 3.88 to 3.44 h (Figure 58). The small difference (0.16 to 0.44 
h) was probably due to the changes of degradation rate with a fluctuating dissolution 
rate caused by the changes in solubility values (163).  
 
The results of PSA indicate that the change of first pass extraction arises mainly due to 
chemical degradation within the stomach and intestine.  This is important evidence to 
support that enhanced absorption of CA in the fed state is due to a low degradation by 
first pass extraction in the gut.  
 
Similarly, human effective permeability, Peff, may affect the amount absorbed, Cmax, 
AUC and Tmax if the Peff range of 0.624-2.494 x10
-4 cm/s was applied. For example, the 
amount absorbed increased from 160 to 250mg, Cmax increased from 2.6 to 4 mg/mL 
as well as AUC from 14500 to 21000 mg∙h/L when Peff was increased from 0.624 to 
2.494 x10-4 cm/s.  On the other hand, the amount of CA absorbed was independent of 
the GI transit time indicating that CA was absorbed mainly in the intestine, which is as 
expected because Zinnat® is an immediate release formulation.  
 
3.7 Results and Discussion of Part 3: PBPK modeling (ITR) 
3.7.1 Prediction of in vivo performance based on PBPK models 
 
In this section, the PBPK predictions of the in vivo behaviour of the amorphous ITR 
formulation (Sporanox®) using GastroPlus® were presented. Firstly, the predictions 
were made based on solubility based models in which the results showed that these 
models were not able to simulate closely the observed in vivo profile (results presented 
in Appendix 8). Secondly, the predictions were made based on the solubility combined 
with the dissolution based model whereby in vitro drug dissolution profiles obtained 






3.7.1.1 Solubility combined with dissolution based model  
Simulated fasted state conditions 
 
a) USP apparatus 2  
 
The plasma concentration-time of simulated (solubility and dissolution-based model) 
and observed (human) profiles after an oral administration of Sporanox®  in fasted state 
with USP apparatus 1 are presented in Figure 59 (single stage dissolution models) and 
Figure 60 (2 stage dissolution models). 
 
Figure 59. Simulation (line) of oral Sporanox
®
 profiles in humans using dissolution profiles 
measured in FaSSIF-V2, SGF and FaSSGF with USP apparatus 1 compared to observed in 
vivo profile (human, fasted; ■)(299). 
The plasma concentration–time profile of ITR was overpredicted by the models with 
dissolution profile with SGF with USP apparatus 1. SGF is the compendial dissolution 
medium recommended by USP (42) which yields more than 50% dissolution in 2 h and 
more than 90% dissolution in 8 h. Apparently, this dissolution profile was higher than 
that of in vivo thus led to an overestimated simulated profile (f1 SGF:123.20). However, 
other media such as FaSSGF and SIF led to an underestimated model (f1 SGF:123.20; 
f1 FaSSIF-V2:98.10; f1 FaSSGF:44.50).  As a BCS Class 2 compound (360), the rate 
limiting step for absorption of ITR from Sporanox® is its dissolution. Apparently, the 
intraluminal dissolution rate was underestimated from the in vitro dissolution results 




































SGF (USP apparatus 1)
FaSSGF (USP apparatus 1)




Figure 60. Simulation (line) of oral Sporanox
®
 profiles in humans using dissolution profiles 
measured in 2 stage media experiments with USP apparatus 1 compared to the observed in 
vivo profile (human, fasted; ■) (299). 
 
As depicted in Figure 60, simulated plasma concentration time profiles with 2 stage-V2 
(FaSSGF/ FaSSIF-V1) dissolution data are more representative relative to the in vivo 
data compared with 2 stage-V1 (FaSSGF/ FaSSIF-V2) (f1 2 stage-V1 (FaSSGF/ 
FaSSIF-V1):79.50; f1 2 stage-V2 (FaSSGF/ FaSSIF-V2):40.70). The result suggested 
that a different degree of precipitation of ITR during pH change from stomach to 
intestine has a significant impact on the simulation. Due to higher dissolution as well as 
lower precipitation of ITR observed in 2 stage-V2, this result was translated into a 
higher simulated plasma concentration time profile. However, due to higher solubility of 
ITR in FaSSIF-V1, the supersaturation level was maintained for a longer period of time 




b) USP apparatus 4  
 
The plasma concentration-time of simulated (solubility and dissolution-based model) 
and observed (human) profiles after an oral administration of Sporanox® in fasted state 
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Figure 61. Simulation (line) of oral Sporanox
®
 profiles in humans using scaled FaSSIF-V1 
solubility and dissolution profiles obtained with USP apparatus 4 compared to the observed in 
vivo profile (human, fasted; ■) (299). 
Based on the dissolution profiles with USP apparatus 4 as input functions, in vivo 
profile of Sporanox® was best predicted by FaSSGF/FaSSIF-V1 compared to 
FaSSGF/FaSSIF-V2 and SGF/SIF (f1FaSSGF/FaSSIF-V1:16.50; f1 FaSSGF/FaSSIF-
V2:21.90; f1 SGF/SIF:46.90). The results seem to suggest that FaSSIF-V1 could mimic 
the in vivo intestinal fluid better than FaSSIF-V2 and SIF. The main reason could be 
that FaSSIF-V1, which had a higher content of bile salt and lecithin than FaSSIF-V2, 
could prevent ITR from precipitatation upon exit from the stomach (50, 51). This is in 
agreement with the results of the ITR precipitation study (Presented previously in 
Section 3.3.5) which showed different ITR (from Sporanox®) recrystallisation rates 

















































Simulated fed state conditions 
 
a) USP apparatus 2  
 
The plasma concentration-time of simulated (Solubility combined with dissolution 
based model) and observed (human) profiles after an oral administration of Sporanox® 
in fed state with USP apparatus 1 are presented in Figure 62 and Figure 63. 
 
Figure 62. Simulation (line) of oral Sporanox
®
 profiles in humans using reference solubility in 
scaled FeSSIF-V1 and dissolution profiles measured in digested early FeSSGF and early 
FeSSGF with USP apparatus 1 compared to the observed in vivo profile (human, fed; ■) (228).  
As depicted in Figure 62, digested early FeSSGF (milk with pH adjusted to 6.4) has an 
impact on the simulation. Compared to early FeSSGF, digested early FeSSGF 
produced a higher peak concentration. This could be due to the higher rate and extent 
of ITR dissolution in digested early FeSSGF than early FeSSGF, which translated into 
a higher simulated plasma concentration.  
  
Figure 63. Simulation (line) of oral Sporanox
®
 profiles in humans using reference solubility-pH in 
scaled FeSSIF-V1 and dissolution profiles measured in FeSSGF and FeSSIF-V2 with USP 








































































Based on the dissolution profiles with USP apparatus 1 as input functions (Figure 63), 
the in vivo profile of Sporanox® is comparatively better predicted by FeSSGF than 
FeSSIF-V2 (f1 FeSSIF-V2:90.8; f1 FeSSGF:59.74). For FeSSGF, the profile was not 
successful in simulating the in vivo plasma profile which has a prominent feature of a 




b) USP apparatus 4 
 
The plasma concentration-time of simulated (Solubility combined with dissolution 
based model) and observed (human) profiles after an oral administration of Sporanox® 
in fed state with USP apparatus 4 are presented in Figure 64. 
 
Figure 64. Simulation (line) of oral Sporanox
®
 profiles in humans using dissolution profiles with 
FeSSGF/FeSSIF-V1 and FeSSGF/FeSSIF-V2 (reference solubility: scaled FeSSIF-V1) with 
USP apparatus 4 compared to the observed in vivo profile (human, fed; ■) (228). 
 
Figure 64 shows that the predicted ITR plasma concentration profiles with 
FeSSGF/FeSSIF-V1 underestimated the in vivo profile (f1:63.0). Meanwhile, in this 
project, the best predicted ITR plasma concentration profile was obtained with 
FeSSGF/FeSSIF-V2 (f1:39.57). The dissolution profile in FeSSGF/FeSSIF-V2 indicated 
a better % dissolved of ITR compared to FeSSGF/FeSSIF-V1 (dissolution profiles 
presented in Figure 33), indicating the effect of the lipolytic product such as 
monoglycerides and fatty acids (57) on the dissolution of ITR. The simulated profiles 
also suggest that FeSSIF-V2 could mimic the in vivo intestinal fluid in the fed state 






































In sum, we successfully developed a validated PBPK model for amorphous ITR 
formulations in fasted and fed states using solubility combined with dissolution profile 
models. The results demonstrated how the knowledge generated by integrating 
biorelevant in vitro solubility, in vitro dissolution data, enzyme and transporter data (Km 
and Vmax), with in vivo humans pharmacokinetics and clinical data, could create a 







3.7.2 Parameter sensitivity analysis 
 
Simulated fasted state conditions 
 









Figure 65. PSA of absorption and pharmacokinetic parameters of ITR (fasted state). 
 
By using the ACAT model in GastroPlus™, it was assumed that only drug in solution 










































































































into the intestinal wall. Once the drug had been absorbed, it was assumed to remain in 
solution (in enterocytes, plasma and all pharmacokinetic compartments). Thus, both 
the rate at which solid drug particles dissolved and the total amount of drug that could 
be dissolved in any compartment at any one time (solubility) had a direct effect on the 
degradation, efflux, metabolism and absorption of the drug (361). Since ITR is a weak 
base, theoretically both the absorption and precipitation of ITR is influenced by the pH 
of the environment. If the drug in solution transits from a compartment of high solubility 
to one of lower solubility, precipitation can occur and indirectly affect the plasma 
concentration vs time profile. However, according to the PSA, the precipitation time, 
duodenum pH and stomach pH have less influence on the pharmacokinetic of ITR 
compared to the amount of dose administered. This is probably due to the formulation 
effect of ITR whereby the HPMC and ITR solid dispersions are more resistant to the 
changes in pH. Thus, the PSA suggested that the dose could be modified to enhance 
the pharmacokinetics of ITR (361).  
 
According to Figure 65, Tmax was mainly affected by dose, solubility and Peff of ITR. For 
instance, by changing the dose administered from 10.0 to 359.4 mg, the Tmax was 
delayed from 2.18 to 5.54 h. Interestingly, when solubility of ITR was increased from 
0.802 to 1.34 µg/mL, the Tmax increased sharply. However, when the solubility was 
further increased from 1.34 to 48.0µg/mL, the Tmax decreased drastically. This seems to 
indicate that after surpassing the solubility threshold of 1.34 µg/mL, the dissolution of 
ITR in GIT is optimised, leading to a peak absorption in a shorter time. Similarly, when 
Peff was increased from 1.73 to 6.92 x10
-4 cm/s, the corresponding Tmax decreased from 
4.48 to 2.72 h mainly due to enhanced permeability of ITR across the enterocytes, thus 















Simulated fed state conditions 
 
The results of the PSA of ITR formulation in a human model (fed state) are presented 






Figure 66. PSA of absorption and pharmacokinetic parameters of ITR (fed state). 
Figure 66 illustrates that dose is the most susceptible parameter to any changes. The 
main parameter affecting absorption and pharmacokinetics is the change of dose (the 
amount of ITR administered). Since absorption is a first order process, the increased 
amount of ITR administered can affect greatly the absorption and pharmacokinetics. 
For instance, when the dose was increased from 10 to 1000 mg, the corresponding 
amount absorbed increased from 2.46 to 147.2 mg, Cmax increased from 0.0006 to 0.52 
mg/mL and AUC increased from 117 to 7009 mg∙h/L. The PSA results suggest that 
increasing solubility by 100 fold (0.00225 to 0.225mg/mL) would have a minimal effect 






























































































3.8 Results and Discussion of Part 3: PBPK modeling (CX) 
 
In the first part of this section, the PBPK predictions of the in vivo behaviour of the 
amorphous CX formulations using GastroPlus® are presented. Predictions were made 
based on the solubility based model (with single solubility value and pH-solubility range 
value) as well as the solubility combined with the dissolution based model, whereby in 
vitro drug dissolution profiles obtained with USP apparatus 2 and 4 were included. 
Profile comparison was performed using plasma concentration vs time profile obtained 
in a clinical in vivo study.  
 
3.8.1 Prediction of in vivo performance based on PBPK models 
 
The plasma concentration-time of simulated and observed (dog) profiles after oral 
administration of 240 mg/tablet CX formulations (Formulation 8 unless indicated 
otherwise as Formulation 4, 5, 6 or 7) in fed state conditions are presented in the 
following sections. 
3.8.1.1 Solubility-based model 
 
The plasma concentration-time of simulated (solubility based model) and observed 
(beagle dog) profiles after oral administration of one CX F8 formulation in fed state are 
presented in Figures 67 and 68. 
Single solubility value model 
 
Figure 67. Simulation (line) of oral CX profiles in dogs using reference solubility measured in 
FaSSIF-V1, FeSSIF-V1, scaled FaSSIF-V1 and scaled FeSSIF-V1 compared to observed in 






































According to Figure 67, the simulation based on solubility of scaled FeSSIF-V1 is very 
similar to the in vivo profile (f1:29.40). This seems to suggest that solubility of scaled 
FeSSIF-V1 mimicked CX solubility of in vivo fed state conditions well and CX solubility 
in intestinal fluid of beagle dogs is likely to be similar to the solubility in the fed state 
human intestinal fluid (equivalent to solubility in scaled FeSSIF-V1). In contrast to 
scaled FeSSIF-V1, the solubility values in FeSSIF-V1, FaSSIF-V1 and scaled FaSSIF-
V1 produced simulated profiles that underestimated the in vivo profile (f1 FeSSIF-V1: 
49.18, f1 FaSSIF-V1:99.50 and f1 scaled FaSSIF-V1: 97.50). This is expected as the in 
vivo data are from the fed state and FeSSIF-V1 does not contain lipolytic products that 
are commonly found in dog’s GIT (362). The simulated profile developed using various 
solubility values also shows that solubility is one of the main rate-limiting physiological 
variables for in vivo absorption of CX. An appropriate biorelevant solubility value could 
accurately simulate the conditions in the dog GIT leading to closer prediction of in vivo 
performance. 
 
pH solubility range model 
 
Figure 68. Simulation (line) of oral CX profiles in dogs using reference solubility-pH range  in 
aqueous buffer pH 3/FeSSIF-V1 and aqueous buffers at pH 1.1, 3, 4.5, 6.8, 7.5 and 8.5 
compared to observed in vivo profile (dog, fed; ■) (252). 
According to Figure 68, using solubility-pH range as an input, in vivo solubility profile of 
buffer at pH 3 plus FeSSIF-V1 was overestimated (f1:99.20), whereas the in vivo 
solubility profiles of aqueous buffers (233) were greatly underestimated (f1:99.60). The 
results suggest that the solubility-pH range using FeSSIF-V1 and aqueous buffers are 





































3.8.1.2 Solubility combined with dissolution based model  
 
Simulated fed state condition 
 
a) USP apparatus 2  
 
The plasma concentration-time of simulated (solubility and dissolution-based model) 
and observed (dog) profiles after oral administration of a CX tablet with USP apparatus 
2 are presented in Figures 69 (single stage dissolution models) and 70 (2 stage 
dissolution models). 
 
Figure 69. Simulation (line) of oral CX profiles in dogs using reference solubility in FeSSIF-V1 
and dissolution profiles measured in SIF-M4 and SIF-M5 with USP apparatus 2 compared to 
observed in vivo profile (dog, fed; ■) (252). 
According to Figure 69, the simulated plasma profiles using SIF-M5 (sodium based SIF 
+1% SLS) underestimated the in vivo profile (f1: 47.40). This is in agreement with its 
dissolution profile that showed a fast precipitation after 1 h of the experiment. The 
simulation seems to indicate that CX in the media containing micelles at pH 6.8, 
nucleation and growth kinetics of CX out of solution may decrease the bioavailability of 
CX. Since the primary site for CX absorption is the proximal small intestine, the 
decreased soluble CX amount due to nucleation and growth out of solution at pH 6.8 is 
expected to be an important parameter in PBPK simulation. 
Meanwhile, the proposed dissolution model for CX (233) (with SIF-M4: SIF+ 1% HTAB, 
dissolution profiles presented previously in Figure 35) seems to have overpredicted 
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a sink condition for CX dissolution (233) could probably have higher micellar 
solubilisation of the bile salt and lecithin in dogs (f1:43.60). 
Figure 70. Simulation (line) of oral CX profiles in dogs using reference solubility in FeSSIF-V1 
and dissolution profiles measured in 2 stage-V1 (FaSSGF/FaSSIF-V1) and 2 stage-V2 
(FaSSGF/FaSSIF-V2) dissolution models with USP apparatus 2 compared to observed in vivo 
profile (dog, fed; ■) (252). 
 
According to Figure 70, the simulation using dissolution profiles of CX in 2 stage-V2 is 
considerably closer to the in vivo profiles compared to 2 stage-V1 (f1 2 stage-
V2=46.10, f1 2 stage-V1=75.40). The difference in the two simulated profiles is mainly 
due to much higher extent and rate of dissolution in FaSSIF-V2 than in FaSSIF-V1 
(Dissolution profiles presented in Figure 36).  
 
b) USP apparatus 4 
The plasma concentration-time of simulated (solubility and dissolution-based model) 
and observed (dog) profiles after oral administration of a CX tablet with USP apparatus 
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Figure 71. Simulation (line) of oral CX profiles in dogs using reference solubility in FeSSIF-V1 
and dissolution profiles measured in FaSSGF/FaSSIF-V1 and FaSSGF/FaSSIF-V2 with USP 
apparatus 4 compared to observed in vivo profile (dog, fed; ■) (252). 
 
Figure 72. Simulation (line) of oral CX profiles of F4, F5, F6 and F7 in dogs using reference 
solubility in FeSSIF-V1 and dissolution profiles measured with FaSSGF/FaSSIF-V2  with USP 
apparatus 4 compared to observed in vivo profile (dog, fed; ■) (252). 
To the best of the author’s knowledge, there is no literature values published on the 
amount of bile salt and lecithin in the GI fluids of the beagle dog. It is known that there 
are differences in the composition of intestinal fluid in dogs and humans, including the 
concentration of bile salts. However, it is known that the amount of bile salt and lecithin 
in dog GI fluids is higher than the human GI fluids (363-365). Although the in vivo data 
was tested in the fed state, it is observed that the FaSSIF-V2 is closer to the intestinal 















































































Meanwhile, the F4, F5, F6 and F7 of CX showed very similar simulated plasma profiles 
(Figure 72). It was expected because these formulations have very similar dissolution 
profiles in FaSSGF/FaSSIF-V2. 
 
 
Figure 73. Simulation (line) of oral CX profiles in dogs using reference solubility in FeSSIF-V1 
and dissolution profiles measured in SGF-M1/SIF-M1, SGF-M1/SIF-M2, SGF-M2/SIF-M3 with 
USP apparatus 4 compared to observed in vivo profile (dog, fed; ■) (252). 
Similar to the simulated profiles in biorelevant media, the modified media do not 
simulate the in vivo dissolution in beagle dogs well (fed state). This is probably due to 
the solubilisation capacity of these modified media that do not match with the bile salt 
micellar solubilisation effect in dogs (f1: SGF-M1/SIF-M1:92.97; SGF-M1/SIF-M2: 95.27 
and f1: SGF-M2/SIF-M3:84.19) (Figure 73). 
 
Figure 74. Simulation (line) of oral CX profiles in dogs using reference solubility in FeSSIF-V1 
and dissolution profiles measured in FeSSGF/FeSSIF-V2 with USP apparatus 4 with F4, F5, F6 


















































































Figure 75. Simulation (line) of oral CX profiles in dogs using reference solubility in FeSSIF-V1 
and dissolution profiles measured in FeSSGF/FeSSIF-V1 and FeSSGF/FeSSIF-V2 with USP 
apparatus 4 with F8 compared to observed in vivo profile (dog, fed; ■) (252). 
Similar to FaSSGF/FaSSIF-V2 (presented in Figure 72), F4, F5, F6 and F7 of CX 
showed very similar simulated plasma profiles (Figure 74) and the dissolution profiles 
of these formulations in FeSSGF/FeSSIF-V2 were very similar (Dissolution profiles 
presented previously in Figure 39). 
According to Figure 75, FeSSGF/FeSSIF-V2 is more predictive compared to -V1 
because the lipolytic products in FeSSIF-V2 mimicked the true in vivo conditions and 
were capable of solubilising the poor water soluble CX molecules. The biorelevant 
dissolution media designed to simulate human conditions does not seem to be able to 
simulate the plasma concentration in dogs well, probably due to the higher amount of 
bile salt and lecithin content of dogs’ GI fluid. The FeSSIF-V2 media indicated a better 
percentage of drug release compared to FeSSIF-V1 media, indicating the effect of the 
lipolytic product on the dissolution of CX and also reflecting on the absorption of the 
drug.  
For compounds with highly pH-dependent solubility such as CX, changes in GI pH due 
to, for example, food intake, can have a large impact on the dissolution and hence 
absorption of the drug (366). Poorly soluble compounds often show an increased 
solubility in the presence of surfactants; for example, bile acid concentration is different 
in the fasted and fed states (54, 366). Therefore, the dissolution profiles in fed state 









































Generally, dissolution profiles with USP apparatus 4 give better simulations compared 
to single dissolution profiles with USP apparatus 2 (f1 FeSSGF=93.55). This shows that 
combining the physiological relevant hydrodynamics and medium change can mimic 
the human GI tract to achieve a predictive model. 
In sum, in order to simulate better drug dissolution in the dog intestine, biorelevant 
dissolution testing taking into account interspecies differences in terms of the higher 
concentrations of bile salts and lecithin in dogs, and dog GIT hydrodynamic and gastric 
emptying time also need to be considered. On the other hand, simulations performed 
using simple aqueous buffers or modified buffers failed to provide a predictive property 
of CX formulations. This further validates the superiority of biorelevant media in 
solubility and dissolution testing of CX formulations than the compendial and simple 
aqueous buffers. Furthermore, preclinical dog data and appropriate physiology input 
parameters are crucial for the successful development of the PBPK model for CX 



















3.8.2 Parameter sensitivity analysis 
 







Figure 76. PSA of absorption and pharmacokinetic parameters of CX (fed state) 
Based on the PSA GastroPlusTM, the oral absorption of this compound is very sensitive 
to the dose administered. This is expected because absorption of CX is a first order 
process, thus the increased amount of CX administered can affect greatly the 
absorption and pharmacokinetics. For instance, the amount absorbed greatly 
increased from 15.82 to 951 mg, Cmax increased from 0.83 to 51.23 mg/L and AUC 
increased from 10000 to 604000 mg∙h/L.  According to Figure 76, Peff and solubility are 

































































































from 1.4 to 5.6 x10-4 cm/s facilitated permeation of CX and enhanced the rate of 
achieving peak concentration, thus reducing Tmax from 3.66 to 3.10 h.  
In sum, it appears that the rate, extent and gastrointestinal location of oral absorption 
of the CA, ITR and CX could be predicted well using the solubility combined with 
dissolution based models. Using the PBPK model, the experimental data of the drug 
was incorporated into the prediction (e.g., Caco-2 permeability, solubility, dissolution) 
along with the built-in physiological values (such as pH and transit time of each 
intestinal segment in humans and dogs) to increase the reliability of the absorption 
prediction. Other absorption related factors, including the time for the rate of 
precipitation, particle size, chemical degradation, were also considered in the 
predictions. In the current study, first pass effect, enzymes and transporter metabolism 
were also included. The PSA performed also increased the understanding of the 
correlations between absorption and associated parameters, such as solubility, dose, 




3.9 Results and Discussion of Part 4: Deconvolution analysis 
3.9.1 CA 
 
Deconvolution of plasma concentration-time profiles after an oral 250mg Zinnat® tablet 
was implemented. The mean cumulative amount absorbed and absorption rate after 




Figure 77. Mean cumulative CA absorbed (A) and absorption rate (B) in fasted and fed state 
(Deconvolution data).  
 
The observed in vivo plasma concentration–time data of CA in fasted and fed states 
were reported by Rojanasthien et al. (287) and Donn et al. (288) respectively. The 
cumulative amount absorbed profiles show the absorption completed in the first 4 h 
after drug administration corresponding to the time passing through the intestine of 
human GIT both in fasted and fed states. The mean amount absorbed was 
approximately 50% in fasted state and 47% in fed state, both reaching a plateau 
around 4 h post administration (Figure 77). The result is close to the reported median 
absorption (30-50%) from the Zinnat® tablets taken during the fasted state (287). 
Similarly, this result is close to the reported median absorption (50-55%) from the 
Zinnat® tablets taken after food (198). Only half of CA was absorbed in the fasted state 
mainly due to the large amount of CA degraded upon exposure to the gastric fluid (pH 
1.6- pH3) (199), especially as the CA degradation follows first order kinetics and CA 
has relatively better solubility in the acidic medium.  





































































Generally administering poor water-soluble drugs in the postprandial state had shown 
increased absorption compared to when administered in the fasting state due to a 
longer residence time and changes in the composition of the gastro-intestinal fluids as 
a consequence of pancreatic and bile secretions (316). An increase in bile salt 
concentrations was shown to increase the solubility of poorly soluble drugs (75, 367). 
However, this enhanced effect in the fed state was not apparent in CA due to other 
confounding factors such as CA degradation and formulation effects (gelling of tablets) 
(240). Evidence from the literature using different model drugs confirmed that gastric 
motility and mixing of stomach content were mild such that different foods ingested 
consecutively were inclined to remain in layers until being emptied from the stomach 
(368). Thus it was highly likely that the full disintegration of the Zinnat® tablet in the 
stomach was hindered leading to gelling of CA itself and limiting absorption. 
Furthermore, the absorption rate profiles indicate that absorption occurs earlier in the 
fasted compared with the fed state, in agreement with the longer gastric transit time in 




Deconvolution of plasma concentration-time profiles after an oral 100mg Sporanox® 
capsule was implemented. The mean cumulative amount absorbed and absorption rate 





Figure 78. Mean cumulative ITR absorbed (A) and absorption rate (B) in fasted and fed state 

























































In vivo plasma concentration-time profiles of Sporanox® tablets were taken from the 
study of Yeates et al. (299) (fasted state) and Yun et al. (228) (fed state). The 
absorption rate profiles indicated that the major portion of  ITR in the capsule was 
absorbed within 4-6 h post dose and absorption after 15 h post-dose was relatively low 
(Figure 80). Meanwhile, the cumulative percentage absorbed profiles showed that the 
absorption was mainly taking place in the first 4 h in fasted state and 6 h in the fed 
state.  The mean percentage absorbed was approximately 28.78% in the fasted state. 
When dosed with a high-fat meal supplement (comprising 150 mL low fat milk), the 
percentage absorbed decreased to about 22.6%. The potential contributing factor for 
the decrease was the change of gastric pH to a less acidic condition with the ingestion 
of a milk based product (369) which adversely affects the dissolution of a weak base 
compound like ITR. The effect of gastric pH on the absorption of ITR from Sporanox® 
was confirmed in a randomised, parallel group, single dose study in 24 healthy 
subjects (229, 230). 
 
 
3.9.3 CX  
 
Deconvolution of plasma concentration-time profiles after a CX oral tablet formulations 
(240mg/tablet; F1-F7) was performed.  
 
Figure 79 and Figure 80 present the average (n=4 dogs) cumulative CX absorption and 
rate after administration of Formulation 1, 2, 3, 4, 5, 6 and 7 (F1-F7; in vivo data of F8 
was not provided thus deconvolution was not performed for F8). The range of CX 
absorbed from F1-F7 was from 100mg to 200mg. Meanwhile, the absorption rate 
profiles indicated that the major portion of CX in the tablet was absorbed within 5 h 







Figure 79. Summary of mean (n=4) cumulative amount absorbed (mg) CX Formulation 
1,2,3,4,5,6 and 7 in beagle dogs. 
 







The cumulative amounts of CX absorbed (data from deconvolution using PCDCON) 
are shown in Figure 81.  
 
 
Figure 81. Mean± SD cumulative amount absorbed (deconvolution using PCDCON).  
 
F1 is the first MBP amorphous formulation produced and its particle size distribution 
data was not given. Since F1 yielded low absorption it is prudent to assume that its 
particle size distribution is larger than the other formulation causing less dissolution 
and absorption. Meanwhile, the absorption of CX from F3, F6 and F7 was lower than 
other MBP formulations (F2, F4 and F5) partly because the particle size distribution 
was higher than F2, F4 and F5. For instance, the particle size distribution is 93.8 µm 
for F3 compared to 37.2 µm for F2 and F5 (Details of CX formulations presented 
previously in Section 2.3.3). 
 
On the other hand, the tableting strength and hardness did not seem to affect the 
absorption of CX. For example F2, hardness 295N and F5 with hardness 341N showed 
similar AUC values, 191.09 and 194.05 µg.h/mL and a similar amount absorbed 101.28 
and 114.25mg, respectively (the tableting strength and hardness for other formulations 
were not given). 
 
In sum, a cumulative amount of drug absorbed and absorption rate vs time profiles 
were successfully generated using numerical deconvolution with PCDCON software. 
These data are useful for the development of IVIVC/IVIVR (Discussed later in Section 
3.10). Meanwhile, the results suggested that absorption of CX is not significantly 
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3.10 Results and Discussion of Part 4: Development of IVIVR/IVIVC models 
 
It is well-known that the bioavailability studies in animals and man are time consuming 
and costly. To the best knowledge of the author, so far there has been no IVIVC /IVIVR 
of CA, ITR or CX reported in the literature. In this section, the qualitative IVIVRs are 
first presented and then the mathematical IVIVCs are presented  
 
3.10.1 Qualitative IVIVRs 
The results of % absorbed in vivo were compared qualitatively with the % dissolved in 





Figure 82. A: % CA absorbed; B:Mean± SD % of CA dissolved from Zinnat
®
 250mg tablet in 
fasted state FaSSGF (8mL/min;1h)/FaSSIF-V1 (4mL/min;3h) and fed state FeSSGF (6mL/min; 
2h)/FeSSIF-V1 (6mL/min;4h) using the USP apparatus 4 (n=3). 
 
The CA dissolution profile in fasted and fed state exhibited the same trend as the 
absorption profiles of CA. For example after 4 h the % absorbed (in vivo study) was 
around 45% in both the fasted and fed states. Likewise, after 4 h of experiment the % 
dissolved from FaSSGF/FaSSIF-V1 and FeSSGF/FeSSIF-V1 studies was around 
60%. This showed that the use of biorelevant media that mimic the human in vivo 































Figure 83. A:% ITR absorbed; B:Mean± SD % of ITR dissolved from Sporanox
®
 capsule in 
fasted state media FaSSGF (8mL/min; 1h)/FaSSIF-V1 (4mL/min; 3h) and fed state media 
FeSSGF (6mL/min; 2h)/FeSSIF-V1 (6mL/min; 4h) using the USP apparatus 4 (n=3). 
 
The in vitro results were translated into the in vivo condition because both fasted and 
fed experiment conditions showed the correct rank order of dissolution and absorption 
(Figure 83). Both in vitro and in vivo results showed higher dissolution/absorption in the 
fasted state. For in vivo condition, the highly supersaturated ITR solution produced in 
the acidic gastric fluid in the fasted state produced a fast absorption of ITR (29). Even 
though in the fed state a higher content of bile salt existed compared to the fasted 
state, still the bile components did not produce sufficient solubility enhancement or 



























Figure 84. A:% CX absorbed (fed state); B:Mean± SD % of CX dissolved from CX formulation 
(F8) in fasted state media FaSSGF (8mL/min; 1h)/ FaSSIF-V1 (4mL/min; 3h) and fed state 
media FeSSGF (6mL/min; 2h)/ FeSSIF-V1 (6mL/min; 4h) using the USP apparatus 4 (n=3). 
 
By comparing the in vivo (only fed state data available) and in vitro results, it seems 
that FeSSGF/FeSSIF-V1 dissolution profile of CX does not correlate well with the in 
vivo absorption profile in the gastric phase (Figure 84). Probably FeSSGF does not 
represent the fed conditions in the beagle dog well thus causing the discrepancy 
























3.10.2 Mathematical IVIVC 
 
In this section IVIVC using linear regression is presented according to the simulating 
fasted and fed state conditions.  
CA 
Simulating fasted state conditions 
 
In vivo percentage of CA absorbed was compared to the corresponding percentage 
dissolved obtained from experiments with USP apparatus 4. The IVIVCs of CA are 
presented in Figure 85. 
 
 
Figure 85. Mean % CA absorbed in humans vs mean % CA dissolved in vitro with USP 


































































Summary of the obtained parameters derived from linear regression of the relation 
between % in vivo absorbed and % in vitro dissolved data of CA from 250mg Zinnat® 
tablet is presented in Table 56.  
 
Table 56. Obtained regression parameters from relations between in vivo absorption and in vitro 
dissolution data (USP apparatus 4) 






 0.98 0.98 0.98 - 0.99 
Gradient 0.82 0.58 0.69 - 0.60 
Intercept -6.66 -5.04 -6.26 - -5.24 
*A linear correlation is not obtained because profile shows more of sigmoidal shape 
 
Table 56 shows that a linear response (R2 close to 1) had been achieved for these 
simulating fasted state experiments apart from FaSSGF/FaSSIF-V1. IVIVC formed with 
in vitro dissolution profile performed with FaSSGF/FaSSIF-V2 with USP apparatus 4 
exhibited a coefficient correlation of R2: 0.99 which shows a good correlation between 
the in vitro dissolution of CA and in vivo absorption of CA. The gradient of 0.60 denotes 
that the in vitro dissolution rate is higher than the in vivo absorption rate. For instance 
80.80% of CA was dissolved whereas only 43.71% of CA was absorbed at 4 h. 
Meanwhile, the negative intercept of -5.24 implies that possibly the Zinnat® formulation 
is able to disintegrate and dissolve faster in the in vitro dissolution experiment with 
FaSSGF thus leading to in vitro dissolution before the corresponding in vivo 
absorption.  
 
The correlation results of SGF-M1/SIF-M2, SGF/SIF, SGF-M1/SIF-M1 indicated a 
faster in vitro dissolution process than the in vivo absorption process. A rank order of 
gradient value (SGF-M1/SIF-M1> SGF/SIF> SGF-M1/SIF-M2) shows that SGF-
M1/SIF-M1 (gradient: 0.82) is closer to the in vivo conditions. The results seem to 
suggest that the best Level A correlation observed was obtained using 
FaSSGF/FaSSIF-V2. The intercept of this linear regression is the closest to zero 










Simulating fed state conditions 
 
The IVIVCs of CA with in vitro dissolution performed with USP apparatus 4 are 
presented in Figure 86. 
 
 
Figure 86. Mean % CA absorbed in humans vs mean % CA dissolved in vitro with USP 
apparatus 4 (fed state models). Inset A: Gastric phase (in vitro time 0-2 h) Inset B: Intestinal 
phase (in vitro 2-6 h). 
 
Summary of the obtained parameters derived from linear regression of the relation 
between % in vivo absorbed and % in vitro dissolved data of 250mg Zinnat® tablet in 
the fed state is presented in Table 57. 
 
Table 57. Obtained regression parameters from relations between in vivo absorption and in vitro 
dissolution data (simulating fed state condition) 











 0.91 0.90 0.99 0.98 
Gradient 0.87 1.06 1.73 0.66 
Intercept -26.60 -27.87 -67.37 -6.46 
 
By applying IVIVC, in vitro dissolution profiles were compared to the corresponding in 
vivo absorption profiles in two phases. IVIVC for CA in FeSSGF/FeSSIF-V1 and 
FeSSGF/FeSSIF-V2 with USP apparatus 4 exhibit two phases in which the time of 
media change setup (in vitro) is at 1 h and 2 h respectively corresponding to 43.96% of 
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CA dissolution and 16.84% of CA absorbed (FaSSGF/FaSSIF-V1) and 43.96% of CA 
dissolution and 22.23% of CA absorbed (FeSSGF/FeSSIF-V2). The dissolution of CA 
in fed state simulated gastric medium, FeSSGF in FeSSGF/FeSSIF-V1 (gradient: 1.06) 
and FeSSGF/FeSSIF-V2 (gradient: 0.87) experiments shows that the dissolution and 
absorption processes occurred at a very similar rate. Nevertheless, the initial Zinnat® 
dissolution was faster before the corresponding absorption could occur (i.e., intercept 
of -26.60 and -27.87 in FeSSGF/FeSSIF-V2 and FeSSGF/FeSSIF-V1 respectively). 
Whereas in the simulating intestinal media, the dissolution rate of CA with FeSSIF-V2 
(gradient: 0.66) was higher and with FeSSIF-V1 (gradient: 1.73) was lower than the in 
vivo absorption rate.   
 
On the other hand, regression of SGF/SIF, SGF-M1/SIF-M1,–M2 and 
FaSSGF/FaSSIFV2 exhibited a gradient lower than 1. This shows that these 
experiments had a higher in vitro dissolution than the corresponding in vivo absorption. 
These results seem to suggest that the in vivo absorption is slower than expected. This 
is in agreement with the findings from the in vitro dissolution which showed that the 
gelling of formulation and fast degradation of CA in GIT could potentially affect 








Simulated fasted state conditions 
 
The IVIVC of ITR with USP apparatus 1 and USP apparatus 4 are presented in Figures 










Figure 88. Mean % ITR absorbed in fasted state humans vs mean % ITR dissolved with USP 
apparatus 4 (A) Biorelevant and compendial media; (B) Modified media. 
y = 0.2465x 






















% dissolved (in vitro) 
y = 2.8237x - 47.36 
R² = 0.9937 
y = 3.3263x - 79.179 
R² = 0.9967 
y = 4.0555x - 43.038 


























y = 0.3712x 
R² = 0.993 
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Summary of the obtained parameters derived from linear regression of the relation 
between % in vivo absorbed and % in vitro dissolved data of ITR from 100mg 
Sporanox® capsule is presented in Table 58.  
 
Table 58. Obtained regression parameters from relations between in vivo absorption and in vitro 
dissolution data (fasted state) 
A SGF 















 0.98 0.99 0.99 0.99 0.99 0.99 
Gradient 0.26 3.33 2.82 4.06 0.35 0.65 
Intercept -1.11 -79.18 -47.36 -43.04 1.15 -0.41 
  
Table 58 shows that a linear response had been achieved for these simulating fasted 
state experiments. IVIVC formed with in vitro dissolution profile performed with SGF 
with USP apparatus 1 exhibited a coefficient correlation of R2: 0.98 which shows that 
there is a good correlation between the in vitro dissolution of ITR with SGF with USP 
apparatus 2 and in vivo absorption of ITR. The gradient of the regression for SGF is 
0.26 which means that the in vitro dissolution process occurred at a higher rate than 
the in vivo absorption process. It is noteworthy that no IVIVR/IVIVC could be 
established for the dissolution profile of ITR with FaSSIF-V2 and FaSSGF with USP 
apparatus 1 because of its low percentage dissolved. 
 
IVIVC formed with in vitro dissolution profile performed in FaSSGF/FaSSIF-V2, 
FaSSGF/FaSSIF-V1, SGF/SIF with USP apparatus 4 show a rank order of gradient 
that follows the sequence of SGF/SIF> FaSSGF/FaSSIF-V1> FaSSGF/FaSSIF-V2. All 
these experiments yielded IVIVC with negative intercept which denotes that initial ITR 
dissolution from the Sporanox® capsule was faster than the corresponding in vivo 
absorption. Regression coefficients for SGF-M1/SIF-M1 and SGF-M1/SIF-M2 are both 
0.99; this highlighted a good correlation; however the gradients of the regression are 
0.37 and 0.63 which means that the use of artificial surfactant (SLS) at 0.2% (SIF-M1) 
and 0.1% (SIF-M2) caused a greater dissolution process than the corresponding in 
vivo absorption.   
 
For the fasted state model, based on regression coefficient and gradient the best Level 






Simulated fed state conditions 
 
The correlations of ITR with USP apparatus 1 and USP apparatus 4 are presented in 





Figure 89. Mean % ITR absorbed in humans (fed state) vs mean % ITR dissolved in vitro with 
USP apparatus 1 (A) and USP apparatus 4 (B). 
 
A summary of the obtained parameters derived from linear regression of the relation 
between % in vivo absorbed and % in vitro dissolved data of 100mg of Sporanox® is 
presented in Table 59. 
 
Table 59. Obtained regression parameters from relations between in vivo absorption and in vitro 
dissolution data in the fed state 









 0.98 - - 0.97 0.91 
Gradient 1.48 - - 2.41 3.13 
Intercept 1.04 - - -1.08 -1.87 
*A linear correlation is not obtained because profile shows more of sigmoidal shape 
 
 
For the dissolution setup with USP apparatus 1, intercept for the correlation with 
digested early FeSSGF is smaller than with FeSSGF, indicating that in vitro dissolution 
for digested early FeSSGF simulated better than the in vivo stomach fluid in the fed 






















































apparatus 1 (Table 59) showed that the best Level A correlation observed was 
obtained using digested early FeSSGF. 
 
In this project we used milk based dissolution media such as FeSSGF, digested early 
FeSSGF, FeSSIF-V1 and FeSSIF-V2 with USP apparatus 1 and 4 for making 
correlations with the relevant in vivo data (228). However, compared to dissolution 
study of ITR with USP apparatus 4, study with USP apparatus 1 yielded a much lower 
rate and extent of ITR dissolution which led to a correlation’s gradient greater than 1. 





Simulated fed state conditions 
 
The correlations of CX with USP apparatus 2 are presented in Figure 90. 
 
 
Figure 90. Mean % CX absorbed in dogs vs mean % CX dissolved in vitro with FeSSGF with 
USP apparatus 2. 
 
According to Figure 90, dissolution data in biorelevant medium simulating the stomach 
in the fed state (FeSSGF) allowed development of point-to-point Level A IVIVC with 
goodness of fit value (R2: 0.98). It is possible that this dissolution setup with USP 
apparatus 2 could be an alternative to the dissolution setup with USP apparatus 4 
(discussed later in this section) as the desired dissolution specifications. 
 
The correlations of CX Formulation 4, 5, 6 and 7 with FeSSGF/FeSSIF-V2 with USP 





Figure 91. Mean % CX Formulation 4, 5, 6 and 7 absorbed in dogs (fed state) vs mean % CX 
dissolved in vitro with FeSSGF/FeSSIF-V2 with USP apparatus 4. 
  
The lower and upper linear portions in Figure 91 indicate that the in vitro and in vivo 
release profiles are superimposable, but only up to a certain duration. The biphasic in 
vitro–in vivo correlation of CX may have many causes. One of the possible reasons is 
the change of dissolution kinetics of CX formulation (both in vitro and in vivo) when 
exposed to a different medium and hydrodynamics. 
 
In our case, clearly the dissolution between 0-120 min in FeSSGF/FeSSIF-V1 and V2 
was low but the corresponding period in vivo had fast absorption (as observed in 
deconvoluted profiles presented previously in Figure 79). As a result, the IVIVR/C for 
CX in FeSSGF/FeSSIF-V1 and –V2 with USP apparatus 4 exhibit two phases in which 
the time of media change setup (in vitro) is at 2 h, corresponding to 3% of drug 
dissolution and 33.4% of drug absorbed (FeSSGF/FeSSIF-V1) and 4% of drug 
dissolution and 32.4% of drug absorbed (FeSSGF/FeSSIF-V2). Since the time of 
transition from the first linear section to the second occurs after about 2 h, it is highly 
likely that this change occurs when the formulation enters the duodenum. 
 
The correlations of CX Formulation F8 with SGF-M2/SIF-M3, FeSSGF/FeSSIF-V1 and 


























% dissolved (in vitro)  





Figure 92. Mean % CX absorbed in dogs vs mean % CX dissolved in vitro with SGF-M2/SIF-M3 




Figure 93. Mean % CX absorbed in dogs vs mean % CX dissolved in vitro with USP apparatus 
4 (F8). Inset A: Gastric phase (in vitro time 0-2 h) Inset B: Intestinal phase (in vitro 2-6 h). 
 
A summary of the obtained parameters derived from linear regression of the relation 












Table 60. (A) Obtained regression parameters from relations between in vivo absorption* and in 
vitro dissolution data (Formulation 8) (B) in vivo absorption
#
 and in vitro dissolution data with 





USP apparatus 4 




















 0.98 0.99 0.99 0.92 0.98 0.98 0.98 
Gradient 10.81 23.18 14.8 5.91 2.47 0.62 1.77 
Intercept -9.65 -27.48 -18.68 -1.42 36.54 41.43 35.39 
*Mean in vivo absorption profiles of Formulation 4, 5, 6 and 7, total n=16 were used 
 
B 
USP apparatus 4 
Gastric phase Intestinal phase 
F4 F5 F6 F7 F4 F5 F6 F7 
R
2
 0.9789 0.99 0.9 0.9922 0.9797 0.98 0.93 0.7378 
Gradient 12.31 19.63 25.61 12.99 0.894 0.64 0.54 0.33 
Intercept -10.37 -32.06 -45.43 -13.63 46.26 41.61 31.63 45.39 
#Mean in vivo absorption profiles of corresponding formulation were used, n=4 of each 
formulation 
 
Linear regression of FeSSGF/FeSSIF-V1, FeSSGF/FeSSIF-V2 (Gastric phase) and 
FeSSGF (USP apparatus 2) gradient values of greater than 1 were observed (in vitro: 
F8). These gradient values indicated that a high degree of CX was absorbed in vivo but 
this is not in tandem with the same degree of CX dissolved in vitro with FeSSGF using 
both USP apparatus 2 and 4. 
 
On the other hand, in the regression of FeSSGF/FeSSIF-V2 (Intestinal phase) a 
gradient of 0.87 was observed in this study. This shows that FeSSIF-V2 gave a higher 
in vitro dissolution than the corresponding in vivo absorption value. Thus it seems that 
the concentration of GMO in FeSSIF-V2 is higher than the one in dogs leading to 
greater dissolution. Furthermore, in regressions of FeSSGF/ FeSSIF-V1, FeSSGF/ 
FeSSIF-V2 (Intestinal phase) and SGF-M2/SIF-M3 a significant positive intercept was 
noted. This pointed out that a considerable amount of CX was absorbed in vivo but the 
same degree of in vitro dissolution did not occur. As a summary, the correlation of 
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dissolution with drug absorption largely relies on the biorelevant conditions and 
discriminatory nature of the dissolution experiment settings.  
 
For these five formulations (F4, F5, F6, F7 and F8) the in vitro dissolution of CX both in 
the gastric and intestinal phase was very similar. The linear regressions produced 
gradients of 17.07± 5.57 and 0.60± 0.20 in the gastric and intestinal phases 
respectively. The gradient in the gastric phase is greater than 1 indicating that for a 
small amount dissolved (e.g., only 4.65% dissolved after 2 h for formulation 4 in 
FeSSGF/ FeSSIF-V2 with USP apparatus 4), a large amount was absorbed at the 
same time point (49.74% absorbed). In contrast, the gradient in the intestinal phase is 





4 Conclusions and future work 
 
The results of the dissolution tests performed demonstrated that the effect of pH, 
content of media, pH change, flow rate and ST changes could affect dissolution of 
amorphous formulations of CA, ITR and CX. The results showed that biorelevant 
media combined with USP apparatus 4 provided dissolution profiles that simulated 
closely physiological in vivo profiles. Furthermore, dissolution kinetic modeling 
dissolution models (such as Power law, Weibull, first order) were successfully applied 
to describe the rate and mechanism of CA, ITR and CX dissolution from its amorphous 
formulations.  
 
From the surface UV dissolution testing, the UV images of absorbance maps and 
contour concentration lines of the dissolved CA during the experiment with media and 
flow rate change (SGF/SIF) revealed that CA dissolved from the compact surface as 
aggregates and formed a supersaturated CA solution that subsequently precipitated 
out. Similarly for ITR,   supersaturation of ITR after media change drastically increased 
the recrystallisation of ITR on the surfaces of the ITR and Sporanox® compacts which 
could lead to ITR crystal growth.  
 
In this project, successful cases of PBPK models and IVIVCs development describing 
physiology of fasted state (CA, ITR) and fed state (CA, ITR and CX) of amorphous 
formulations were presented. The differences in predictions mediated by in vitro drug 
dissolution as input profiles and the importance of biorelevant dissolution tests for more 
accurate prediction of in vivo performance were also shown and verified.  
 
As an overall conclusion, this project successfully provides a comprehensive 
methodology which a pharmaceutical scientist could follow to characterise the 
dissolution profiles of the compound of interest, develop PBPK models and IVIVCs 
simulating fasted and fed states for orally administered amorphous formulations. In this 
study, the hypothesis of biorelevant dissolution media combined with USP apparatus 4 
could achieve a good PBPK model and IVIVC were proven correct.  
 
Future work that is worth performing includes using dissolution media with higher 
concentrations of bile salts, lecithin and lipolytic products than FeSSIF-V2 to simulate 
better CX dissolution in the dog intestine. A closer simulation of human and dog 
differences in terms of the content and hydrodynamic and gastric emptying time could 
be investigated too. Meanwhile, future work for surface UV dissolution imaging is to 
perform surface UV dissolution experiments for CA (with media change using 
biorelevant dissolution media) and CX. These were not performed in the current study 
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due to time limitation. Lastly, future work that could be performed for PBPK modeling 
includes further refinement of the developed models based on the latest clinical data 
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Figure A1: Chromatogram of a sample from a 240 μg/mL solution of CA in SG. Retention time: 
diastereomer A:5.8 and diastereomer B:6.5 min). 
Note: CA is a 50:50 mixture of diastereomers A and B. The HPLC assay for CA 
involves summing the A and B isomers in the mixture (206). 
ITR 
 








Figure A3: Chromatogram of a sample from a 40 μg/mL solution of Compound X in SGF. 







Calculation of extinction coefficient using Beer’s law (Equation A1)(116) 
                          Equation A1 
where A is absorbance, ε is the extinction coefficient (units: M-1cm-1), b is the path 
length that the light has travelled (units: cm) and c is concentration (units: M).  
Absorbance of the standard solution at various known concentrations need to be 
measured and then a graph of absorbance versus concentration need to be plotted.  
The graph is interpreted with linear function (y = mx) where y = Absorbance, x = 
concentration, m (slope)= εb. The length of the ActiPixTM quartz cell (path length is 0.4 






Scaling of FaSSIF-V1 and FeSSIF-V1 solubility of ITR and CX was performed using 
measured humans HIF values (fasted and fed state) data presented in literature (103, 
292). The reported solubility values of the model compounds in HIF, FaSSIF-V1 and 
FeSSIF-V1 were categorised according to the weak acid (CX) and weak base 
compounds and  these values were plotted using log-log scale (Figure A4: fasted state 
and Figure A5: fed state conditions).  
 
Fasted state conditions 
 
 
Figure A4. Mean solubility in fasted HIF as a function of mean solubility in FaSSIF-V1, the weak 
base  (A, for ITR) and weak acid (B, for CX) model drugs. The correlation line and correlation 




y = 0.6068x + 1.0272 





























log solubility in FaSSIF-V1 (µM) 
 B 
y = 0.7933x + 0.8385 






































Figure A5. Mean solubility in fed HIF as a function of mean solubility in FeSSIF-V1 the weak 
base (A, for ITR) and weak acid (B, for CX) model drugs. The correlation line and correlation 
function between both parameters are indicated.  
The regression functions were used to scale the solubility value of ITR and CX based 
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The Caco-2 value used in GastroPlus™ Caco-2 converter (163) is presented in Table 
A1. 
Table A1: Caco-2 value used in GastroPlus™ Caco-2 converter 










1 Amoxicillin 0.08 8 Hydrochlorothiazide 0.051 
2 Antipyrine 2.82 9 Terbutaline 0.038 
3 Atenolol 0.02 10 Ranitidine 0.049 
4 Cephalexin 0.05 11 Cimetidine 0.074 
5 Metoprolol 2.37 12 Desipramine 2.16 
6 Naproxen 3.95 13 Ranitidine 0.049 
7 Piroxicam 3.56 14 Propranolol 4.19 








Plasma concentration profile after IV administration of CA, ITR and CX (Figure A6). 
 
Figure A6: Mean plasma concentration vs time profiles of cefuroxime (humans), itraconazole 






































Composition and ionic strength of SGF-M1 and fasted state human gastric fluid are 
presented in Table A2. 
Table A2. Composition and ionic strength of SGF-M1 and human gastric fluid. 











SLS (mM) 0.346 - 





























*Reported in literature (72) 
Ionic strength is defined by the Equation A2 (72): 
                                                            I = ½ S zi2mi    Equation A2 
where mi is the concentration of the i-th ion concentration, z is the valence factor. The 





Prediction of CA in vivo performance based on PBPK models 
Solubility-based model 
 
The plasma concentration-time of simulated (solubility-based model) and the observed 
(humans) profiles after an oral administration of Zinnat® tablet in fasted state is 
presented in Figure A7, A8 and A9. 
 
Single solubility value model 
 
 
Figure A7. Simulation (line) of oral Zinnat
®
 profiles in humans using solubility measured in SGF 









































Figure A8. Simulation (line) of oral Zinnat
®
 profiles in humans using solubility measured in SIF 
and FaSSIF-V2 compared to the observed in vivo profile (human, fasted; ■)(287). 
 
The simulation using solubity value of CA in SGF and FaSSGF is comparable to the in 
vivo profiles (f1 SGF: 18.99, f1 FaSSGF: 21.18) mainly because both media have 
similar solubility. In contrast, the solubility values of SIF and FaSSIF-V2 are different (f1 
SIF: 45.10, f1 FaSSIF-V2: 29.56). It must be noted the profile for SIF was simulated 
using SIF dissolution profile that has lower dissolution due to high degradation rate of 
CA in SIF. 
 
pH solubility range model 
 
 
Figure A9. Simulation (line) of oral Zinnat
®
 profiles in humans using solubility-pH in biorelevant 










































































As seen in Figure A9 (solubility-pH range based), the simulations are less predictive 
compared to individual solubility with compendial media (SGF and SIF) leading to 
underestimation of the observed profile while the solubility with biorelevant media 
(FaSSGF and FaSSIF-V2) shows a much closer simulation (f1 SGF and SIF: 39.82; f1 
FaSSGF and FaSSIF-V2: 28.21). 
 
The plasma concentration-time of simulated (solubility-based model) and the observed 
(humans) profiles after an oral administration of Zinnat® tablet in fed state is presented 
in Figure A10. 
 
Figure A10. Simulation (line) of oral Zinnat
®
 profiles in humans using reference solubility-pH in 
FeSSIF-V2, FeSSGF and solubility-pH range (FeSSGF and FeSSIF-V2) compared to  the 
observed in vivo profile (human, fed; ■)(288). 
 
The simulation using solubity value of CA in FeSSIF-V2 (0.372 mg/mL) and FeSSGF 
(0.535 mg/mL) and combination of FeSSGF and FeSSIF-V2 all overestimated the in 









































Appendix 8  
Prediction of ITR in vivo performance based on PBPK models 
Solubility-based model 
 
The plasma concentration–time of simulated (solubility based model) and observed 
(human) profiles after oral administration of one Sporanox® capsule in fasted state is 
presented in Figure A11 and A12. 
Single solubility value model 
 
Figure A11. Simulation (line) of oral Sporanox
®
 profiles in humans using solubility measured in 
SGF and FaSSGF compared to the observed in vivo profile (human, fasted; ■)(299). 
 
Figure A12. Simulation (line) of oral Sporanox
®
 profiles in humans using solubility measured in 
HIF, SIF, FaSSIF-V1 and FaSSIF-V1 (Scaled solubility) compared to the observed in vivo 







































































The solubility of ITR in human gastric fluids and FaSSGF is 3.19 and 2.08 µg/mL 
respectively (30). Interestingly, an approximately 50% increase in the ITR solubility in 
the FaSSGF could lead to a huge difference in the simulated profiles (Figure A11). 
According to Figure A11, the simulated profile using ITR solubility in SGF and FaSSGF 
underestimated the in vivo profile (f1 SGF: 94.77; f1 FaSSGF: 95.92). 
  
Similarly, the same trend is observed from simulated profiles using solubility measured 
in SIF, FaSSIF-V1 and scaled FaSSIF-V1 (ITR solubility, according to the sequence  
6.21, 0.003, 0.34, 4.81 µg/mL) (30). It is apparent that the in vivo solubility of ITR with 
the presence of bile salts and lipids in the intestinal fluids changed significantly the 
solubility compared to that in compendial medium. According to Figure A12, the 
simulated profile using ITR solubility in humans intestinal fluid overestimated the 
observed in vivo profile (f1 scaled FaSSIF-V1: 131.97) whereas underestimation 
occurred for SIF and FaSSIF-V1 (f1 SIF: 100.00; f1 FaSSIF-V1: 78.47).  
 
pH solubility range model 
 
The plasma concentration–time of simulated (solubility-pH based model) and observed 
(humans) profiles after oral administration of one Sporanox® capsule in fasted state is 
presented in Figure A13. 
 
 
Figure A13. Simulation (line) of oral Sporanox
®
 profiles in humans using solubility-pH range 
measured in SGF-SIF and FaSSGF-FaSSIF-V1 compared to the observed in vivo profile 






































According to Figure A13, pH-solubility range using FaSSGF and FaSSIF-V1 simulated 
better the observed in vivo profile compared to SGF and SIF (f1 FaSSGF and FaSSIF-
V1:80.8;  f1 SGF and SIF:95.3). Even though both simulated profiles underestimated 
the observed in vivo profile, the results show more accurate prediction compared to the 
single solubility based model (as presented previously in Figure A11 and A12).  
 
The plasma concentration-time of simulated (solubility based model) and observed 
(humans) profiles after an oral administration of Sporanox® capsule in fed state is 




Figure A14. Simulation (line) of oral Sporanox
®
 profiles in humans using reference with single 
solubility measured in FeSSIF-V1, humans intestinal fluid (fed) and scaled FeSSIF-V1 (using 
HIF fed) compared to observed in vivo (human, fed; ■)(228). 
The reported ITR solubility in scaled FeSSIF-V1 are 12.35 µg/mL and 22.50 µg/mL 
(30) which are approximately 17 and 31 times higher than the solubility in FeSSIF-V1 
(0.73 µg/mL), respectively. According to Figure A14, the simulated profile using ITR 
solubility in scaled FeSSIF-V1 overestimated the observed in vivo profile (f1 scaled 
FeSSIF-V1: 99.68). On the other hand, the simulated profile using ITR solubility in 
FeSSIF-V1 greatly underestimated the observed in vivo profile (f1 FeSSIF-V1:99.95). 
 
ITR solubility value is a critical factor for an accurate prediction because the closest 
solubility value to the in vivo value will estimate for the true amount of ITR absorbed as 





































In vivo (human) Scaled FeSSIF-V1
FeSSIF-V1
